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 Abstract  
This study concerns a new antiretroviral drug named CRS 74. This molecule has a 
limited bioavailability because of its low aqueous solubility, poor water wettability and low 
dissolution rate. In an attempt to improve these properties, CRS 74 was recrystallized by 
using a Liquid Anti-Solvent (LAS) crystallization process. The chosen solvent is the ethanol 
and the anti-solvent the water. So solid-liquid equilibria in binary mixtures ethanol/water 
were measured at 30°C. The obtained solubility data were represented using UNIQUAC-
based model. The experimental and calculated solubilities permitted to estimate the optimal 
ethanol/water mass ratios (25/75 % w/w) in order to maximize the theoretical yield of solid. A 
double-jet with premixing (T-mixer) has been used to mix the two solutions. Particles of 
recrystallized CRS 74 seemed more agglomerated and the dissolution profile was not 
modified compared to the original drug. Furthermore, the study of crystals obtained at the exit 
of the mixer showed that the growth and agglomeration rates of crystals are high.In an 
attempt to improve its dissolution properties, CRS 74 has been recrystallized using different 
additives to optimize process and formulation parameters. Conclusively, produced 
microcrystals exhibited significantly faster dissolution rates than the original CRS 74 crystals. 
The improved dissolution is attributable to the modification of the particle size of drug 
crystals and enhancement of wetting properties due to specific interactions between the drug 
and the additives.  
Keywords: antiretroviral drug, solubility, bioavailability, dissolution rate, Liquid Anti 
Solvent crystallization, additive 
 
 Résumé 
Cette étude concerne une nouvelle molécule antirétrovirale nommée CRS 74. Cette 
molécule présente une biodisponibilité limitée à cause de sa faible solubilité en phase 
aqueuse, sa mauvaise mouillabilité et sa faible vitesse de dissolution. Afin d’améliorer sa 
biodisponibilité, la molécule CRS 74 a été recristallisée par effet anti-solvant. Le solvant 
choisi est l’éthanol et l’anti-solvant l’eau. L'équilibre solide-liquide dans des mélanges 
binaires éthanol/eau a été mesuré à 30°C. Les solubilités obtenues ont été représentées en 
utilisant le modèle UNIQUAC pour le calcul des coefficients d’activité. Les solubilités 
expérimentales et calculées ont permis d’évaluer le ratio éthanol/eau optimum (25/75 % m/m) 
pour maximiser le rendement théorique en solide. Un mélange double jet avec pré-mélangeur 
type mélangeur en T a été choisi pour réaliser la cristallisation. Le solide cristallisé dans ces 
conditions semble plus aggloméré et son profil de dissolution comparé à celui du solide initial 
est inchangé. De plus, l’étude des cristaux obtenus en sortie de pré-mélangeur a montré que 
les vitesses de croissance et d’agglomération des cristaux sont élevées. Des additifs ont donc 
été utilisés en vue de modifier les propriétés de dissolution des cristaux, et d’optimiser les 
paramètres de formulation et de cristallisation. Les microcristaux produits en présence 
d’additifs présentent des profils de dissolution significativement plus rapides que les cristaux 
de la molécule initiale. Cette modification est attribuable à la modification de taille des 
cristaux et l'amélioration du mouillage en raison des interactions spécifiques entre la surface 
des cristaux et les additifs.  
Mots clés : molécule active antirétrovirale, solubilité, vitesse de dissolution, 
cristallisation par effet anti-solvant, additifs, biodisponibilité 
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INTRODUCTION 
An increasing number of newly developed drugs are poorly soluble in aqueous media. 
Poorly water soluble drugs are specially challenging, as they cannot achieve dissolution and 
therefore they have a very difficult pass through the dissolving fluid to contact the absorbing 
mucosa and to be absorbed. If the dissolution process of the drug molecule is slow, due to the 
physicochemical properties of the drug molecules or formulation factors, then dissolution 
may be the rate-limiting step in absorption and will influence drug bioavailability. This is the 
case of a new compound, (2S, 3S, 5S)-2, -5 bis- [N-[N-[[N- methyl- N-[(2-isopropyl- 4- 
tiazolyl) methyl] amino] carbonyl] vanilyl] amino- 1,6- diphenyl- 3- hydroxyhexane, named 
CRS 74.  
This promising candidate against HIV infections has high biological activity as 
disclosed in PCT documents WO 2005/111006; US 2010/7763733 (BOCKELMANN, M.A. 
et al, 2005; BOCKELMANN, M.A. et al, 2010) but its bioavailability is limited because of its 
low aqueous solubility and dissolution rate. Such properties pose difficulties not only in the 
design of pharmaceutical formulations but may result in biovariability. Moreover, because of 
their low solubility, such drugs require high doses to be administered in order to obtain their 
pharmacological effect, increasing the side effect incidence. 
Drug dissolution is a prerequisite to drug absorption and clinical response for almost all 
drugs given orally. Solid forms that have been investigated for drug dissolution enhancement 
include salts, polymorphs and amorphous, among others. High energy polymorphs and 
amorphous formulations can achieve improved solubility but the system is at serious risk of 
crystallizing the thermodynamically stable form, even in the solid state (YU, 2011; 
RODRIGUEZ-SPONG et al., 2004). Such transformations can compromise the performance 
of the formulation. 
To save time and resources in product development, relatively simple approaches 
should be tried first like crystallization. The Liquid Anti-Solvent (LAS) crystallization 
process is an attractive method. It requires mild conditions (ambient temperature and 
atmospheric pressure) with no requirement for expensive equipment. In LAS process, 
crystallization of solute is achieved by decreasing the solubility of solid in the system. This is 
Introduction
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done by addition of a non-solvent component for solute called anti-solvent and miscible with 
the solvent. 
This thesis presents efforts to develop and assemble tools required for improving the 
dissolution rate of CRS 74 by LAS crystallization process. It is divided into five chapters.  
Chapter 1 is devoted to review literature themes. Many strategies to increase the 
dissolution rate of poorly soluble drugs and the key determinants of drug bioavailability are 
presented. It also focuses on topics of interest for our work, like properties of drugs 
influencing dissolution behavior. Emphasis was given to the LAS crystallization process.  
The first elements of the understanding of the drug properties are given in Chapter 2. 
The original (as-received) molecule was characterized in terms of its physical properties 
(particle shape and size), crystal structure (crystalline, amorphous) and surface properties 
(wettability), solubility and dissolution properties in aqueous media. The methodology 
utilized and the results obtained are summarized in this Chapter. This characterization study 
was crucial to evaluate possible changes on drug properties after recrystallization by LAS 
process. 
The solvent selection is one of the essential parameters to envisage any crystallization 
process. Therefore, the knowledge of the solubility of a target component in different solvents 
is required. The solubility of CRS 74 in ethanol and ethanol-water binary mixtures was 
measured in the temperature range of 5 -30oC and this study is presented in Chapter 3. 
Moreover, Chapter 3 outlines the experimental apparatus and procedures used for LAS 
crystallization studies. Two high jet velocity devices were tested to provide adequate mixing 
to incorporate the anti-solvent into the bulk solution. Recrystallized solids were compared to 
the original drug crystals in terms of particle size, solid state, thermal and dissolution 
properties. 
Finally, LAS crystallization of CRS 74 in presence of additives is the subject of the 
Chapter 4. The study describes the use of different additives, which were introduced in the 
drug solution or in the anti-solvent or in both phases, to achieve optimum crystal properties of 
CRS 74. The effect of additives on the crystals particle size, dissolution kinetics and drug 
wettability could be investigated and are discussed in this Chapter.  
Chapter 5 summarizes the main results of this research and suggests future work.
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 Résumé Chapitre 1- Revue Bibliographique 
Ce chapitre constitue une revue bibliographique sur l’amélioration de la 
biodisponibilité de médicaments peu solubles dans l’eau. 
Un nombre croissant des nouveaux médicaments développés par l’industrie 
pharmaceutique sont peu solubles dans les milieux aqueux. L’industrialisation de ces 
médicaments devient donc un réel défi, du fait de leurs faibles vitesses de dissolution et, par 
conséquent, de leurs difficultés à traverser les membranes corporelles afin d'être absorbés. Si 
le processus de dissolution de la molécule est lent, en raison de ses propriétés physico-
chimiques ou des facteurs de formulation, la dissolution peut être le facteur limitant de 
l'absorption et aura une influence directe sur la biodisponibilité du médicament. 
Le terme médicament faiblement soluble dans l’eau fait généralement référence à un 
médicament dont la solubilité aqueuse est inférieure à 1mg/ml. Des exemples de médicaments 
couramment commercialisés qui sont peu solubles ou insolubles dans l'eau comprennent les 
analgésiques, les cardiovasculaires, les hormones, les antiviraux, les immunosuppresseurs et 
les antibiotiques (BERGESE, 2003). De plus un médicament ayant une meilleure solubilité 
dans l'eau peut être administré à une plus faible dose réduisant ainsi leurs effets secondaires 
systémiques. Ceci est crucial pour les médicaments ayant d'importants effets secondaires, tels 
que les antibiotiques, les antifongiques ou les antirétroviraux. 
Afin d'améliorer la solubilité dans l'eau et la vitesse de dissolution de ces médicaments 
hydrophobes dans le tractus gastro-intestinal et/ou au site d'absorption, plusieurs techniques 
peuvent être utilisées, telles que la formation de sels, la complexation, par exemple avec des 
cyclodextrines, la vectorisation, des modifications chimiques ou encore des modifications 
physiques comme, par exemple, la réduction de taille du solide. En effet, la vitesse de 
dissolution est directement proportionnelle à la surface spécifique (loi de Noyes-Whitney). La 
dissolution peut donc être effectivement augmentée en réduisant la taille des particules. Par 
conséquent, de nombreux efforts ont été consacrés au développement d’opérations faciles, 
économiques et efficaces pour la fabrication de particules plus fines
 Des micro ou nano-particules peuvent être produites par deux approches différentes. 
La première consiste, à partir d’un matériau massif, à le fractionner afin de réduire sa taille, 
c’est l’approche « top-down ». Par exemple, le broyage est une méthode « top-down » 
traditionnelle de réduction de la taille de matières particulaires (MENG, 2011).  
La seconde au contraire, consiste en l’assemblage d’atomes ou de molécules 
(cristallisation),  c’est l’approche « bottom-up ». La cristallisation par effet anti-solvant est 
considérée comme une opération bottom-up. Cette dernière est une approche efficace pour la 
précipitation de fines particules en solution, en présence d’un anti-solvant. L'introduction d’un 
anti-solvant dans une solution  contenant le principe actif, génère une sursaturation élevée qui 
induit simultanément la nucléation, la croissance et l’agglomération des particules. Le grand 
défi de l’utilisation de cette opération est le contrôle des propriétés du solide cristallisé tels 
que la croissance des cristaux et leur agglomération. 
Ces dernières années, de nombreuses méthodes de production de particules utilisant la 
cristallisation par effet anti-solvant ont été développées. Elles permettent un meilleur contrôle 
de la taille, de la cristallinité et de la morphologie des particules obtenues avec des méthodes 
« bottom up ». Le procédé de cristallisation est applicable à une large gamme de composées 
pharmaceutiques BCS de classes II et IV afin de produire des micro/nanoparticules. La 
diminution de taille des particules augmente la surface spécifique, ce qui augmente la vitesse 
de dissolution de médicaments peu solubles et, par conséquent, leur biodisponibilité 
(LIVERSIDGE et LIVERSIDGE, 2008). 
Deux paramètres opératoires influençant les propriétés du solide formé ont été évalués 
dans ce chapitre : le mélange et l’utilisation d’additifs. Le premier est une étape essentielle 
pour maintenir un niveau constant et homogène de sursaturation dans le cristallisoir, induisant 
une nucléation uniforme et le contrôle de la formation de ces petits cristaux (DOUROUMIS 
et FAHR, 2006). Les additifs utilisés durant une opération de cristallisation peuvent être 
absorbés directement sur les particules formées permettant ainsi de produire des poudres avec 
des propriétés physico-chimiques optimales (ZIMMERMANN et coll., 2009). Il a été montré 
que la présence d'additifs dans la solution peut affecter les différents mécanismes comme la 
nucléation et/ou la croissance et l’agglomération et donc les propriétés du solide, comme sa 
solubilité, le faciès des cristaux le composant (KUBOTA et coll, 2000; GARNIER et coll, 
2002; VETTER et coll., 2011), et la forme cristalline (CHONG et coll, 2002; SONG et 
CÖLFEN, 2011). De plus, l'adsorption des additifs sur la surface des particules peut 
 provoquer une inhibition de la croissance et de l’agglomération, en occupant des sites 
spécifiques et, par conséquence arrêter ou ralentir ces deux processus. 
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
1.1. THE BIOAVAILABILITY OF DRUGS 
 Absorption and bioavailability 1.1.1.
The term bioavailability is usually defined as the rate and extent of absorption of a drug 
from its dosage form into the systemic circulation (BLANCHARD and SAWCHUK, 1979). 
By definition, when a medication is administered intravenously, its bioavailability is 
100%. However, when a medication is administered via other routes (such as orally), its 
bioavailability (oral bioavailability) is usually less than 100%, caused by degradation or 
metabolism of the drug prior to absorption, incomplete absorption and first-pass metabolism 
not seen with intravenous administration (OSCIER et al., 2007). 
The therapeutic effect of drugs depends on the drug concentration at the site of action. 
The absorption of the drug into the systemic circulation is a prerequisite to reach the site of 
action for all drugs, except those drugs that are applied at the site of action, or those that are 
intravenously injected.  
When a drug is taken orally administration (gastrointestinal route) it passes through the 
mouth, esophagus, stomach, duodenum, jejunum (small intestine), colon (large intestine) (see 
Figure 1.1) and finally leaves the body if not absorbed. Indeed, it must withstand the effect of 
several physiological fluctuations like a large variation in pH along the gastrointestinal tract 
(Table 1.1), the presence of bile salts, food, enzymes, bacteria and the motility of the gut. 
 
Figure 1.1. Anatomy of digestive tract (Modified from: MARTINEZ et al., 2002). 
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Table 1.1. Transit time and pH conditions along the GI tract (MARTINEZ et al., 2002). 
GI segment Transit time pH 
Stomach 2 h 2.0 ± 1.9 
Duodenum 10 min 6.6 ± 0.5 
Jejunum 2 h 7.4 ± 0.4 
Ileum 1 h 7.5 ± 0.4 
Colon 36-72 h 7.0 ± 0.7 
 
Absorption of drugs after oral administration of pharmaceutical dosage forms (drug 
powder, tablet, capsule…) may occur at the various body sites between the mouth and rectum. 
After oral administration, the pharmaceutical product reaches quickly the stomach passing 
through esophagus. However, the small intestine has the largest surface for drug absorption in 
GI tract (PODCZECK et al. 2007). 
After disintegration of the pharmaceutical dosage form in the gastrointestinal tract, the 
first requirement for absorption is that the drug dissolves. In fact, only drug that is dissolved 
has the ability to permeate the intestinal membrane. The oral bioavailability of a particular 
drug is thus determined by the magnitude of the solubility and/or permeability limitations that 
exist for it within the GI tract, which is an aqueous environment. These two aspects, 
illustrated in Figure 1.2, form the basis of the Biopharmaceutical Classification System 
(BCS), which is incorporated in the guidelines of the Food and Drug Administration (FDA) 
established by AMIDON et al. (1995) and often cited in the literature. According to the BCS, 
four different types of drug absorption regimes are distinguished. They are explained in Table 
1.2. 
According to Biopharmaceutical Classification System (BCS), Class I drugs dissolve 
rapidly in an aqueous environment and are rapidly transported over the absorbing membrane.  
For Class II drugs, the dissolution rate in vivo is usually the rate limiting step in drug 
absorption. Drugs of this group are poorly water soluble. 
Class III drugs dissolve readily, but cannot penetrate biomembranes of GI tract. 
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Class IV drugs are characterized by poor solubility and poor permeability. Oral 
administration is not recommended (LINDENBERG et al., 2004) and, subsequently, Class IV 
drugs are often administered parentally using formulations containing solubility/permeability 
enhancers. 
 
 
Figure 1.2. Parameters limiting absorption of drugs taken orally (Adapted from 
ENGMAN, 2003). 
 
Table 1.2. Biopharmaceutical Classification System according to AMIDON (1995). 
Class 
Solubility in aqueous 
environment 
Permeability over 
(intestinal) membrane 
I High High 
II Low High 
III High Low 
IV Low Low 
 
Gastrointestinal tract 
Dosage Form Drug 
Solution 
Dissolution  
Limited 
Permeability  
Limited 
Celular 
Membrane 
Systematic 
Circulation
( Blood) 
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It is clear that, depending on the classification of the drug, different strategies can be 
applied to increase or accelerate the absorption of a drug taken orally, either increasing the 
amount of dissolved drug or increasing the permeability of the dissolved drug through the 
absorbing membrane.  
To sum up, Class I drugs do not need a formulation strategy to increase the absorption. 
The rate of absorption of Class II drugs can be enhanced by accelerating the dissolution. 
This has proven to be effective in many studies (YELLELA, 2010; PATEL et al., 2011; 
VIÇOSA et al., 2012). 
The strategy for Class III drugs is to increase the permeability of the absorbing 
membrane. Numerous studies deal with increasing membrane permeability in the gastro-
intestinal tract (NEELAM et al., 2012; SHAIKH et al., 2012).  
For a Class IV drug, both dissolution as well as permeability must be increased. 
Over 90% of the marketed drugs qualify under Class II and Class IV (GRIFFIN. 2012). 
The oral bioavailability of these drug compounds is limited due to slow drug dissolution in 
the gastrointestinal tract. Therefore, it is desirable to improve the solubility of these drug 
compounds by using various pharmaceutical technologies that will be discussed later in this 
Chapter. 
 Poorly-water soluble drug molecules 1.1.2.
Poorly-water soluble drugs describe a heterogeneous group of drug compounds that 
exhibit poor solubility in water but are typically soluble in various organic solvents. 
The degree of water solubility for drug compounds can be defined as slightly soluble (1-
10mg/mL), very slightly soluble (0.1-1 mg/mL), and practically insoluble (<0.1mg/mL) 
(MENG, 2011) 
The expression poorly-water soluble drug generally refers to a drug whose aqueous 
solubility falls into the range of slightly soluble and below. Examples of commonly marketed 
drugs that are poorly soluble or insoluble in water include analgesics, cardiovasculars, 
hormones, antivirals, immune suppressants and antibiotics (BERGESE, 2003). A drug with 
improved water solubility can be administrated in a lower concentrated dose, with a reduction 
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of local and systemic side-effects. This is crucial for drugs with important side-effect profiles, 
such as antibiotics, antifungals or antiretrovirals. 
The drug we deal with in this thesis belong to the category of insoluble drugs; at the 
best of our knowledge, it is not yet classified according to the BCS classification. 
 
1.2. ENHANCEMENT OF SOLUBILIZATION AND 
BIOAVAILABILITY OF POORLY SOLUBLE DRUGS
 Concept of dissolution 1.2.1.
Drug must first be dissolved in the medium at the absorption site. The process that a 
drug particle dissolves is called dissolution.  
The dissolution of a solid in a solvent is a rather complex process determined by a 
multiplicity of physicochemical properties of solute and solvent. However, a more intuitive 
approach was interestingly proposed by Bergese (2003) to describe the dissolution of a solid, 
regardless of the mechanism by which dissolution occurs, as a consecutive process driven by 
energy changes (Figure 1.3). 
 
Figure 1.3. Energy diagram of the dissolution of a solid phase. Adapted from 
BERGESE, 2003. 
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The first step consists in the contact of the solvent with the solid surface (wetting), 
which leads to the production of a solid-liquid interface. Following the description given by 
Bergese (2003), the break of the molecular bonds of the solid and the molecules passage to 
the solid-liquid interface (solvation) are the second and third step. 
The final step sees the transfer of the solvated molecules from the interfacial region into 
the bulk solution (diffusion). Each stage requires a certain amount of energy to be completed; 
the target of drug activation is to lower the overall dissolution energy.
Solvation and diffusion depend on solid and solvent chemical nature and on the system 
conditions (temperature, mechanical agitation…), while wetting and fusion also depend on 
microstructure of the solid. In the case of a given poorly water-soluble drug that dissolves into 
the gastrointestinal tract it is not possible to modify neither the drug molecules nor the 
dissolution environment (solvent and system conditions). So the efforts in enhancing drug 
dissolution rate are essentially spent (in trying) to tailor the drug microstructure. 
To outline the properties of solids that determine their dissolution rate we start from the 
simplest model for the dissolution of a solid in a solvent, i.e. the Nernst’s film theory (1904), 
considering a single particle dissolving into a large volume of solvent, under agitation (Figure 
1.4). 
  
Figure 1.4. Dissolution of a single particle in a large volume of solvent (Model of 
Nernst). Adapted from BERGESE, 2003. 
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The concentration of the pure molecule at the solid surface, is assumed to be equal to 
the saturation concentration, Ceq; the concentration in the bulk solution will be denoted with 
C. Despite of agitation, it can be assumed that the solid is surrounded by a stagnant film of 
liquid of constant thickness. Solid molecules spontaneously diffuse through this film and 
reach the bulk solution. If we assume steady state conditions, diffusion is described by the 
Fick’s first law: 
 (1.1) 
 
where Ji is the diffusion current (defined as the amount of material i passing per unit time 
perpendicularly through a unit surface area), Ci the molar concentration of molecule i, Di the 
diffusion coefficient of molecule i, and ∂Ci/∂s the concentration gradient through the film.  
In this particular case, ∂Ci/∂s is constant, since in the stagnant film laminar condition 
holds. To sum up, there is a linear concentration gradient from the solid surface to bulk 
solution that can be analytically expressed as ∂Ci/∂s = (Ci,eq –Ci)/h. Using this expression, and 
denoting the volume of the solvent V and the surface area of the dissolving solid A, Equation 
(1.2) becomes: 
 (1.2) 
 
The more familiar form of the dissolution equation (also called Noyes-Whitney 
equation), which describes the increase of the mass of solute dmi in the time dt due to 
dissolution, is obtained rearranging Equation (1.2): 
 (1.3) 
where Mi  is the molar weight of solid. 
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To eliminate the saturation effect of the solvent and increase the ability of the solid to 
dissolve the expected amount of drug, dissolution methods on “sink condition”, have been 
proposed in the literature (GIBALDI and FELDMAN, 1967; ROHRS, 2001, 
GOWTHAMARAJAN and SINGH, 2010). In practice, if the quantity of the medium 
dissolution is sufficiently large, between 3 and 10 times, of the volume needed to completely 
solubilize the drug, it is said that we are on sink-condition (ABDOU, 1989; ROHRS, 2001; 
GOWTHAMARAJAN and SINGH, 2010). When sink condition holds (<< , Equation 
simplifies to: 
 (1.4) 
 
 Dissolution testing for poorly-water soluble drugs 1.2.2.
For a dosage form to produce its effect after oral administration, drug must be released 
and generally should be dissolved in the fluids of the gastrointestinal tract. Drug dissolution 
testing plays an important role as a routine quality control test and to characterize the quality 
of the product (FDA, 1997).  
Dissolution from the dosage form involves mainly two steps: liberation of the drug from 
the formulation matrix (disintegration) followed by the dissolution of the drug (solubilization 
of the drug particles) in the liquid medium. The overall rate of dissolution depends on the 
slower of these two steps. In the first step of dissolution, the cohesive properties of the 
formulated drug play a key role. 
For solid dosage forms, these properties include disintegration and erosion. If the first 
step of dissolution is rate-limiting, then the rate of dissolution is considered disintegration 
controlled. In the second step of dissolution (i.e., solubilization of drug particles), the 
physicochemical properties of the drug such as its chemical form (e.g., salt, free acid, free 
base) and physical form (e.g., amorphous or polymorph and primary particle size) play an 
important role. If this latter step is rate-limiting, then the rate of dissolution is dissolution 
controlled. This is the case for most poorly soluble compounds in immediate-release 


 


 	
  
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formulations whose solubility is less than 1–2 mg/L in the pH range of 2–8 
(GOWTHAMARAJAN and SINGH, 2010). 
For poorly soluble compounds, dissolution study is particularly important. Different 
techniques have been used to improve the maximum dissolvable dose in the dissolution 
medium in discriminatory dissolution studies, such as addition of organic solvents to aqueous 
medium (DANIEL et al., 2012), increase of the dissolution medium volume, pH changes 
(TALARI et al., 2009), and addition of surfactants (JINNO et al., 2000; ROHRS, 2001).  
Some dissolution parameters involved in the phase transformation can affect dissolution 
method efficiency. The dissolution of most solids is an endothermic phenomenon, thus 
increases in temperature tend to increase the speed, which the substance dissolves. Because of 
this, the United States Pharmacopeia recommends 37±0.5°C media temperature for 
dissolution tests.  
The dissolution kinetics depends on the local mass transfer coefficient (which in turn is 
a function of suspension state and the local turbulence level). Because of this some authors 
have established a relationship between the intensity of agitation and dissolution rate constant 
(cm.sec-1). Generally, higher stirring rates result in higher dissolution rates and ideally stirring 
conditions must somehow simulate peristalsis physiological. The diffusion rate can decrease 
too, with increasing media viscosity, which implies a decrease of the dissolution rate. Another 
parameter that can influence the dissolution rate of a solid in a liquid is the solid wettability. 
For complete drug dissolution it is necessary that wetting is complete. The ability of wetting 
of a solid by a liquid is expressed by the contact angle. 
Countless are the variables that can modify the results of dissolution tests. All should be 
considered, but some must be strictly monitored to obtain reliable results. Finally, 
construction of in vitro-in vivo correlation provides the most valuable data for selection of the 
most appropriate dissolution method and testing conditions that can be prognostic of in-vivo 
dissolution. 
Micro/nanonization during crystallization (RASENACK and MÜLLER, 2002; 
RASENACK and MÜLLER, 2004; BADAWI et al., 2011; VIÇOSA et al., 2012), surface 
modification (HAN et al., 2011) and crystal structure modification (EERDENBRUGH et al., 
2009) may improve the dissolution rate of poorly water-soluble APIs. 
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Several studies have shown that modification of the crystalline form of the drug , by the 
inclusion of specific additives increases the rate of dissolution of the pharmaceutical form, 
which can strongly affect the physicochemical properties and kinetic of absorption of the drug 
from the final product (SHEKUNOV and YORK, 2000). 
It is known that a substance in crystalline form has a lower solubility, while at the same 
amorphous form has higher solubility and low thermal stability. Formulations where the drug 
is mainly crystalline and amorphous or metastable forms, are much more soluble than the
drug-containing highly crystalline. Drug amorphization can be used to promote a quicker 
therapeutic effect by enhancement of drug absorption rate and dissolution rate. However, 
formulations containing metastable amorphous forms are less stable than those prepared with 
the crystalline forms of the drug. Because there is generally a risk of crystallization during the 
production process and shelf life of the product. Such products are generally very reactive and 
less stable when exposed to heat and mechanical stress, and very susceptible to moisture 
absorption (SINGHAL and CURATOLO, 2004) 
The dissolution rate can be enhanced by size reduction that can be explained by the 
Noyes-Whitney equation (Equation. 1.3). This is possible due to the special features of drug 
size reduction:  
1. Increased surface area A; 
2. Increased  saturation concentration and dissolution pressure (    Ceq; pX ); 
3. Increased adhesiveness to surfaces/cell membranes (see Figure 1.5). 
 
The increased area increases the dissolution rate. Moreover the transfer of particles from 
the macrosize range to the nanodimension changes their physico-chemical properties. This 
strategy also modifies the saturation concentration of the drug in solution (Ci,eq), which means 
an additional increase with increased speed dissolution of particles in this size range. In 
addition, the size reduction can increase the adhesiveness into the skin due to the increase in 
the saturation, leading to a larger concentration gradient and the larger gradient promotes 
penetration (MÜLLER et al., 2011). 
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Figure 1.5. Features of size reduction: 1. Increased dissolution velocity due to increased 
surface area ; 2. Increased saturation solubility due to increased dissolution pressure of 
strongly curved small nanocrystals (upper); 3. Increased adhesiveness of reduced material due 
to increased contact area of small versus large particles. Modified from MÜLLER et al., 2011. 
Fa
cto
r o
f s
ur
fa
ce
 ar
ea
 (A
) i
nc
re
as
e 
0
500 
1000 
1500 
2000 
2500 
3000 
3500 
4000 
4500 Nanonization Micronization 
0,01 0,1 1 10 
1. Increase in surface area (A) 
50 nm 
100 nm 
500 nm 10 µm 100 µm 
log particle size (µm) 
5000 
5500 
6000 
100 µm 
10 µm 
 
0.5 µm 
 
Micronization Nanonization 
2. Saturation solubility (Ceq) 
= f (size) 
=f (curvature) 
=f (dissolution pressure-px) 
px px px 
100 µm 
3. Adhesiveness 
=f (size) 
=f (contact area) 
1 microcrystal 
Increased contact area 
18 Nanocrystals 
200 nm 
CHAPTER 1 
 38 
 
 Strategies to increase the amount of dissolved drug at the absorption site 1.2.3.
To enhance the aqueous solubility and the dissolution rate of hydrophobic drugs at the 
absorption site several strategies can be used. These methods (alteration of solvent 
composition, complexation, carrier system, chemical modification and physical modification) 
are shown in Figure 1.6. The following section is a brief review on the state of the art of this 
topic. 
 
Figure 1.6. Strategies to increase the amount of dissolved drug at the absorption site 
(Modified from LAKSHMI et al., 2012). 
1.2.3.1. Alteration of pH and solvent composition 
 Salt formation/pH control 1.2.3.1.1.
It is well documented that the bioavailability of pharmaceuticals products is influenced 
by the changes in pH within the GI tract. The absorption of drug is largely dependent on 
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diffusion, which varies with pH of the individual regions within the GI tract, pKa of the drug, 
and permeability, that depends of regional pH effects upon drug ionization.  
Poorly water soluble drugs can be protonated (base) or deprotonated (acid) and may 
potentially be dissolved in water by applying a pH change. The presence of salts can act as 
alkalising or acidifying agents, and may increase the solubility of weakly basic or acid drugs. 
After pH adjustment, ionisable compounds are stable and soluble at selected pH. 
Salts of acidic and basic drug have, in general higher solubility values than their 
corresponding acid or basic forms (GRAHAM et al., 1986).  
Generally a salt of a drug is frequently less stable chemically compared to crystalline 
solid. At pH extremes drug is dissolved, which can increase the chance of hydrolysis, catalyze 
or other degradation mechanisms (VENKATESH et al., 1996). Another disadvantage is the 
risk for precipitation upon dilution with aqueous media having a pH at which the compound is 
less soluble. Intravenously this may lead to emboli, orally it may cause variability and toxicity 
(local and systemic) related to the use of non physiological and extreme pH (GIACONA et 
al., 1982). 
 Cosolvency 1.2.3.1.2.
Co-solvent system works by reducing the interfacial tension between the aqueous 
solutions and hydrophobic solute by solvent blending or cosolvency. This method is based on 
the mixing of solvents of different polarities to form a solvent system of optimum polarity to 
dissolve the solute. Co-solvent formulations of poorly soluble drugs can be administered 
orally and parentally (THELLY et al., 2000; BOYLAN, 1987). This type of formulation can 
increase the solubility of poorly soluble compounds several thousand times compared to the 
aqueous solubility of the drug alone. However, these modifications can cause serious side 
effects due to solvents use. 
Yeh (2009) realized a formulation study of tenoxicam, a poorly water-soluble drug, by 
use of a ternary cosolvent system, DMSO/polyethoxylated castor oil/ethanol system, that had 
significantly enhanced the solubility. Additionally, the relative bioavailability was improved. 
This study provided a novel strategy for improving tenoxicam solubility, but also helps 
further scientific knowledge for the development of parenteral formulations. 
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Seedher and Bhatia (2003) investigated that the aqueous solubility of celecoxib, 
rofecoxib and nimesulide could be enhanced significantly by using ethanol as the second 
solvent and PEG-400-ethanol had highest solubilization potentiality among the mixed solvent 
systems.  
Large quantities of organic solvent used in cosolvent formulations may result in the loss 
of solvent capacity of the formulation upon dilution in aqueous media in vivo. For drugs Class 
II and IV, administered orally, the use of cosolvents technique may not increase the 
bioavailability dramatically because the poorly soluble drug can typically uncontrollably 
precipitate into a crystalline or amorphous precipitate. In this case, dissolution of this 
precipitate is required for oral absorption. A major concern for the use of this technique is the 
biocompatibility, tolerability and toxicity of used solvents formulations and the loss of solvent 
capacity in aqueous media in vivo.  
1.2.3.2. Inclusion complexes/complexation 
 Cyclodextrin (CD) 1.2.3.2.1.
Another approach used to improve drug solubilization is based on the formation of 
inclusion complexes between molecular assemblies and drug molecules, like cyclodextrins 
(CD). CDs are cyclic oligosaccharides composed of glucopyranose units and adopt a 
truncated cone structure with hydrophobic cavity (SAENGER, 1980). 
Cyclodextrins and their derivatives have been employed as complexing agents to 
increase water solubility, dissolution rate and bioavailability of lipophilic drugs for parenteral 
or oral delivery (SRIDEVI et al., 2003; MORIWAKI et al., 2008). 
An inclusion complex is produced by inclusion of a non polar molecule or the nonpolar 
region of a molecule (known as the guest) into the nonpolar cavity of another molecule or 
group of molecules (known as the host), as shown in Figure 1.7. When the guest molecule 
enters the host molecule, they are temporarily locked or caged within the host cavity. Giving 
rise to beneficial modifications of guest molecules, as solubility improvement for example. 
Furthermore these complexes have a broad range of utilizations in different applications; they 
are used in the food and cosmetics industries and the pharmaceutical sector (DEL VALLE, 
2004). 
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Figure 1.7. Schematic illustration of the association of free cyclodextrin (CD) and drug 
to form drug–CD complexes  and a truncated cone structure of CD (Modified from: DEL 
VALLE, 2004). 
The three cyclodextrins α-, β-, and γ- (CD) are composed of six, seven, and eight 
glucopyranose units, and are produced in industrial scales (MORIN-CRINI and CRINI, 
2012). These agents have a torus structure with primary and secondary hydroxyl groups 
orientated outwards, as shown in Figure 1.8. 
 
Figure 1.8. Schematic representations of Cds (a) α- CD, (b) β-CD, (c) γ-CD. 
Containing 6,7 and 8 glucopyranoside units, respectively (MORIN-CRINI  and CRINI, 2012). 
For Class IV drugs, the cyclodextrin complexation may not improve their oral 
bioavailability. However, cyclodextrins are able to improve aqueous solubility of some large 
lipophilic molecules leading to increase drug availability at the mucosal surface. This will 
frequently lead to increased oral bioavailability (LOFTSSON et al., 2005). 
Even though CD seems to be ideal carriers, they possess some limitations, related to 
toxicological considerations, formulation and production cost. In general, the complexation 
Hydrophobic cavity 
Hydrophilic  exterior 
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efficiency of cyclodextrins is low and thus relatively large amounts of cyclodextrins are 
needed to complex small amounts of drug (LOFTSSON and O’FEE, 2003). 
1.2.3.3. Carrier System 
 Micelles 1.2.3.3.1.
Micelle solution is another formulation strategy to increase drug solubility. According 
to IUPAC (Compendium of Chemical Terminology) (1972) micelle solubilization can be 
defined as colloidal association in a solvent system for solubilization of a component into or 
on micelles. 
Of the above mentioned, for colloidal association, the use of surfactants into the media 
is the most popular method for micelle formation. Various synthetic surfactants can simulate 
the surfactants present in the gastrointestinal fluid, e.g., bile salts, lecithin, cholesterol and its 
esters (YALKOWSKY, 1999). 
Surfactants are molecules with distinct polar and non polar regions. In water, as the 
concentration of surfactant increases above a critical value, its molecules self-associate into 
soluble structures called micelles. The concentration at which they begin to form is called the 
critical micelle concentration (CMC) (FLORENCE and ATTWOOD, 1981 ; MYRDAL and 
YALKOWSKY, 2002 ).  These micelles are normally spherical with the nonpolar regions of 
surfactant molecules gathered in the center (core) and surrounded by a shell of the polar 
region which are in contact with the water. 
Micelle is a nanoparticle structured by one hydrophilic shell and one hydrophobic core 
(Figure 1.9), which are capable of encapsulating drug molecules, resulting in reduction in the 
interfacial tension and improved solubility of the drug in the medium (SUBHASHI et al., 
2009). 
The stability of drug carrier micelles is the biggest challenge for the use of this 
technique. When in aqueous media, in vivo micelles become much diluted by blood (below 
CMC) and may be gradually disintegrated into unimers. In addition, the low drug loading 
efficiency and the difficulty in transporting through cell membranes, has also retarded the 
development of effective micellar drug (KIM et al., 2010). 
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Figure 1.9. Schematic representation of a hydrophobically assembled polymer micelle. 
The hydrophobic core loading lipophilic drugs is protected from the environment by the 
hydrophilic shell (KIM et al., 2010). 
 Micro/Nanoemulsion 1.2.3.3.2.
Microemulsion consists of dispersions of two immiscible or partially miscible liquids 
(water in oil or oil in water) that present droplets ranging from 5-100 nm. They are 
thermodynamically stable and do not require power supply for their formation (ROSSI et al., 
2007). The main difference between microemulsions and nanoemulsions is that 
microemulsions are self-assembling nano-scale emulsions, whereas nanoemulsions are nano-
scale emulsions formed under intense mechanical shear (WHITESIDE and GRZYBOWSKI, 
2002). 
All types of emulsions should be prepared with a certain amount of surfactant. 
Surfactants can promote the formation of emulsion as they reduce the interfacial tension 
between oil and water by attaching to the liquid-liquid interface (SHINODA, 1967). The main 
difference between surfactant micelles and emulsion is the liquid phase. Typically, micelles 
are formed by adding surfactant to a single liquid phase, either oil (reversed micelles) or 
water, whereas emulsions are prepared by adding surfactant to a double liquid phase (oil and 
water) 
Microemulsions are suitable carriers for poorly water soluble drugs, because they can 
be dispersed easily in gastrointestinal juice in microemulsion form. Furthermore, 
microemulsions can enhance the drug absorption due to their small particle size. Also the 
drugs can be stored longer because of the stability of microemulsions (MALMSTEN, 1999). 
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The disadvantage of microemulsions as drug carriers is that the toxicity of the drugs tends to 
increase due to a large amount of the surfactant utilized in microemulsion formulation. 
1.2.3.4. Manipulation of solid state 
 Co-crystals 1.2.3.4.1.
Co-crystals are solids that are crystalline materials composed of two or more molecules 
in the same crystal lattice (FDA, 2011). The formation of pharmaceutical co-crystals has 
gained attention as attractive alternate solid forms for drug development. Their formation 
involves incorporation of a given API with one or more pharmaceutically acceptable molecule 
(Coformers) in the crystal lattice (Figure 1.10), that is a solid under ambient conditions. The 
co-crystals do not affect pharmacological activity of API but can improve physical properties, 
such as solubility, hygroscopicity, compaction behavior (RODRIGUEZ-HORNEDO et al., 
2007 ; ZAWOROTKO, 2008). Of these properties, solubility is the most widely appreciated 
in the literature. 
 
Figure 1.10. Possible solid forms of a drug cocrystal . Modified from  ALHALAWEH, 
2012). 
Poor aqueous solubility can compromise drug performance, and co-crystals are an 
emerging strategy to design materials with desirable properties. Co-crystal solution phase 
behavior was first investigated by Higuchi and Connors (HIGUCHI and CONNORS, 1965).  
Co-crystals are usually prepared by evaporation from a solution containing 
stoichiometric amounts of components (co-crystal formers). However sublimation, blending 
of powders, sonication, growth from melt, slurries and grinding of the components together 
are suitable methodologies (KRISHNAIAH, 2010). 
The major disadvantage of co-crystals technique is the notoriously difficult situation of 
these systems related to their preparation— it has been known to take 6 months to prepare a 
single co-crystal of suitable quality for single X-ray diffraction analysis (PORTALONE and 
 
    
  
  
  
  
API 
Coformers  
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COLAPIETRO, 2004). In addition, for solution co-crystallization, the two components must 
have similar solubility; otherwise the least soluble component will precipitate out exclusively. 
On the other hand, similar solubility of two components alone will not promise success. It has 
been recommended that it possibly useful to consider polymorphic compounds which exist in 
more than one crystalline form as co-crystallising components (BLAGDEN, 2007). 
 Amorphous Solid dispersion 1.2.3.4.2.
In amorphous solid dispersion, drug molecules are dispersed molecularly but irregularly 
within amorphous excipient (biologically inert matrix) (Figure 1.11). Chiou and Riegelman 
(1971) defined the term solid dispersion as ‘‘a dispersion of one or more active ingredient in 
an inert carrier or matrix at solid state prepared by the melting (fusion), solvent or melting-
solvent method’’. This method, involves the formation of eutectic mixtures of drugs with 
water-soluble carriers by the melting of their physical mixtures. 
 
Figure 1.11. Amorphous solid dispersion (From GHASTE et al., 2009). 
There are various reasons for the improvement of solubility of poorly water-soluble 
drug using solid dispersion technology. The reasons for solid dispersion or advantages of 
solid dispersions are as follows: particle size reduction, improved wettability, higher degree 
of porosity, drugs in amorphous state (KUMAR et al., 2011).  
The major disadvantages of solid dispersions are related to their instability. During 
processing (mechanical stress) or storage (temperature and humidity stress) the amorphous 
state may undergo crystallization and dissolution rate decrease with ageing. The effect of 
moisture on the storage stability of amorphous pharmaceuticals is also a significant concern. 
By absorbing moisture, phase separation, crystal growth or a change from metastable 
crystalline form to stable form can take place which leads to the reduction of drug solubility, 
dissolution rate, and consequently a bad in vivo drug performance (WANG et al., 2005). 
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1.2.3.5. Physical Modification 
It has been proven, as expressed by Noyes-Whitney (equation 1.3, section 1.2.1), that 
the dissolution rate is directly proportional to the specific surface area, which can be 
effectively increased by reducing the particle size. Therefore, considerable efforts have gone 
into developing reliable and efficient methods for the manufacture of fine particles. 
Micro- or nano-particles can be produces by two different technology approaches as 
illustrated in Figure 1.12, called “top-down” and “bottom-up” technologies. Top-down 
technologies start with coarse materials and apply forces to break down into micro or nano-
particles, while bottom-up technologies start with the molecules in solution and the molecules 
are aggregated to form the solid particles (RABINOW, 2004). 
 
Figure 1.12 Schematic representation of ‘bottom up’ and top down’ technology 
approaches for ultra-fine particles production (micro- or nanometric scale of particle size). 
Modified from FLORENCE and KONSTANTIN, 2010.
Top  Down 
Bottom Up 
Atoms 
Clusters 
 MICRO/NANOPARTICLES 
Bulk 
Powder 
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Milling 1.2.3.5.1.
Milling and homogenization are the traditional top-down methods for size reduction of 
large quantities of particulate materials (MENG, 2011). In the milling operation, the applied 
stress is applied on the material, which causes the breakage of the particle. 
Drug particles can be broken between moving pearls by shear forces and forces of 
impaction generated by a movement of the milling media (MÜLLER and AKKAR, 2004), as 
schematized in Figure 1.13. 
 
Figure 1.13. Particle size reduction by milling of drug particles between moving pearls 
schema. 
This process can reduce drug particle size, depending on the drug hardness and drug 
quantities to be milled. Milling period and speed had critical impact on particle size 
distribution (CHE et al., 2012). However, this method has limited opportunity to control the 
final particle size, shape, morphology, surface properties and electrostatic charge and it is 
difficult to reduce the particle size below 1 μm because of the cohesiveness of the particle 
(BHAKAY et al., 2011). 
There are different milling materials available, traditionally steel, glass, and zircon 
oxide and more recently, special polymers (hard polystyrene) are used. A problem associated 
with the pearl milling technology is the erosion from the milling material during the milling 
process. In general, very few data have been published on contamination of pharmaceutical 
drug suspensions by erosion from the milling material.  Of course it should be noted that the 
extent of erosion depends on the solid concentration of the macrosuspension to be processed, 
Drug particle 
Moving Pearls 
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the hardness of the drug, and based on this, the required milling time and milling material. 
Apart from the milling material, the erosion from the container also needs to be considered. 
Moreover, disadvantages that have also been reported are potential growth of germs in 
the water phase when milling for a long time, and time and costs associated with the 
separation procedure of the milling material from the drug suspensions (CHE et al., 2012). 
High-pressure homogenization (HPH) has been utilized for many years for production 
of emulsion and suspensions (TIPPETTS and MARTINI, 2009; LOVELYN and ATTAMA, 
2011 ; LACERDA et al., 2011). Piston-gap principle and jet-stream technology are the two 
basic technologies for most homogenizers, illustrated in Figure 1.14. For instance, in the 
piston-gap homogenizer, particles to be milled suspended in a liquid medium coming from 
the sample container are forced to pass through a tiny gap (e.g., 10 mm), and the particle 
diminution is affected by shear force, cavitation and impaction. In jet-stream homogenizers, 
the collision of two high-velocity streams leads to particle diminution mainly by impact 
forces. 
 
Figure 1.14. Basic homogenization principles: piston-gap (left) and jet-stream 
arrangement (right). Adapted from SIVASANKAR and KUMAR, 2010. 
High pressure-homogenization (HPH) has been used to generate nanosuspensions of 
many poorly water soluble drugs such as azithromycin, quercetin and nitrendipine (ZHANG 
et al., 2007; KAKRAN etl., 2012; QUAN et al., 2012).  
Original dispersion Dissipation volume 
 

Particle suspension with reduced particle granulometry  
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Generally, high-energy input resulting in enormous impact forces produced effective 
size reduction of a suspension (median diameters less than 500 nm have been reported by 
Muller and co-workers (MÜLLER et al., 2001; MÜLLER et al., 2004). However, only fragile 
drug candidates can be broken up into nanoparticulates using this technique (RADZUAN, 
2010). 
In general, the particle size decreases with an increasing number of cycles and 
increasing homogenization pressure and they are mainly influenced by the hardness of the 
drug, the finesse of the starting material (GRAU et al., 2000; SALAZAR et al., 2011). The 
optimum number of homogenization cycles is determined by considering the particulate size 
and polydispersity index of the drug after each cycle.  
During milling, additives such as surfactants and stabilizers have been used for the 
physical stability of the produced drug with reduced particle size (BHAKAY et al., 2011). 
 LAS Crystallization 1.2.3.5.2.
Particle size reduction technologies such as milling or high-pressure homogenization 
have been used over the years. However, controlling of size distribution, morphology, and 
surface properties can be challenging. As many hydrophobic drugs are soluble in various 
water miscible organic solvents, an effective approach is the precipitation of fine particles 
from solution phase while mixing with an anti-solvent.  
 LAS crystallization is considered as a bottom-up process, which means that one starts 
from the molecular level, and goes via molecular association to the formation of a solid 
particle (GASSMANN et al., 1994; RASENACK and MÜLLER, 2003).  
The basic advantage of anti-solvent technique is the use of simple and low cost 
equipment, compared with milling and high-pressure homogenization technique. Typically, 
the drug is first dissolved in an organic solvent and the drug solution is mixed with an anti-
solvent (Figure 1.15). The solvent and the anti-solvent must be miscible at the operating 
conditions.  One of the advantages of the method is to avoid the use of high energy like in 
disintegration technique as used for milling, which prevents denaturation of drug due to high 
energy input (ZHONG et al., 2005). 
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Figure 1.15. Approach for drug particle formation by LAS crystallization. 
The introduction of the drug solution to the anti-solvent generates high supersaturation 
that subsequently induces nucleation and simultaneous growth by condensation and 
coagulation. The whole process is schematized in Figure 1.16. One formidable challenge 
remains to control the properties of the crystallized solid such as crystal growth and 
agglomeration to ensure good further dispersion for dissolution. 
 
Figure 1.16. Schematic representation of the different steps involved in drug particle 
formation by an LAS crystallization process. Adapted from MENG, 2011. 
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The next section reviews in more details some concepts in the crystal engineering field, 
with emphasis on the driving force for crystallization, control of the two key steps (nucleation 
and growth) and of solid properties. 
1.3. CRYSTALLIZATION 
Crystallization is a key process in the manufacturing of most pharmaceutical 
compounds. Over 90% of all pharmaceutical products, such as tablets, aerosols, capsules, 
suspensions and suppositories contain drug in particulate, generally crystalline, form 
(VALDER and MERRIFIELD, 1996). The most common type of crystallization is 
crystallization from solution, in which a material that is a crystalline solid at a temperature of 
interest is dissolved in a solvent while crystallization is induced by changing the state of the 
system in some way that reduces the solubility of the solute. That results in the formation of a 
crystalline or amorphous solid (MYERSON, 1999). 
Crystallization process is considered a two-stage process. Nucleation is the first step in 
which the “birth” of nuclei (a new solid phase) from the supersaturated solution occurs. The 
stable crystal grows in size, going from dissolved drug in solution to solid in suspension.  
The crystallization process is governed mainly by the kinetics of nucleation and crystal 
growth, and these processes depend on the driving force called supersaturation (i.e. the 
concentration of the solute exceeds its equilibrium concentration). This can be achieved in 
several ways − for example by cooling a solution, or by solvent evaporation, or by the 
addition of an anti-solvent, or by changing the solution pH. 
 Thermodynamic background 1.3.1.
For crystallization to occur, the system must be brought into a non-equilibrium state 
where the concentration of the solute exceeds its equilibrium concentration (i.e. the solution is 
supersaturated). This phenomenon is better represented in the phase diagram (Figure 1.17), 
represented by a curve of the equilibrium concentration of solute as a function of temperature 
(solid line). At concentrations below solid line, the solid will dissolve until equilibrium is 
reached. At solid concentrations between the dashed and solid lines, crystals will grow by 
seeding but fresh crystals will not nucleate. This is the "metastable zone", which defines the 
compositions at which spontaneous crystallization occurs and the region bounded by the 
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solubility curve and the metastable limit. Above the dashed line, the solution produces 
crystals spontaneous; in this region the supersaturation is achieved. 
 
Figure 1.17. The solubility / supersolubility phase diagram. Modified from DAVEY 
and GARSIDE, 2000. 
 
 Nucleation 1.3.2.
The nucleation is the stage of solid formation from a supersaturated mother phase 
(DAVEY and GARSIDE, 2000). Supersaturation generated leads to nucleation and 
precipitation. According to equation 1.5, nucleation rate J depends to the supersaturation 
ratio. It is defined as: 
 (1.5) 
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where   

 is the supersaturation ratio, T the temperature, C the actual concentration of 
API in the solution (mol/L) and Ceq the solubility (mol/L) of API in a mixture of organic 
solvent and water. The ratio of activity coefficient 

 is assumed to tend towards 1. 
Unfortunately, the mechanisms of nucleation are very poorly understood which leads to 
significant problems in the design, operation and control of crystallization processes. 
Nucleation is therefore an important issue. Crystal nucleation denotes the formation and 
physical characteristics (i.e. size distribution, habit morphology) of new crystalline solid. It 
involves the aggregation of dissolved molecules in solution, leading to the formation of a 
nucleus.  
In general, nucleation mechanisms can be divided into three main categories: 
homogeneous, heterogeneous, and secondary nucleation (Figure 1.18).  
If a solution contains neither solid foreign particles nor crystals of its own type, nucleus 
can be formed only by homogeneous nucleation. This type of nucleation rarely occurs in 
volumes larger than 100 μl, since “real” solutions tend to contain random impurities which 
may induce nucleation (PEREPEZKO, 1997). If foreign particles are present, nucleation is 
facilitated and the process is know by heterogeneous nucleation.  
On the other hand, secondary nucleation can only happen when crystals of the solute are 
already present or are deliberately added to the solution, as seeds. This nucleation mechanism 
generally occurs at much lower supersaturations than homogeneous or heterogeneous 
nucleation, and it is caused mostly by collisions of crystals with crystallizer and mixer. 
Nucleation processes are of practical importance in production of pharmaceutical 
compounds, for example: A great interest in pharmaceutical research are the concepts of 
heterogeneous nucleation to be applied in the directed nucleation of specific polymorphs 
(WEISSBUCH et al., 1987). These studies provide us with the attractive possibility that “a 
library” of organic seeds can be used to control polymorphism, or to search for unknown 
polymorphs (WARD, 1997). 
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Figure 1.18. Various kinds of nucleation. Modified from MARSMANN et al., 2001. 
 
 Crystal growth 1.3.3.
Once formed, nucleus begins to grow larger through the addition of solute molecules to 
the crystal lattice, and this stage of crystallization process is known as crystal growth. The 
nucleation and growth processes compete for solute molecules in function of their dependence 
on supersaturation, and their relative rates will determine the crystal size distribution 
(RODRIGUEZ-HORNEDO and MURPHY, 1999). The sites to capture arriving growth units 
can be differentiated in kink, ledge and flat faces (Figure 1.19). Growth process occurs by 
diffusion of solute molecules (atoms, molecules, ions) from the bulk solution to the interface 
by diffusion and convection and then integration of the solute molecules into the crystal 
lattice, under supersaturation conditions. The first step is the diffusion of growth units from 
the growth medium to an impingement site (step I) of the crystal to adsorb on the surface. In 
most cases (except rough growth), the growth can migrate to the surface of crystal to a step or 
a growth site (step II). Finally, either the growth unit back in the solution (phase II*), either it 
becomes part of the growth site and incorporate into the crystal lattice. Desolvation of the 
growth unit may take place anywhere in step II or the solvent may be adsorbed with the 
growth unit. The relative importance of each step depends on the surface structure of the 
crystals and the properties of the solution (MEENAN et al., 2002). 
 
Homogeneous 
Heterogeneous 
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Figure 1.19. A three-dimensional crystal surface showing three type of growth sites and 
different steps ( I, II and II*) involved in the process of growth to unit cubic. Modified from 
MERSMANN, 2001. 
 
In pharmaceutical field, particles of uniform size in a product are desirable for the 
convenience of selection of filter, washing, uniform time of dissolution and good appearance 
of product. Besides this, caking tendency of crystals during pharmaceutical form storage 
period can be prevented since number of points of contact between crystalline particles is 
significantly less in uniform crystals size. 
 Effect of supersaturation on nucleation and growth 1.3.4.
Supersaturation (see section 1.3.2) is defined as a measure of the deviation of a 
dissolved molecule from its equilibrium value (MYERSON, 1993). 
Supersaturation can have a profound effect on crystal growth, resulting in 
morphological changes in the crystallizing compound over a range of supersaturations 
(YOSHIZAKI et al., 2001; RISTIC, 2002). The variation of the ratio C/Ceq (section 1.2.3) 
enables control of particle size. In general, the number of crystals produced increases with the 
supersaturation, while the size of crystals decreases (GARNIER and COQUEREL, 2002). For 
a very high supersaturated solution, crystals nuclei are formed rapidly and may produce a vast 
quantity of small, elongated crystals over a very short timescale. In the extreme case, when 
the material is completely and fastly precipitated (larger number of nuclei produced per unit 
of time) in the form of primary particles, lacking time sufficient for crystal growth, so that 
Growth unit 
Ledge 
Step Kink 
I 
II 
II* 
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smaller crystals are obtained. If the degree of supersaturation is low, relatively few nuclei are 
formed and the growth rate is low due to the dissolution of the material. In these conditions, a 
few crystals are formed, but perfect. In this case is likely to produce larger, granular-shaped 
crystals over a longer period (HALEBLIAN, 1975). The size and habit of many crystalline 
products are particularly sensitive to degree of supersaturation (RISTIC et al., 2001). 
 Choice of solvent 1.3.5.
The manufacture of pharmaceuticals often involves crystallization from organic 
solvents or mixtures of solvents. Generally, solvents are selected based on the resulting 
solubility, the mode of crystallization and the type of crystals, but the role of solvents in 
different parts of pharmaceutical processes and some of the limitations and difficulties are 
related to their toxicity. 
Solvent can strongly affects the nucleation rate and habit of crystalline materials in 
enhancing or inhibiting crystal growth of each crystal face by its properties in solution (e.g. 
density, viscosity, diffusivity), solubility of the crystallizing species and surface-solvent 
interactions. For example, changing the solvent polarity during crystallization of ibuprofen 
provided crystals with a polyhedral crystal habit for ethanol and methanol and needlelike for 
hexane. Furthermore the results showed that crystal habit modification had a great influence 
on the mechanical properties (compressibility, flow rate, and bulk density) (GAREKANI et 
al., 2001). 
The solvent composition may also influence the aggregation properties, as well as the 
solvent incorporation of the crystals (KLUG, 1993).  
To date, although the role played by the solvent at the molecular level is still not 
completely understood (WEISSBUCH et al., 1995), two theories have been proposed 
regarding the influence of the solvent on nucleation and growth.  
In one theory, favourable interactions between solute and solvent on specific faces may 
lead to a reduction in solid-liquid interface energy. Hence, the activation energy for 
nucleation on the crystal is reduced and the crystal becomes rougher, leading to enhanced 
faster surface growth. In the second one, it has been proposed for solvent molecule interaction 
that can be strongly bound to the crystallizing compound; the preferential adsorption of 
solvent molecules at specific faces may inhibit their growth as removal of bound solvent 
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poses an additional barrier for continued growth. In the latter case, solute−solvent interactions 
at the crystal interfaces could be similar to stereospecific interaction of tailor-made impurities 
(LAHAV and LEISEROWITZ, 2001). 
1.4. LAS CRYSTALLIZATION TO IMPROVE DISSOLUTION 
PROPERTIES AND SOLUBILITY OF POORLY SOLUBLE  
DRUGS 
Considerable research efforts have been made to optimize crystals properties for 
pharmaceutical products. The complexity and variety of crystallization pharmaceutical 
processes can provoke significant changes in the crystal properties, such as their 
granulometry. 
Particle size is one of the physicochemical properties influencing the performance of the 
drug product and its manufacturability. In addition, a very strict control is needed to achieve 
particle size requirements, which is defined depending on the pharmaceutical dosage form 
prepared with the drug crystals and of its administration route (see Table 1.3). 
Table 1.3. Particle size distribution of pharmaceuticals with respect to dosage form and 
route of administration (SHEKUNOV et al., 2007). 
Dosage form or route of administration           Particle size (µm) 
 Min Max 
Oral granules  200 1000 
Oral depot  50 200 
Intraperitoneal 10 50 
Nasal  5 20 
Aerosols 1 5 
Ocular 0.1 2.5 
Intravenous/intramuscular  0.2 2 
Gene delivery  0.2 0.9 
Transdermal 0.06 0.6 
Long-circulating (brain, tumor) 0.06 0.2 
Lymphatic 0.01 0.06 
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In practice, crystal morphology is usually described in terms of length, width and 
thickness. The classifications of crystal shapes adopted by either British Standard (BS 
2955:1993) or the US Pharmacopoeia (monograph 776) (Table 1.4) are commonly used for 
routine microscopically examination of solid pharmaceutical materials. 
 
Table 1.4. Classification of common crystal morphologies for pharmaceutical solids 
accepted by the US Pharmacopoeia
Morphology Description Diagram 
Equant 
Crystal with similar 
length, width, and 
thickness 
 
Flakes Thin, flat crystals of similar width and length 
Plates 
Flat, tabular crystals 
with similar width and 
length but thicker than 
flakes 
Laths Elongated, thin and blade-like crystals 
Needles 
Acicular, thin and 
highly elongated crystals 
having similar width and 
breadth 
Columnar 
Elongated, prismatic 
crystals with greater width 
and thickness than needles 
 
Particle size control during crystallization is a challenging area, mainly for the synthesis 
of nano/microparticles (CHOW et al., 2007). As already said, the growth rates of the different 
crystal faces are determined by intermolecular interactions between molecules in the crystal 
as well as by a number of external parameters such as solvent, supersaturation, temperature, 
and impurities (MYERSON, 1999). Changes in any of these parameters may lead to 
significant modifications in crystal morphology. This gives rise to crystal habit diversity of a 
chemical entity grown under various crystallization conditions and provides the basis for 
morphological crystal engineering.  
Plate 
(tabular) 
Flake 
Equant 
Lath 
(blade) 
Columnar 
(prismatic) 
Needle 
(acicular) 
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Besides particle size, other crystal properties can be strongly modified by  
crystallization as summarized in Table 1.5.  
Table 1.5. The most important solid-state characteristics, which are affected by 
crystallization, and the influence of these properties on the stability and downstream 
processing of pharmaceutical materials. Modified from SHEKUNOV and YORK, 2000. 
Crystal properties Effect on drug substance and/or drug product 
Structural  
Crystallinity (existence of amorphous 
and semi-crystalline forms)  
 
•  
• Physical and chemical stability  
Polymorphism 
Polymorphs 
Solvates (hydrates)  
Salts  
Crystal defects 
 
• Solubility profile and dissolution rate  
• All aspects of processing 
Dimensional  
Particle size distribution  
Particle surface structure 
• Processing behavior: bulk density, 
agglomeration, flow, compaction  
• Particle permeability (i.e. particle adsorption)  
• Bioavailability (drug absorption)  
• Consistency and uniformity of the dosage form 
Chemical  
Presence of impurities, residual solvent, 
and decomposition products  
Chiral forms and chiral separation 
 
 
• Toxicity  
• Chemical, physical, and enantiomeric stability 
Mechanical  
Brittle/ductile transitions, fracture stress, 
indentation hardness, stress/strain 
relaxation, Young’s modulus 
 
 
• Milling and tableting behavior 
Electrical  
Electrostatic charge distribution 
• Agglomeration and flow properties 
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The next sections introduce LAS crystallization in the context of process design and 
what role additives currently play in LAS crystallization research. 
Previous works 1.4.1.
In recent years, many methods of particle production using LAS crystallization have 
been developed, as shown in Table 1.6. They allow a better control of the size, crystallinity, 
and morphology of particles that not achieved with top-down methods. The crystallization 
method is applicable for a wide range of pharmaceutical drugs BCS Class II and IV to prepare 
micro/nanoparticles. Decrease in particle size increases the surface area, which increases the 
solubility and dissolution rate of poorly water soluble drugs and hence bioavailability 
(LIVERSIDGE and LIVERSIDGE, 2008), as discussed befeore in the section 1.2.2.  
Table 1.6 reveals that several poorly soluble drugs are crystallized by LAS 
crystallization using different apparatus in laboratory scale like batch reactors, magnetic 
stirring, injection method and sonoreactors. The drug powders obtained in these studies 
presented particle size in a range between 0.010- 20 µm.  
It could be noted from this literature review, that the major crystallization assays were 
realized in presence of additives like surfactants (ionic or non ionic) and polymers or both. 
Since the molecules have a different orientation at the different crystal faces, the additives 
will have different effect on the growth rate of different faces. Each additive can act like a 
stabilization agent through a different mechanism; these mechanisms are a relatively less 
explored area but are important for morphologic, polymorphic and technologic screening of a 
compound during its developmental stage. Any relationship between the chemical structure of 
the stabilization agent and the chemical structure of the drug to be stabilized against growth is 
related in the literature. However the attempt of the use of stabilizers agents is actually turned 
on the changes of drug compound characteristics.  
The majority of the recrystallized drugs investigated is asymmetric drugs and do not 
posses a very large molecular structure, which facilitated the achievement of crystals with a 
reduced size, generally in presence of additives. The different aspects to controlled LAS 
crystallization will be discussed in more detail in the following sections. 
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 Control of process parameters 1.4.2.
Mixing devices  
Mixing between drug solution and anti-solvent is a critical step to maintain a constant 
level of supersaturation throughout the crystallizer, uniform nucleation and control of small 
embryo particles formed in the process (DOUROUMIS and FAHR, 2006). 
The initial contacting between the drug solution and the anti-solvent is an important 
parameter, which will influence the nucleation rate. Two different manners to bring them into 
contact are illustrated in Figure 1.20. 
Single-jet configuration is the simplest manner by which one solution is pumped into 
the stirred vessel containing the other liquid (Fig. 1.20a). Alternatively, two solutions can be 
premixed before entering the tank as a single jet (Fig. 1.20b). The two feeding configurations 
have different temporal and spatial supersaturation profiles. 
  
(a) Single-jet (b) Double-jet with premixing 
Figure 1.20. Feeding configuration for anti-solvent crystallization  
(a) single-jet, (b) double-jet with premixing. 
 
Typically, mixing is divided into three main groups: macromixing, mesomixing and 
micromixing. Macromixing is the mixing occurring on a crystallizer scale, which represents 
the uniformity of the local average of the concentrations of all the species within the entire 
crystallizer. Mesomixing is the mass transfer of a solution, also known as turbulent mixing 
and micromixing comprises the molecular diffusion and engulfment of different solvent 
composition region, which represents molecular scale mixing (BALDYGA and BOURNE, 
1989). 
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Actually, to achieve the rapid mixing the high jet velocity mixing devices have been 
described in the literature. These mixing devices are reported in the literature as static mixer, 
high gravity jet, confined impining jet, multi-inlet vortex mixer (MIVM), Y-shaped 
microchannel reactor, Y and T-mixer, Roughton mixer, as illustrate in Figure 1.21. They 
show advantages when compared to the traditional CSTR (Continuous Stirring Tank 
Reactor), such as small space requirement, low equipment cost, no power required except 
pumps, short residence times and good mixing at low shear rates (THAKUR et al., 2003). 
Because of this they have been extensively related in the literature for LAS crystallization of 
drugs. The details of such mixing devices are reported in Table 1.7. 
   
A- Roughton mixer B- Tee-mixer C- Multi-inlet vortex mixer 
   
D- Static mixer E- Y-mixer F- Confined impining jet 
G- High gravity jet  
Figure 1.21. Schematics of mixing devices used in chemical and pharmaceutical field. 
Modified from THORAT and DALVI, 2012. 
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1.5. ADDITIVES IN CRYSTALLIZATION 
Additives in crystallization processes have gained attention in recent years, 
because they can be adsorbed directly onto drug particles to produce powders with 
optimized physicochemical properties (ZIMMERMANN et al., 2009).  
It has been shown that the presence of additives in solution can affect all 
parameters of crystallization, either the solubility, the nucleation or growth, and hence 
the resulting morphology (KUBOTA et al., 2000; GARNIER et al., 2002; VETTER et 
al., 2011) and polymorphic form (CHONG et al., 2002; SONG and CÖLFEN, 2011) 
Some theories are presented in literature to describe the mechanisms of additive 
influence on crystallization process, which comprises: 
• Inhibition of nucleation by formation of hydrogen bonds between the additive 
and the molecule. This interaction inhibits or retards the formation of nucleus by 
collision and therefore the induction time period is different from that of pure 
systems (TAYLOR and ZOGRAFI, 1997);  
• Adsorbed additives on crystal surface form a mechanical barrier that prevents 
the diffusion of solute molecules from the bulk solution to the crystal surface 
(ZILLER and RUPPRECHT, 1988); 
• Additives do not inhibit nucleation, but just reduce supersaturation of the 
solution by modifying the saturation of solute. Consequently the width of the 
metastable zone is also influenced (RODRIGUEZ-HORNEDO and MURPHY, 
1999; MERSMANN, 2001); 
• Non-adsorbed additive are rejected by the crystal surface and accumulate in the 
boundary region. This creates a greater resistance to drug molecules limiting 
their diffusion through the barrier and leads to growth inhibition, as shown in 
Figure 1.22 (RAGHAVAN et al., 2001). 
 
The adsorption of additives at different sites can cause growth inhibitions, even 
block the growing surface and in consequence stop the growth process. However, the 
adsorbed impurities may simultaneously lead to a reduction in the edge free energy, 
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which results in an increase in crystal growth rate (RAK et al., 2005). For 
pharmaceutical technology, understanding of these mechanisms may help to control the 
quality and purity of raw crystalline substances and, consequently, to improve the 
manufacture and performance of the final dosage forms. 
 
Figure 1.22. Schematic diagram showing the mechanism of growth inhibition 
and habit modification of crystals by polymers. Modified from RAGHAVAN et al., 
2001. 
 Additives in LAS crystallization  1.5.1.
The stabilization and controlled crystal growth mechanism during LAS 
crystallization depend on the strength of adsorption of stabilizer molecules on the drug 
surface. Two main mechanisms have been investigated in additive screening studies on 
drug LAS recrystallization: steric stabilization and electrostatic repulsion (WU et al., 
2011; THORAT and DALVI, 2012), as illustrated in Figure 1.23. 
Each mechanism has its benefits for particulate systems. The stabilization 
mechanisms used in LAS crystallization, described in the literature, are summarized in 
Table 1.6. 
In the case of steric stabilization, non ionic surfactants, polymers and amphiphilic 
block copolymers are usually used (MATTEUCCI et al., 2008; KUMAR et al., 2009; ). 
Drug molecule 
Additive (polymer) 
C
rystal 
Diffusional boundary layer 
Liquid 
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Block copolymers are particularly well suited for steric stabilization, as they can 
provide a high degree of coverage with strong adsorption while still having extended 
tails which interact favorably with the medium (BUDIJONO et al., 2010). 
 
 
Steric stabilization Electrostatic stabilization 
Figure 1.23. Types of colloidal stabilization. Modified from WU et al., 2011. 
 
Stabilization by steric mechanism is achieved by attaching of hydrophobic group 
of the drug and polymer. The resulting polymer layer masks the attractive force and also 
provides a repulsive force. There are several mechanisms proposed in the literature for 
steric stabilization as discussed below: 
• Drug-polymer interaction: The interaction between polymers and particle 
surface has been extensively studied for decades due to its wide application. The 
adsorption properties of stabilizers can be affected by  the nature of stabilizer and drug 
surface, for example molecular weight is an important factor for polymeric 
stabilizers. The chain length should be high enough, so that polymers chain have an 
optimum length to overcome the Van der Waals forces of attraction (PELTONEN and 
HIRVONEN, 2010). Furthermore, another important factor is the size of the polymer. 
The polymer’s chain was divided into three sub-types: trains, loops and tails. (as shown 
in Figure 1.24). Trains are all contacted (adsorbed) with the particle surface. Loops are 
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not in contact with the particle surface, but connect with two trains. Tails are non-
adsorbing chain ends. The portion of polymer chain in solution provides the steric 
protection depending on molecular weight of polymer (NAPPER, 1983). 
 
 
Figure 1.24. Schematic illustration of adsorbed polymer layer. From NYLANDE 
et al., 2006. 
Apart the size and the molecular weight the effect of polymer concentration is an 
important aspect to be considered. For polymer concentration, there is a maximum 
value full coverage of surface, or saturated adsorption (SCHOTT,1980;  
OTSUBO,2003) concentration with free polymer in the dispersion medium, above a 
critical volume fraction of polymer in solution. This phenomenon is called depletion 
flocculation. This one occurs when the distance separating two colloidal particles is too 
small to admit the presence of polymer coils in solution. They are forced out of the 
space in between, resulting in an osmotic pressure difference between the area in 
between the particles and the rest of the bulk solution. As a result, an attractive force is 
generated which pushes the particles together, leading to agglomeration. (OTSUBO, 
2003). 
Another such mechanism is the formation of hydrogen bond between the 
stabilizer molecule and the particle surface. Some functional groups in polymers, such 
as carboxyl, hydroxyl, amine, and ester group play an important role in the steric 
stabilization. These functional groups can interact with the particle surface and act as 
good anchors (SHI, 2002) 
The adsorption of polymer on crystal surface can occur as a result of forces as 
those arising from hydrophobic interactions. It has been observed that these 
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hydrophobic interactions can enhance the stability by occupying the adsorption sites and 
inhibiting the incorporation of drug molecules in solution in crystal lattice 
(RAGHAVAN et al., 2001). 
Actually in the literature there are a lot of reports that describe the use of block 
co-polymers for stabilization of crystals obtained by LAS crystallization. Hydrophobic 
part of block copolymers gets anchored on the hydrophobic drug surface and 
hydrophilic chains extend in solution. Depending on the solvent quality, affinity of the 
chain monomers to the surface and crowding conditions on the surface, the 
conformation of polymer chains on a surface can be rather different. Chain exists as 
isolated free coils in solution, also called the “mushroom” regime (Figure1.25 A). In 
this case, chain will lay almost flat on the surface. When more block copolymer is 
attached the chains will extend perpendicularly to the hydrophobic surface, called “semi 
brush”(Figure 1.25B). When the surface gets more crowded, the chains will start to 
mutually interact, eventually resulting in a stretching of the individual chains away from 
the surface leading to a so-called “brush” formation (Figure 1.25C). This state is the 
result of a balance, where at full equilibrium the free energy of the stretched chain 
balances the interfacial energy of the solvent–particle surface (S.J. BUDIJONO et 
al.,2010). 
(a) (b) (c) 
Figure 1.25. Different conformations of polymers at surfaces: (a) mushrooms 
conformation of a single adsorbed, where chains are non-interacting on the surface and 
achieve a size given by the polymer (b) semi-brush where crowding among chains 
causes extension of the chain from the surface, and (c) brush conformation for high 
grafting densities, leading to extension of the chains away from the surface. Modified 
from J. BUDIJONO et al., 2010. 
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The use of block co-polymers play a key role in both halting particle growth and 
stabilizing particle suspensions during rapid LAS crystallization. Its use as stabilization 
agent has been reported for LAS crystallization of Itraconazole, Odanacatib (KUMAR 
et al., 2009), ß-carotene (JOHNSON and PRUD'HOMME, 2003 ; J. BUDIJONO et 
al.,2010 ; SHEN et al., 2011 ; CAPRETTO et al., 2012). According to these reports, 
with a rapid change in solvent conditions, the drug and polymer precipitate, the polymer 
assembling around the drug. The particle size is controlled by the polymer concentration 
and the mixing time. 
• Solvent-polymer interactions: Solvent-polymer affinity is a very important factor 
in steric stabilization. Choi et al. (2002) have shown that solvent–polymer interaction is 
very important for the effective formation of nanoparticles. Choi et al. (2002) obtained 
PLGA using different solvents (ethyl acetate, methyl ethyl ketone, propylene carbonate, 
and benzyl alcohol). Ethyl acetate solvent formed the smallest nanospheres (approx. 120 
nm in size). In this case, the authors suggest that solvents with low exchange ratio 
between diffusion from solvent to water and vice versa, form small nanoparticles due to 
small supersaturation region produced.  
• Drug-polymer-solvent interaction: The polarity of the solvent can affect the 
relative diffusion rates of polymer and drug molecules towards the solid–liquid 
interface. It has been also reported that slower diffusion of API molecules and relatively 
quick adsorption of stabilizer molecules on particle surface leads to inhibition of growth 
and hence, smaller particle size (THORAT and DALVI, 2012). 
In electrostatic stabilization ionic surfactants and polymers are usually used to 
prevent aggregation and have stable crystalline particles. The ions in solution adsorb 
onto the surface of a particle and the substances acquire surface electrical charges when 
brought in contact with a polar medium. The surface charge influences the spatial 
distribution of ions or molecules in the surrounding solution, attracting ions of opposite 
charge but repelling ions of similar charge from the surface. 
The electrostatic stabilization depends on DLVO theory (DERJAGUIN and 
LANDAU, 1941 ; VERWEY and OVERBEEK in 1948) i.e. repulsive electrostatic 
forces and attractive Van der Waals forces. Therefore, electrostatic stabilization of 
dispersion occurs when the electrostatic repulsive force overcomes the attractive Van 
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der Waals forces between the particles (WU et al., 2011). Due to the charge on particle 
surface, there exists a double layer surrounding the particle surface. This double layer is 
referred as electric double layer (GRAHAME, 1947). There exists a potential difference 
between bulk of solution and the outer layer of double layer which is called zeta 
potential. The magnitude of the zeta potential gives an indication of the potential 
stability of the colloidal system. The zeta potential is a measure of the stabilization 
provided by electrostatic stabilization. If all the particles in suspension have a large 
negative or positive zeta potential (>±30 mV) then they will tend to repel each other, 
i.e. good suspension stability. 
Surfactants can provide stabilization at concentrations below critical micelle 
concentration (CMC). When concentration is increased above the CMC, the number of 
micelles increases leaving the particles unprotected (WU et al., 2011 ; THORAT and 
DALVI, 2012). In the order hand, some literature reports have focused on beneficial 
effects of additives, which have the capacity to form micelles, above the CMC. For 
example, Santander-Ortega et al., (2006) observed a variety of stabilization mechanisms 
for the Pluronic-coated PLGA nanoparticles. These complexes were completely stable 
by adding poloxamer at concentrations above the CMC, The explanation was the 
formation of surface aggregates that gives a highly enriched polymer layer 
concentration.  
The synergistic effects of a neutral polymer and an ionic surfactant together can 
enhance the stabilization effect. This synergistic behavior is typically brought about by 
the interaction between different types of stabilizing molecules, which provides a 
driving force for the mixtures to form mixed aggregates or structures. However, the 
ability of synergistically stabilizing depends on the pair of stabilizers used. Hu et al. 
(2011) observed the synergistic effect of Sodium dodecyl sulfate (SDS) and 
hydroxylpropyl methyl cellulose (HPMC) E3, such as an effective system to retain the 
particles of fenofibrate within the nanosized range by minimizing particle aggregation. 
Actually both steric and electrostatic stabilizing agent (polyelectrolytes) have been 
studied in the literature (ZHU et al., 2010 ; PATTEKARI et al., 2011 . They form a 
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strong double layer around hydrophobic drug particle and, adsorbs loosely, the 
extending polymer loops provide the steric stabilization, if the polyelectrolyte adsorbs 
on particle surface. Chitosan can be cited as an example. The chitosan is a cationic 
polyelectrolyte of natural origin. Furthermore, chitosan is physiologically safe. It can be 
biodegraded by several human enzymes. It is inexpensive and approved as a safe 
dietary. The properties of chitosan include the ability to adhere to mucosal layers, due to 
the electrostatic interaction with negatively charged mucus. This makes chitosan 
especially useful for poorly water soluble drug delivery and targeting (ZHU et al., 
2010 ). 
Finally, it has been shown that additives can increase their dissolution rate by 
increasing aqueous wettability of LAS recrystallized drugs of (SRITAPUNYA et al., 
2012). This ability of additives will permit the gastrointestinal fluids to wet more 
effectively and to come into more intimate contact with the solid dosage forms, which 
will tend to increase the dissolution and absorption rates of the drugs (BUCH et al., 
2011 ; SAHARAN and CHOUDHURY, 2012). 
It has been reported in the literature, that poloxamer 407 (P-407) has improved 
significantly the dissolution of poorly water soluble drugs (DUMORTIER et al., 2006 ; 
VIKRANT et al., 2009 ; CHOWDARY and ANNAMMA, 2012). P-407 is characterized 
by its highest hydrophilicity and surfactant property, that results in greater wetting and 
increases the surface available to dissolution by reducing interfacial tension between the 
hydrophobic drug and dissolution medium (VIKRANT et al., 2009). 
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1.6. THESIS OVERVIEW 
This Chapter reviewed the literature about the improvement of bioavailability of 
poorly water soluble drugs. It focuses on topics of interest for our work, like properties 
of drugs influencing dissolution behaviour, technologies to enhance dissolution rate and 
solubility of this category of drugs. Emphasis was given to the LAS crystallization 
process.  
An overview of the literature on LAS crystallization summarized the main results 
of previous works. The main points to be highlighted are: 
• Till now, several poorly water soluble drugs have been micronized by 
various particle formation processes for particle size and morphology but the 
main challenges are the control of particle size distribution and particle 
growth.  
• The continuous production of recrystallized drug particles can be achieved 
by using rapid mixing devices such as impinging jets and static mixers, 
among others. Moreover, polymers and surfactants are used in most cases for 
prevent crystal growth and/or agglomeration. However, the selection of 
correct stabilizers for the LAS crystallization of a given drug is of crucial 
importance.  
This chapter concludes with a statement of research objectives:  
LAS crystallization is used for particle formation of a new antiretroviral drug 
named CRS 74. The objective is to enhance dissolution properties by reducing particle 
size of an original (as-received) sample from industry.  
To generate high mixing rates and help in generating rapid and uniform 
supersaturation, rapid mixers are used (T-mixer, Roughton mixer). 
The best conditions for LAS crystallization of this new molecule are defined 
through solubility studies, dissolution method development and screening of LAS 
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crystallization process parameters such as ratio between drug solution and anti-solvent 
and additive screening study. 
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Résumé Chapitre 2- Caractérisation du CRS 74 
Cette étude porte sur un nouveau composé, l'acide (2S, 3S, 5S) -2, -5 bis-[N-[N-
[[N-méthyl-N-[(2-isopropyl-4 - tiazolyl) méthyl] amino] carbonyl ] vanilyl] amino-1,6 - 
diphényl-3 - hydroxyhexane, nommée par la suite CRS 74. Ce principe actif possède 
une activité de l’inhibition du VIH (virus de l'immunodéficience humaine) protéase, une 
enzyme essentielle impliquée dans le processus de réplication du VIH. 
Dans la première partie de notre étude, cette molécule a été caractérisée sous 
forme solide en terme de faciès et de taille de particules, de structure cristalline, de 
mouillabilité, de solubilité en milieu aqueux à 37 ° C. Un test de dissolution a été 
développé en milieu aqueux à 37 °C afin de déterminer les profils de libération de la 
poudre initiale et des poudres synthétisées, car ce test n’existait pas dans le littérature.  
Cette molécule sous forme solide a une solubilité aqueuse limitée (<0.5µg/mL), 
qui peut être expliqué par sa cristallinité, son point de fusion et son enthalpie de fusion 
élevés (188,6 °C et 86,6 J/g). Elle présente aussi un faible taux de dissolution dans l’eau 
pouvant être liée à sa large distribution granulométrique, sa faible solubilité et sa 
mouillabilité très faible (θ = 136,4 ± 0,8 °).  
Afin d’améliorer son taux de dissolution une opération de cristallisation par effet 
anti-solvant a été proposée afin d’augmenter sa surface spécifique et améliorer sa 
mouillabilité. 
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2.1. INTRODUCTION 
In the first part of our study, the selected molecule (as-received) was characterized 
in terms of their physical properties (particle shape and size), crystal structure, surface 
properties (wettability), solubility and dissolution properties in aqueous media at 37°C. 
The methodology used and the results obtained are summarized in this Chapter. 
 The molecule: CRS 74 2.1.1.
This study concerns a new compound, (2S, 3S, 5S)-2, -5 bis- [N-[N-[[N- methyl- 
N-[(2-isopropyl- 4- tiazolyl) methyl] amino] carbonyl] vanilyl] amino- 1,6- diphenyl- 3- 
hydroxyhexane, named CRS 74. Its chemical formula is C46H66N8O5S2 and its 
molecular weight 875.2 g/mol. Its molecular structure is shown in Figure 2.1. It is 
obtained as courtesy from Cristália Ltda (Itapira, SP, Brazil). The drug samples have a 
purity of 99 %. 
 
(a) CRS 74 - (2S, 3S, 5S)-2, -5 bis- [N-[N-[[N- methyl- N-[(2-isopropyl- 4- tiazolyl) 
methyl] amino] carbonyl] vanilyl] amino- 1,6- diphenyl- 3- hydroxyhexane, is disclosed at 
PCT document number WO 20005/111006; US 2010/7763733 (BOCKELMANN et al., 
2005; BOCKELMANN et al., 2010). 
 
(b) RITONAVIR - (2S, 3S, 5S)-5-[N-[N-[[N-methyl-N-[(2- isopropyl-4-thiazolyl) 
methyl] amino] carbonyl] vanilyl] amino- 2- [N [(5-thiazolyl) methoxycarbonyl] amino-1,6-
diphenyl-3-hydroxyhexane, is disclosed at PCT document number WO 94/14436 (KEMPF 
et al., 1994). 
Figure 2.1. Chemical structures of (a) CRS 74 and (b) Ritonavir. 
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This compound can be prepared by methods disclosed in PCT document WO 
111006 and US 7763733 (BOCKELMANN et al., 2005; BOCKELMANN et al., 2010) 
following the scheme shown on Figure 2.2. In a general way, the compound (4) can be 
obtained by coupling the compound (1) and (2), wherein Y can be OH or an activate 
ester group and P is a N-protective group, to the formation of (3) following the N-
deprotection. Finally the compound (4) is coupled to the compound (5) wherein Z can 
be OH or an activate ester group to provide the analogous compound (6). 
 
Figure 2.2. Schematic synthesis of CRS 74 (BOCKELMANN et al., 2005; 
BOCKELMANN et al., 2010). 
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CRS 74 has activity for inhibiting HIV (Human immunodeficiency virus) 
protease, an essential enzyme involved in HIV replication process (see Appendix I). 
Consequently, this new compound can be used for the treatment of HIV infections, 
itself or in combination with other anti-HIV medicines.  
CRS 74 is an analogous compound of Ritonavir, an important antiretroviral drug 
developed and patented by Abbot Laboratories (WO 94/14436; KEMPF et al., 1994.). 
The chemical structure of Ritonavir can be compared to that of CRS 74 in Figure 2.1 
and their physicochemical properties in Table 2.1.
Table 2.1. Physicochemical properties of Ritonavir and its analogous compound 
CRS 74 . 
Drug identification 
Name of the drug  
 
Ritonavir CRS 74 
Molecular formula 
 
C37H48N6O5S21 C46H66N8O5S23 
Molecular weight (g/mol) 
 
7211 875.23 
Innovator 
 
Abbot Laboratories (USA) Cristalia Laboratories (BR) 
Therapeutic category HIV protease inhibitor HIV protease inhibitor 
Physicochemical properties 
Melting point (°C) 
 
122-124 2 180-1853 
Polymorphism 
 
Form I and II4 * 
Description 
 
 
white or almost white 
powder1 
white powder3 
Solubility Soluble in ethanol, 
methanol, sparingly soluble 
in acetone R and very 
slightly soluble in 
acetonitrile and insoluble in 
water 1 
* 
*Data not determined 
1-The International Pharmacopoeia. Fourth edition, 2011. 
2-ALENCAR et al., 2006. 
3- Patent WO 2005/111006 and US 7763733 (BOCKELMANN et al, 2005 ; BOCKELMANN et al., 2010)  
4-BAUER et al., 2001 
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To date, there are some ambiguities regarding the BCS of Ritonavir. This 
molecule has been classified as a molecule belonging to Class II (WU and BENET, 
2005; SINHA et al., 2010) or Class IV (HERMAN et al., 1989; WILLIAMS and 
SINKO, 1999;  LINDENBERG et al., 2004; GOYAL and VAVIA, 2012) of the 
Biopharmaceutical Classification System (AMIDON et al., 1995).  
Published data have shown that Ritonavir presents crystalline polymorphism 
(BAUER et al., 2001). Crystalline polymorphism, or the ability of a compound to exist 
in multiple solid-state structures, has significant impact on the physical properties, 
performance, and safety of an active pharmaceutical ingredient (API) and its formulated 
product(s). From the discovery of Ritonavir until the new drug application (NDA) 
filing, only one crystalline form was known to exist (Form I). Attempts to identify other 
possible crystal forms were unsuccessful. Ritonavir is marketed as Norvir. Two years 
after the launch of Norvir to the market, some lots of Norvir capsules failed a 
dissolution specification. Investigation of this phenomenum revealed the existence of a 
crystal form of Ritonavir other than the one already known (Form I). This new crystal 
form was designated as Form II. The two crystal forms are polymorphs and differ 
substantially in their physical properties such as solubility, as given in Table 2.2. 
Table 2.2. Solubility of Ritonavir polymorphs at 5°C in hydroalcoholic solvent 
systems (CHEMBURKAR et al., 2000). 
Ethanol/water (w/w) 100/0  75/25
Form I (mg/mL) 90 170
Form II (mg/mL) 19 30
 
The key challenge of this antiviral drug present on the Market is still drug 
reformulation to modify its bioavailability and pharmacokinetics. Improving 
bioavailability of Ritonavir (in most case, solubility) is a subject of current interest as 
confirmed by numerous research works in the last decade, among them: 
• Nanonization by wet milling, homogenization or sonication (BALKUNDI et al, 
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2011); 
• Prodrug synthesis (HAMADA et al., 2002). A prodrug is a drug that is 
administered in an inactive (or significantly less active) form. Once 
administered, the prodrug is metabolised in vivo into an active metabolite; 
• Inclusion complexes with cyclodextrins and surfactants (GOYAL and VAVIA, 
2012; CHOWDARY et al., 2012); 
• Solid Dispersions (LAW et al., 2004 ; SINHA et al., 2010; MUSLE, 2012); 
• Micro/nano-encapsulation in polymeric micelles (BORGMANN et al., 2011); 
• Self-emulsifying drug delivery systems (SEEDS) (LEI et al., 2010). 
One of the requirements for a drug to be considered suitable for a therapeutic 
usage is its therapeutic efficacy, so, to achieve such requirement, the drug should 
present adequate characteristics of bio-absorption and bioavailability. CRS 74 has high 
biological activity as disclosed at PCT document WO 111006 and US 7763733 
(BOCKELMANN et al, 2005; BOCKELMANN et al., 2010, respectively) but is 
bioavailability is limited because of its low aqueous solubility and dissolution rate. Such 
properties pose difficulties not only in the design of pharmaceutical formulations but 
may result in bio-variability. 
2.2. CHARACTERIZATION OF CRS 74 
 Methods 2.2.1.
Samples of CRS 74 were characterized as received by using different instrument 
and measurement techniques that will be described in the following.  
2.2.1.1. Particle size measurement 
Mean particle size and particle-size distribution are the most important parameters 
in designing a novel formulation and are routinely the first to be measured.  Particle size 
distribution of the powder samples was determined by laser diffractometry. The 
technique of laser diffraction is based on the principle that particles passing through a 
laser beam will scatter light at an angle that is directly related to their size: large 
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particles scatter at low angles, whereas small particles scatter at high angles. The laser 
diffraction is accurately described by the Fraunhofer approximation and the Mie theory, 
with the assumption of spherical particle morphology.  
The equipment used for the measurements was a MasterSizer 3000 laser 
granulometer (Malvern Instruments, United Kingdom), which has a reading range of 
0.1-3500 μm. All the dry samples were firstly mixed with Tween 20 and then dispersed 
in water until achieve the good obscuration. The laser diffraction data obtained were 
evaluated using the volume distribution diameters dv10%, dv50% and dv90%. The diameter 
values 10% to 90% indicate the percentage of particles possessing a diameter equal or 
lower than the given size value. 
2.2.1.2. Density measurement 
In this work, the true densities of CRS 74 powder sample (0.9282 g) was 
determined using a helium pycnometer (Accupyc 1330, Micromeritics, UK) that was 
operated according to the manufacturer’s recommended procedures. Calibration was 
performed using standard stainless steel spheres of known mass and volume. The 
sample was used as they were received from the supplier. Mean values and standard 
deviations were determined from 25 successive measurements. 
2.2.1.3. Thermal Analysis 
Thermal analysis of the CRS 74 powder was performed to characterize the 
properties of this material as they change with temperature. Two different thermal 
techniques were employed here distinguished by the property which is measured: mass 
loss by thermogravimetric analysis (TGA) and enthalpy of transition (melting, 
crystallization) by differential scanning calorimetry (DSC). 
 Thermogravimetric Analysis (TGA)  2.2.1.3.1.
Thermogravimetric Analysis (TGA) measures the amount and rate of change in 
the weight of a material as a function of temperature or time in a controlled atmosphere. 
The technique can characterize materials that exhibit weight loss or gain due to 
decomposition, oxidation, or desolvatation (dehydration). Measurements were 
conducted here to predict the thermal stability of CRS 74 at temperatures up to 300°C. 
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Thermogravimetric analysis (TGA) of original CRS 74 crystals was performed by a 
thermogravimetric analyser TG-DSC 111 (SETARAM, France). The dynamic 
thermogravimetric curve was recorded with a mass of sample of around 5 mg packed in 
aluminium cell under a dynamic nitrogen atmosphere (50 mL.min-1). The experiments 
were run from 20 to 300˚C at a heating rate of 10˚C /min. 
 Differential scanning calorimetric analysis (DSC) 2.2.1.3.2.
Differential scanning calorimetric (DSC) is based upon the detection of changes 
in the heat content (enthalpy) or the specific heat of a sample at a certain temperature. 
As thermal energy is supplied to the sample, its enthalpy increases and its temperature 
rises by an amount determined for a given energy input by the specific heat of the 
sample. The specific heat of a material changes slowly with temperature in a particular 
physical state, but alters discontinuously at a change of state. As well as increasing the 
sample temperature, the supply of thermal energy may induce physical or chemical 
processes in the sample, e.g. melting or decomposition, accompanied by a change in 
enthalpy, the latent heat of fusion, heat of reaction etc. Such enthalpy changes may be 
detected by thermal analysis and related to the processes occurring in the sample (GILL, 
1984). 
DSC measurements were carried out using a DSC-Q200 thermal analyzer (TA 
Instruments, France) in a temperature range of 20 to 210°C at a heating rate of 
10°C/min under nitrogen atmosphere (50 mL.min-1). The samples (about 3 mg) were 
placed in a hermetically closed aluminium pan. The transition temperature and the 
enthalpy of fusion (ΔHt ) were calculated using the DSC software. 
2.2.1.4. X-Ray Diffraction Analysis (XRD) 
X-ray diffraction is based on constructive interference of monochromatic X-rays 
and a crystalline sample. These X-rays are generated by a cathode ray tube, filtered to 
produce monochromatic radiation, collimated to concentrate, and directed toward the 
sample. The interaction of the incident rays with the sample produces constructive 
interference (and a diffracted ray) when conditions satisfy Bragg's Law (nλ=2d sin θ). 
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These diffracted X-rays are then detected, processed and counted. Conversion of the 
diffraction peaks to d-spacing allows identification of the material. 
X-rays diffraction patterns (diffractograms) can be used to confirm the crystalline 
nature of a sample. Therefore, this information is used to verify whether the substances 
are amorphous, partially amorphous crystalline or fully crystalline (MAULUDIN, 2008) 
as well as the polymorphic form being present. A powder X-ray diffractometer 
(XPERT,Philips) was used here for diffraction studies. X-ray diffraction analysis was 
conducted with CuKα radiation at a scanning rate of 1.228°/min from 5 to 30°, applying 
40 kV at 30 mA. 
2.2.1.5. Scanning electron microscopy analysis (SEM) 
The surface morphology of powder samples was viewed under a scanning 
electron microscope (ESEM, FEG, Philips) operated at an excitation voltage of 20 kV. 
The powder samples were fixed on an SEM stub using double-sided adhesive tape and 
sputter coated with platinum at 50 mA for 6 min using an ion sputter (SC7640, 
Polaron), before analysis. 
The principle of this technique consists in the emission of primary electrons. Once 
they reach the sample surface, they interact with the atoms of the material, giving rise to 
secondary electrons, backscattered electrons and photons. The number of electrons 
emitted varies according to the geometry and other properties of the sample. These 
electrons are collected by a detector, producing image. 
2.2.1.6. Contact angle measurement (sessile drop method) 
Contact angles (θ) of water on drug substrates were measured by the sessile drop 
method using a Contact Angle Measuring Instrument DSA30E (Kruss Instruments, 
France). This method of contact angle measurement uses optics to measure the angle of 
a drop sitting level on a surface. The drop shape is recorded with a high speed framing 
camera, images are then processed by a computer and stored. The camera determines a 
baseline, forms a line around the drop, and calculates the contact angle. The powder 
sample was placed on the sample holder. A 5 µL droplet of the liquid probe (deionized 
water) was placed on the sample surface and the image of the drop was captured by a 
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CCD digital video camera. All measurements were performed in air under ambient 
conditions and the reported values are an average of at least three measurements for 
each experiment. 
2.2.1.7. In Vitro Dissolution Testing 
 Defining the operating conditions for in vitro dissolution 2.2.1.7.1.
To date, there is no published dissolution test for the evaluation of in vitro release 
profiles of CRS 74 from immediate-release solid oral dosage forms (powders for 
example). To study the dissolution properties of the CRS 74 powder sample, this part of 
the work was planned with the following objectives: 
1. To develop and validate a dissolution methodology for this newer 
antiretroviral drug; 
2. To estimate antiretroviral drugs by HPLC method. 
A dissolution tester DT 60 (ERWEKA, Germany) was used in this study. A 
schematic diagram of the type II dissolution apparatus is shown in Figure 2.3, where 
paddle was used as the source of agitation (the paddle method). 
Three different dissolution media (pH 6.8 phosphate buffer, 0.1 M hydrochloric 
acid and deionized water) without additives were tested to find the best conditions to 
evaluate the drug dissolution rate. From preliminary experiments whose results will be 
shown in the section 2.3.6, the selected medium was 0.1 M HCl. 
Three different rotation speeds were tested before setting a rotation speed of 75 
rpm for the CRS 74 dissolution study (no enough powder dispersion in the medium at 
50 rpm; no additional effect on powder dispersion at 100 rpm). In the following, 
experiments were carried out using 30 mg of the reference product (as received CRS 74) 
in 900 g of 0.1 M HCl at 75 rpm and 37.0 ± 0.5°C. Two milliliters samples were 
withdrawn at specific intervals. The samples were filtered through a 0.22 µm filter 
before the injection (20 µL) into the HPLC system (Agilent 1100 Series) for evaluate 
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the amount of CRS 74 dissolved. The sample volume taken was not replaced by fresh 
dissolution medium to prevent any possible interference with the chemical equilibrium. 
 
 
Figure 2.3. Schematic diagram of Apparatus II (Paddle Apparatus):D: vessel diameter; 
h: paddle width, c: distance between the paddle and the vessel bottom, H: liquid height 
into the vessel. 
 
 High Performance Liquid Chromatography (HPLC) to determine the 2.2.1.7.2.
content of the dissolved drug 
Dissolved drug in dissolution media was determined by high performance liquid 
chromatography (HPLC). This technique utilizes different types of stationary phases 
contained in columns, a pump that moves the mobile phase and sample components 
through the column and a detector capable of providing characteristic retention times for 
the sample components and area counts reflecting the amount of each analyte passing 
through a detector (Figure 2.4).  
The HPLC system consists of an Agilent chromatograph (Model 1100 series) 
equipped with a UV-vis detector. There are several parameters that quantitatively 
measure how well a HPLC column separates the components of interest. These 
Thermostated bath- 37°C 
C
D 
h 
H 
D= 10.5 cm 
c= 2.85 cm 
h= 6.5 cm 
H= 11.7 cm 
0.1M HCl 
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parameters will vary based on the dimension of the column, type of column, type of 
mobile phase or stationary phase used, and HPLC instrument. The different HPLC 
conditions tested during our method development were shown in Table 2.3. The mobile 
phase was chosen after several trials with acetonitrile, methanol and phosphate buffer 
pH 4.0 in different volume proportions. Finally, a mobile phase consisting of 
acetonitrile/water (50:50) in an isocratic mode was selected to achieve maximum 
separation. 
 
Figure 2.4. Schematic representation of a High Performance Liquid 
Chromatography system.  
 
Flow rates were arranged between 0.8 and 1.3 mL/min (Table 2.3). A flow rate 
of 1.0 mL/min gave an optimum signal/noise ratio with a reasonable separation time (10 
min) between the analyte peak and dissolution media peak. After comparison between 
the different columns shown in Table 2.3 such as C8 Prontosil 100 mm x 4.6 mm, 5µm, 
C8 Prontosil 250 mm x 4.6 mm, 5 µm and C18 Prontosil 250 mm x 4.6 mm, 5 µm, the 
Solvent 
(Mobile Phase) 
Reservoir            
Pump Solvent Manager  
Solvent Delivery Ssytem           
Injector  
Auto Sampler 
Sample Manager  
Sample 
HPMC Column 
Packing Material 
Detector  
Computer Data Station  
Waste  
Chromatograms  
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best separation efficiency was obtained using ProntoSIL 120-5 C8 SH, 150 x 4.0 mm 
column. 
The retention time, i.e., the time taken for CRS 74 molecule to reach the detector 
once it has been injected into the system, was observed to be 12 min. UV spectrum – of 
CRS 74 showed maximum absorption at 210 nm; therefore, the compounds were 
monitored at this wavelength. In summary the best conditions were set to the HPLC 
analyses: the elution was done using a mobile phase consisting of acetonitrile/water in 
the ratio of 50:50 on HPLC column ProntoSIL 120-5 C8 SH, 150 x 4.0 mm ID, at a 
flow rate of 1.0 mLmin-1 with UV detection at 210 nm. Each experiment was carried out 
in quadruplicate. 
There is no monograph of this drug in any pharmacopoeia. After setting the HPLC 
parameters for analysis, the HPLC quantification method was developed for the 
quantification of CRS 74 concentrations and two validation parameters were tested 
through specificity and linearity.  
Specificity of the method was determined by analyzing the dissolution media with 
and without the standard substance to verify the interference of the eluent in the CRS 74 
concentration measurements. To assess the linearity of the method, seven calibration 
standard solutions of CRS 74 dissolved in 0.1 M HCl were prepared over the 
concentration range of 13- 289 µg/gsolution. The calculation of regression line was carried 
out by plotting the peak area against standard concentration.  
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Table 2.3. Different HPLC parameters tested during the HPLC method 
development. 
Column Mobile phase (volume %) 
Flow rate 
(mL/min) 
Volume 
injection 
(µL) 
C8 PRONTOSIL 
100mmx4.6mm, 
5µm 
 
ACN: 50% ; PB : 40% ; MeOH : 
10% 
1.3  10  
C8 PRONTOSIL 
250mmx4.6mm, 
5µm 
 
ACN : 50% ; PB : 40% ; MeOH : 
10% 
1.0  
10  
0.8  
ACN : 50% ; PB : 50% 
1.0  20  
0.8  
ACN : 30% ; PB: 70% 0.8  20 
ACN: 50%; PB: 40% ; MeOH: 10% 
 
1.0  10 
C18 PRONTOSIL 
250mmx4.6mm, 
5µm 
 
ACN : 50% ; PB: 30% ; MeOH : 
20% 
 
1.0  
 
10  
 
ACN : 60% ; PB: 30% ; MeOH : 
10% 
 
1.3   
10  
1.0 
Prontosil 300-5-
ODSH, 5µm 
ACN : 70 % ; Pure water : 30% 1.0 20 
ProntoSIL 120-5 C8 
SH, 150 x 4.0 mm, 
5µm 
ACN : 50 % ; Pure water : 50% 1.0 20 
ACN: Acetonitrile;  PB: Phosphate buffer ; MeOH: Methanol. 
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The obtained results in HPLC analysis were used to calculate the percentage 
dissolved at each time of dissolution profile. The cumulative percentage of dissolved 
drug was plotted against time, in order to obtain the dissolution profile and to calculate 
the in vitro dissolution data, using the equation (2.1). 
 (2.1) 
 
where Absstd is the absorbance of the standard solution containing the original CRS 74 
100% dissolved, Abssample the absorbance of the sample during the dissolution essay as a 
function of time and StdPurity (%) the purity of the raw material, provided by the 
supplier. 
Drug solubility in dissolution media 2.2.1.7.3.
The solubility of CRS 74 was determined by equilibrating an excess of CRS 74 in 
5g of 0.1 M HCl at 37°C ± 0.5°C in a temperature-controlled bath for 24 h (Figure 2.5). 
 
Figure 2.5. Experimental setup for solubility measurements. 
 
The flasks were sealed for the duration of the tests and the concentration was 
determined by removing the solid phase by filtration (0.22 µm pore size) and injection 
of the filtered solution into the HPLC system to be analyzed at wavelength of 210 nm.  
The HPLC parameters were already presented in the methodology. 
Dissolved  Drug (%) = Abssample
Absstd
 StdPurity(%)
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2.3. RESULTS AND DISCUSSION 
 Particle size, true density and morphology 2.3.1.
The particle size distribution is shown in Figure 2.6. Laser diffractometry yields 
the volume-weighted diameters. Particle size analysis values of dv90% dv50% and dv10% 
were 515 µm, 101 µm and 4.3 µm, respectively. The broad particle size distribution 
exhibited by the original drug powder is confirmed by the SEM micrographs (Figure 
2.7). 
 
Figure 2.6. Particle size distribution for as-received CRS 74 powder sample.  
 
In addition, the SEM images at a higher magnification showed that the original 
CRS 74 sample consisted of columnar crystals that were several micrometers long 
(Figure 2.7 (b)). SEM images show the presence of agglomerates of small columnar 
crystals (Fig 2.7 (a)) 
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(a) (b) 
Figure 2.7. SEM micrographs of the original CRS 74. 
 
 Density 2.3.2.
The powder had a true density of 1.2295 ± 0.0205 g/cm3 when analyzed using 
helium pycnometry. 
 
 XRD analysis 2.3.3.
XRD analysis was performed to detect the changes in the physical state and 
crystalline phases of the drug, before and after LAS crystallization. Figure 2.8 shows 
the XRD patterns for the as-received powder sample. CRS 74 shows peaks at 
approximately 8.5, 14, 16.9, 18.7, 19.4 and 21.3°, indicating that the drug was a 
crystalline powder.  
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Figure 2.8.  X-Ray diffractograms of the as-received CRS 74 sample. 
 
 TGA and DSC analysis 2.3.4.
Thermogravimetric analysis (TGA) was used in this study to determine the 
thermal stability of CRS 74 by monitoring the weight change that occurred as the 
sample was heated. From TGA data (Figure 2.9) it was observed that the drug becomes 
thermally unstable from 215°C. Mass loss and a large peak were observed respectively 
on the mass loss and on the heat flow at 242oC. This endothermic peak was observed in 
an only one step. It probably characterizes the degradation of the drug. For this reason, 
in the following, DSC analyses were carried out between 20 and 210°C to avoid the 
drug thermal degradation. 
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Figure 2.9. TGA-DSC curve of CRS 74 run in a nitrogen atmosphere and heating 
rate of 10°C/min. 
 
The DSC thermograms of CRS 74 powder, is presented in Figure 2.10. During the 
heating-cooling cycle it was observed a broad endotherm peak at 188.6°C, which may 
correspond to the melting of crystalline product.  
Crystal energy is known to correlate with Tm(Onset) (onset melting point) and ΔHm 
(enthalpy of melting), which refers to the energy a compound must overcome to 
dissolve the drug (VIPPAGUNTA et al., 2007). The onset melting point and fusion 
enthalpy obtained from the DSC study are summarized in Table 2.4. The molecule was 
then characterized by a high melting point (188.6oC) and a high enthalpy of fusion (86.6 
J/g). 
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Figure 2.10. DSC thermograms of as-received CRS 74 sample (first heating), 
which consists of a melting endotherm (peak onset temperature) Tm(Onset) = 188.6oC. 
 
Table 2.4. Melting Temperature (Tm(Onset)), Enthalpy of fusion (ΔHm) for as-
received CRS74 sample. 
Thermal 
parameters 
Cycle 1 
(heating-cooling) 
Tm(Onset)(°C) 188.6 
ΔHm (J/g) 86.6 
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 Determination of surface properties 2.3.5.
The surface properties of drug samples were investigated to find a possible 
relation between surface properties and dissolution. Sessile drop contact is most 
commonly measured on compacted powder disc surface. However, compaction of the 
material can alter the particle morphology and surface energy (BUCKTON, 1955). 
Alternatively, some of the authors (AHFAT et al, 2000; HE et al, 2008) have reported 
the use of powder layer adhered to an inert support. The powder layer was adopted for 
the present work as it allows the study of “as is” powder properties. This method gave 
reproducible values. It has been seen that contact angle measurements can vary with 
experimental methodology, however the technique was used for evaluation of the 
surface properties of original drug powder.   
The contact angle of drop deposited on powder surface was plotted as a function 
of time from 0 to 10 s, beyond which there was no significant change in the contact 
angle. With water as the wetting liquid, original drug crystals exhibited a contact angle 
almost unchanged with time from 136.4 ± 0.8° (0 s) to 136.6 ± 0.6°(10 s), as shown in 
Figure 2.11. 
 
Figure 2.11. Contact angle (o) of water as a function of time for original CRS 74. 
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The wetting process with water was quantified for the work of adhesion (Wa), 
calculated using a combination of the Young and Dupré Equations (SCHRADER, 
1995), cohesion (WCL) and the spreading coefficient (λLS), are calculated by the 
following equations, derived from the Young’s equation (IVESON et al., 2001): 
  (2.2) 
  (2.3) 
  (2.4) 
 
where, γ is the surface free energy and L, S and V refer to the state as being liquid, solid 
and vapor respectively. Equation 2.3 is only valid for θ higher than 0, which is a 
common case for hydrophobic powders. The contact angle made at 0 s was considered 
as the initial contact angle and the surface tension of water was taken from the literature 
(72.8 mN/m; PURI et al., 2010). These values were used to determine Wa, WCL and λLS 
from equations (2.1), (2.2) and (2.3) for the drug powder (Table 2.5). 
 
Table 2.5. Work of adhesion (WA), work of cohesion (WCL) and spreading 
coefficient (λLS) for CRS 74. 
Sample WA (mN/m) WCL (mN/m) λLS (mN/m) 
CRS 74 20.08 145.6 -125.6 
 
The thermodynamic driving force for each process is indicated by the work value, 
where a negative value denotes the spontaneity of the process (YOUNG and 
BUCKTON, 1990). The positive Wa and WCL obtained for this new antiretroviral drug 
WCL = 2γLV
WA = γSL − γSV +γLV( ) = γLV cosθ +1( )
λLS = WA −WCL
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indicated that the adhesion and the cohesion processes are not spontaneous over the 
original powder sample. Further, a negative spreading coefficient (λLS < 0) means that 
this powder displayed an unfavorable spreading of water (NGUYEN and HAPGOOD et 
al., 2010). 
 Dissolution studies 2.3.6.
 
2.3.6.1. High Performance Liquid Chromatography (HPLC) to determine the 
content of the dissolved drug 
 
Specificity of the HPLC method 
The specificity of a method gives us the guarantee that the result of the method 
only comes from the analyte. Specificity of our method was determined by analysing 
the dissolution media with and without the reference product to verify the interference 
of the eluent in the CRS 74 concentration measurements.  
The specificity of the HPLC quantification method was demonstrated in Figure 
2.12. No interferences from the dissolution medium with the peak of interest were 
observed in the HPLC chromatograms, confirming the selectivity of the method. 
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(a) 
 
(b) 
Figure 2.12. Specific test for CRS 74 in dissolution medium (0.1M HCl); (a) 
HPLC chromatograms of placebo (dissolution medium); (b) HPLC chromatograms of 
the component of interest dissolved in the dissolution medium. Flow rate of 1.0 
mL/min; mobile phase consisted of acetonitrile:water (50:50). 
 
 
HCl peak 
CRS 74 peak 
HCl peak 
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Linearity of the HPLC method 
A linear analytical method indicates that it has the ability to demonstrate 
experimentally that the results obtained are directly proportional to the concentration of 
analyte in the sample within a specified range (FDA, 1997). To assess the linearity of 
the method, seven solutions of CRS 74 dissolved in 0.1M HCl were prepared: 13 
µg/gsolution, 26 µg/gsolution, 34 µg/gsolution, 51 µg/gsolution, 99 µg/gsolution, 213 µg/gsolution and 
289 µg/gsolution. 
The standard curve (Figure 2.13) showed an excellent correlation in the 
concentration range of 13- 289 µg/gsolution (y = 36.2x, r2 = 0.99917, exceeding 0.99, 
which is the minimum recommended by the regulating agencies ICH, 1996 and FDA, 
1997). The limit of quantification (LOQ) of the assay was 0.5 μg/mL. The calculation 
method used is based on the standard deviation (SD) of the y-intercepts of regression 
lines and the slope of the calibration curve (S), according to the formula: LOQ = 
10(SD/S) (ICH, 1996). 
 
Figure 2.13. Standard curve used for the determination of CRS 74 in samples 
produced during dissolution experiments.  
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CRS 74 solubility in dissolution medium and sink conditions 
Sink conditions describe a dissolution system that is sufficiently diluted so that 
dissolution process is not impeded by approach of saturation of compound of interest 
(ROHRS, 2001). The amount of reference product (30 mg) set for our experiments 
assured the presence of sink conditions in the dissolution medium because it 
corresponds to a maximum drug concentration in the acidic medium 33 µg/gsolution, three 
times less the equilibrium concentration of  the drug in this medium, also determined 
experimentally, 102 ± 8 µg/gsolution  at 37°C.  
Any optimal separations and symmetrical chromatographic peaks were observed 
in HPLC chromatograms for CRS 74 in water or phosphate buffer 6.8 (Figures 2.14-a 
and 2.14-b, respectively), reason for which the dissolution method were tested only in 
acidic medium. 
Most drugs are weak acids or weak bases that are present in solution as both the 
ionized and unionized species. The solubility of a weak acid or a weak base is related to 
pH.  Acids ionize in alkaline medium, while bases ionize in acidic medium. The pKa is 
the pH at which concentrations of ionized and un-ionized forms are equal (NEAU, 
2008). 
CRS 74 is a new ritonavir analogous compound (BOCKELMANN et al., 2005; 
BOCKELMANN et al., 2010). Ritonavir is a weak base with two ionisable sites that 
dissociate below pH 3 (BERTZ et al, 2004). The pKa of 2.8 for ritonavir refers to loss of 
a hydrogen from a protonated thiazole group because thiazole itself is a weak base 
(pKBH+, 2.4) (LIDE, 1988). Analogous to Ritonavir, CRS 74 is probably a weak base 
with a pKa close to 3 with similar pH-dependent solubility behaviour. 
According to the literature, Ritonavir is poorly water soluble with a solubility of 
400μg/mL in 0.1M HCl at 37oC, which is reduced to 1 μg/mL at phosphate buffer pH 
6.8 (LAW et al, 2001). In comparison, the solubility of CRS 74 experimentally 
measured in this work was 102 μg/mL in 0.1M HCl and not detected (<0.5 μg/mL) by 
HPLC in phosphate buffer pH 6.8 or water at the same temperature. 
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(a) 
 
(b) 
Figure 2.14. HPLC chromatograms of the component of interest dissolved in (a) 
water and (b) phosphate buffer pH 6.8.  
 
2.3.6.2. In vitro dissolution testing  
Figure 2.15 shows the dissolution profiles of original CRS 74 drug in 0.1 M HCl 
(pH 1.2). It can be seen that the as-received drug did not even reach 20% dissolution 
within 3h, confirming its poor tendency to dissolve in aqueous media. The poor 
dissolution rate measured in this study can be related to the poor surface properties of 
the powder presented in section 2.3.5, such as unfavourable spreading of water (λLS <0) 
Water pH 7.0 
Phosphate buffer pH 6.8 
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and not spontaneous adhesion and the cohesion processes (positives values of Wa and 
WCL). 
 
Figure 2.15. Dissolution profile of CRS 74 in 0.1 M HCl at 37°C (n=4; SD =±2). 
 
The dissolution step seems to be the limiting step of this process of CRS 74 
release in the aqueous medium. The model of Hixson–Crowell (HIXSON and 
CROWELL, 1931) describes the release from dosage forms, which show dissolution 
rate limitation and which do not dramatically change during the release process. The
equation of Hixson–Crowell cube-root kinetic model is given by Equation 2.5. 
  



  (2.5) 
where k is the kinetic constant (min -1), Mt is the mass of the drug dissolved in time t 
and M0 is the initial drug  mass in the dissolution medium. 
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Our dissolution data were then plotted in accordance with Hixson–Crowell cube 
root law (Figure 2.16) (correlation coefficient r2 = 0.984) to determine the dissolution 
rate constant k, as given in Table 2.6. 
  
Figure 2.16. Application of Hixson-Crowell mathematical model on CRS 74 
release profile. 
 
Table 2.6. Values of k and regression equations for the mathematical models of 
Hixson-Crowell applied to the CRS 74 dissolution data. 
Sample Hixson-Crowell 
 k (min -1) Linear equation 
CRS 74 0.0008 y = 0.0008 x - 0.0017** 
k = dissolution rate constant.  
** x = t (min) and y = 1-[(1-%Dissolved/100) 1/3 ] 
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2.4.CONCLUSIONS 
As-received CRS 74 was characterized by laser diffractometry, powder X-ray 
diffraction (XRD), thermal gravimetric analysis (TG), differential scanning calorimetry 
(DSC), scan electronic microscopy (SEM), surface properties and dissolution testing. 
The results were presented and discussed in this chapter. 
The saturation concentration of this molecule in water and phosphate buffer 6.8 
was not detected by HPLC analysis. The molecule is slightly soluble in acid medium 
(0.1M HCl pH 1.2) : 102 ± 8 µg/gsolution. Its low aqueous solubility can be explained by 
its high crystallinity, its high melting point (188.6oC) and high enthalpy of fusion 
(86.6 J/g).  
The dissolution in vitro test is an important tool in quality control of drugs and it 
becomes more important for drugs with low aqueous solubility such as CRS 74. Some 
characteristics of this drug are not well defined, for instance, its classification in the 
biopharmaceutical classification system. The aim of the dissolution study carried out 
here was to contribute to define CRS 74 dissolution conditions, what can be the focus 
for further studies. To date, there is no published dissolution test for the evaluation of in 
vitro release profiles of CRS 74 from immediate-release solid oral dosage forms. 
Therefore, we developed a dissolution method for CRS 74 to determine its release 
profiles from powder samples. The low dissolution rate presented by this molecule can 
be related to its large particle size (micrometric range, with a broad particle size 
dispersion) and very poor water wettability (θ =136.4 ± 0.8°).  
Physical factors important to drug dissolution include particle size, molecular size, 
hydrophobicity, and crystalline structure. Physical modifications often aim to increase 
the surface area, solubility, and wettability of the powder particles and, therefore, 
typically focus on particle size reduction or generation of amorphous states. This work 
planned to improve the dissolution rate of as-received CRS 74 molecule using a Liquid 
Anti-Solvent crystallization process to increase the surface area and improve its 
wettability. 
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Résumé Chapitre 3- Étude de la solubilité et développement du 
protocole expérimental   
Le choix du solvant est un des paramètres essentiels pour pouvoir envisager une 
opération de cristallisation. La connaissance de la solubilité d'un composant dans 
différents solvants est requise. L’éthanol et l’eau ont été retenus respectivement comme 
solvant et anti-solvant. 
Dans ce chapitre, la solubilité du CRS 74 en mélanges binaires éthanol et éthanol-
eau a été mesurée dans la plage de température de 5 – 30 °C, afin de déterminer le cadre 
expérimental pour permettre la cristallisation par effet anti-solvant. 
Dans un premier temps, les équilibres solide-liquide dans l’éthanol pur et dans des 
mélanges binaires (éthanol/eau) ont été étudiés pour une gamme de température 
comprise entre 5 et 30 °C. Le solide étudié est très soluble dans l'éthanol à 30 °C : 92,6 
mg/g de solution. A 30°C, la solubilité de la molécule diminue quand la quantité d’eau 
dans le mélange augmente. Les solubilités obtenues ont été représentées en utilisant le 
modèle UNIQUAC pour le calcul des coefficients d’activité. Les solubilités 
expérimentales et calculées présentent un bon accord. La solubilité calculée dans des 
mélanges eau-éthanol présente un maximum de 130,20 mg/g de solution pour un ratio 
massique éthanol/eau de 0,83/0,17 (w/w). Les résultats de la modélisation indiquent que 
ce modèle est l'outil approprié pour représenter le comportement de solubilité de CRS 
74 dans des mélanges de solvants (éthanol-eau). Les solubilités expérimentales et 
calculées ont permis d’évaluer le ratio éthanol/eau optimum (25/75 % m/m) pour 
maximiser le rendement théorique en solide. 
Dans un second temps, un mélange double jet avec pré-mélangeur type mélangeur 
en T ou mélangeur Roughton a été choisi pour réaliser la cristallisation. Dans les deux 
cas, des nanoparticules sont créées en sortie du pré-mélangeur. Des expériences 
préliminaires ont montré que le solide présente des vitesses de croissance et 
d’agglomération élevées. Les particules obtenues avec le mélangeur en T semblent 
moins agglomérées.  
Ce type de mélangeur a donc été retenu pour la suite de l’étude. Deux principaux 
résultats ont été obtenus.
  
Le solide cristallisé est toujours aggloméré. Son profil de dissolution dans une 
solution acide (0,1M HCl) reste inchangé. À partir de ces résultats, il a été conclu que 
les débits d’entrée des solutions (paramètre opératoire) n'ont pas d'influence sur les 
particules recristallisées. Après avoir défini, les paramètres du processus de 
cristallisation, le produit synthétisé ne présente pas de changements de cristallinité ni de 
changements liés aux propriétés de surface (mouillabilité). Toutefois, une diminution de 
la taille des particules a été observée. Aucun réel impact sur la vitesse de dissolution de 
la poudre synthétisée par effet anti-solvant n’a été observé. 
Le mélangeur se colmate après quelques minutes d’utilisation. Il peut s’agir d’un 
problème d’affinité du solide avec la paroi inox du pré-mélangeur et/ou d’un 
phénomène d’agglomération très rapide. Afin d’améliorer la cinétique de dissolution de 
la poudre recristallisée, il est nécessaire de rendre leur surface plus hydrophile en 
utilisant par exemple des additifs différents afin d'optimiser les paramètres du procédé 
et de formulation. 
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3.1. INTRODUCTION 
Chapter 2 summarizes the crystal properties, which are experimentally 
determined in this work. The poor water solubility, bad wettability and the low 
dissolution rate in acidic medium could be confirmed. In order to modify these 
properties, this work proposed a recrystallization using an Anti-Solvent-Liquid process.  
The solvent selection is one of the essential parameters to envisage any 
crystallization process. Therefore, the knowledge of the solubility of a target component 
in different solvents is required. In this work, the solubility of CRS 74 in ethanol and 
ethanol-water binary mixtures was measured in the temperature range of 5 -30oC. 
Although experimental data on solubility are essential to provide information 
about a system and help to understand its behavior, correlations and prediction models 
are also required for the correct design of crystallization processes. Solid-liquid 
equilibria of ternary mixtures containing ethanol (solvent), water (anti-solvent) and the 
new antiretroviral drug were studied. The solubility data were estimated using 
UNIQUAC-based model.   
After determining the solubility of the active ingredient in ethanol (solvent)- 
water (anti-solvent), an experimental system was developed to study CRS 74 
recrystallization. As mentioned in Chapter 1, crystal properties are influenced by a 
number of operating variables in anti-solvent crystallization, some of which are more 
influential than others.  
The present Chapter is composed of two sections. The first one concerns the 
solubility study and the second one the crystallization process design. The methodology 
and the results obtained are presented. 
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3.2. MATERIALS AND METHODS  
 Materials   3.2.1.
The active pharmaceutical ingredient (CRS 74) with 99% purity was provided as 
courtesy from Cristalia Ltda (Itapira, SP, Brazil), ethanol (EtOH) from Fluka Analytical 
(Sigma–Aldrich, France) and acetonitrile (ACN) high performance liquid 
chromatography (HPLC) grade from Scharlau Chemie (Barcelona, Spain). Ethanol and 
Acetonitrile had purity higher than 99%. All products were used as supplied.  
 Methods for solubilty measurements 3.2.2.
The solubility of CRS 74 was determined by equilibrating an excess of CRS 74 
in 5 g of water, ethanol and different ethanol/water combinations at 30 ± 0.5°C in a 
temperature-controlled bath for 72 h (Figure 2.5). The flasks were sealed for the 
duration of the tests and the concentration was determined by removing the solid phase 
by filtration (0.22 µm pore size) and injection of the filtered solution into the HPLC 
system to be analyzed at wavelength of 210 nm. The HPLC system consisted of an 
Agilent Chromatograph (Model1100 series) equipped with a UV-vis detector, and of an 
HPLC column ProntoSIL 300-5-ODSH 5µm, 250x4 mm ID. The flow rate of mobile 
phase (acetonitrile/water in the ratio of 70:30) is 1.0 mLmin-1.  
 Methods for Liquid Anti-Solvent (LAS) crystallization 3.2.3.
After drug solubility characterization and definition of the best crystallization 
conditions, some process parameters were evaluated. In this part of the study, different 
essays at different operational conditions were realized in order to evaluate the influence 
of the process parameters on the final size and agglomeration state of particles at the 
end of the crystallization process. 
The original CRS 74 crystals were recrystallized by a LAS crystallization 
method. As already discussed in Chapter 1, this method is based on saturation changes, 
when the drug is dissolved into a solvent and then this solution is mixed with an anti-
solvent of solute.  
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Anti-solvent and saturated solutions can be brought into contact in several 
manners: single-jet, double-jet or double-jet with premixing (Chapter 1). 
In the crystallization proceeding for CRS 74 (expensive pharmaceutical drug) 
the use of single jet was not viable due to use of a large amount of drug for each 
experiment. So, a double-jet with premixing has been used. So rapid mixers combined 
with a stirred vessel were used as process configuration. Briefly, the drug was 
recrystallized via the concurrent introduction of the CRS 74 ethanol solution and an 
anti-solvent stream of water in stainless steel mixers specially manufactured for this 
study, on the basis of previous works published in the literature (LINDENBERG et al., 
2008; LINDENBERG, 2009). The experimental setup is shown in Figure 3.1, in which 
the mixing device can be easily changed to test different mixers, which are presented in 
more details hereafter.  
Briefly, a certain amount of original CRS 74 samples was completely dissolved 
in ethanol at 30 ± 0.5°C at definite concentration (90 mgCRS 74/gsolution). The solution was 
filtrated through 0.22 µm pore size membranes to remove the possible particulate 
impurities. To each experiment the solutions were fed into the mixing device by gear 
pumps (mzr-7255-hs-f S, mzr-7205-hs-f S; HNP Mycrosysteme). The freshly formed 
crystals were collected in a vessel under magnetic stirring and then they were filtered 
and dried under vacuum at 50 ± 1°C for 24h. The dried samples produced by this LAS 
crystallization process were characterized by laser diffractometry, differential scanning 
calorimetric analysis, X-ray diffraction analysis, scanning electron microscopy analysis, 
wetting properties and dissolution testing. 
The flow rates of CRS 74 ethanol solution and water were fixed at flow rates of 
11.29 g/min and 33.22 g/min respectively, such after mixing a definite supersaturation 
ratio (S) was calculated from the conditions at the entries of the T-mixer 
(S = C/Ceq = 894). Gear pumps and a digital mass flow meter/controller (M1X, 
Bronkhorst) were used in the experimental process to ensure minimal flow rate 
fluctuations and good mixing. In order to validate the flow of gear pumps the pumps 
were previously calibrated (data shown in Appendix II). 
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Figure 3.1. Schematic of the experimental apparatus used for the LAS 
crystallization experiments. 
 
Mixers  
Two different types of mixers were tested: a T-mixer with two radial entries and 
a two jets vortex mixer also called Roughton mixer. The T-mixer had two radial entries 
with a diameter of 1 mm and its outlet tube had a diameter of 2 mm and a length of 
17.5 mm. The Roughton mixer has a mixing chamber diameter of 3 mm and its outlet 
tube has a diameter of 1.75 mm and a length of 15 mm.  A schematic of both mixers is 
showed in Figures 3.2a and 3.2b. 
 
Drug solution at 30°C* 
Solvent=Ethanol 
Final drug suspension in 
the water-ethanol 
solution 
Gear pump 

	
Water at 30°C* 
(anti-solvent)  
Gear pump 
L 
L 
* Temperature-controlled bath  
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(a) (b) 
Figure 3.2. Sketch of the mixers used: (a) Roughton mixer, (b) T-mixer. 
 
3.2.3.1.Characterization methods for particles in suspension 
Particle size analysis 
The mean size and particle size distribution of the drug particles generated by 
LAS recrystallization were analysed in different phases of the process. 
Firstly, freshly particles were analysed by Photon correlation spectroscopy (PCS) 
using a Zetasizer Nano Zs (Malvern Instruments, United Kingdom) to measure the 
mean size at the exit of the mixer right after the mixing proceeding (from the outlet of 
the mixer), as shown in Figure 3.3. Two measurements are made at 0 and 150 seconds 
(measure time). Before analysis, the suspension was diluted 5 times using a saturated at 
30°C. This saturated solution was composed by water, ethanol and drug, to achieve 
appropriate measurement concentration. It was filtrated through 0.22 µm pore size 
membranes to remove the possible particles. The new supersaturation of solution S’ can 
be calculated by this expression: 
3mm 
3mm 
2m
m
 
17
.5
m
m
 
1mm 
2m
m
 
15
m
m
 
2mm 1.75mm 
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S’= 5/6 + S/6 (3.1) 
In a second time the drug suspension was analysed by laser granulometry, using 
a MasterSizer 3000 (Malvern Instruments, United Kingdom). The samples were taken 
from the outlet of the mixer (right after the mixing) and immediately diluted with the 
same saturated solution in order to monitor the evolution of crystal size as a function of 
the time in the cell of the granulometer, as shown in Figure 3.3.  
 
 
Figure 3.3. Sketch of particle size analysis for particles in suspension by PCS and 
laser granulometry. 
 
Optical microscopy analysis 
Samples were taken from the final suspension into the vessel and immediately 
analysed by optical microscopy.  
 
Final drug suspension 
in the water-ethanol 
solution 
Sampling 
Dilution  
Measure time (s) 
t0 t150 
Particle size evolution 
PCS 
Particle size evolution 
Laser Granulometry  
 
Sampling 
Dilution  
Measure time (min) 
t0 t10 
Particle size range 0.15nm-10µm 
Particle size range 0.1-3500µm 
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3.2.3.2. Characterization methods for dried powder 
The dried samples were analysed by laser diffractometry, powder X-ray 
diffraction (XRD), thermal gravimetric analysis (TG), differential scanning calorimetry 
(DSC), scan electronic microscopy (SEM), contact angle measurement and dissolution 
testing, using the same procedure already described in Chapter 2. Furthermore, purity 
and solvent content were determined too. 
Purity  
In order to evaluate the purity of drug solid, approximately 1.5 mg of CRS 74 
was solubilized in approximately 40 g of ethanol. This solution was then assayed by 
HPLC analysis at wavelength of 210 nm to evaluate the amounts of dissolved drug. The 
HPLC system consisted of an Agilent Chromatograph (Model1100 series), equipped 
with a UV-vis detector, column Prontosil 300-5-ODSH 5µm (5 µm, 250x4 mm). The 
flow rate of mobile phase (acetonitrile/water in the ratio of 70:30) is 1.0 mL min-1. All 
experiments were carried out in triplicate. The purity is the ratio between the measured 
concentration of the synthetized powder and the initial concentration of the raw 
material. The purity of the synthesized powders was calculated as shown below. 
 
Purity(%) = Abssample
AbsCRS 74
× Purity
CRS 74
(%)  (3.2) 
 
where AbsCRS 74 is the absorbance of the standard solution containing the raw material 
100% dissolved, Abssample is the absorbance of the sample containing the synthesized 
material 100% dissolved. And PurityCRS 74 is the purity of the raw material, provided by 
supplier. For all purity results, the standard deviation was not shown, because it was not 
significant. 
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Residual solvent content  
The residual solvent (water+ethanol) content was determined using Infrared 
balance (LJ16, Mettler) at 100°C until constant weight was achieved. 
 
3.3. RESULTS AND DISCUSSION ON SOLUBILITY STUDY 
 Measurement and correlation of solubility of CRS 74 in water-ethanol 3.3.1.
mixtures 
3.3.1.1. Experimental determination  
Solubility data were experimentally measured in the temperature range of 5 to 
30oC for pure ethanol and for a mixed solvent system containing 95%(w/w) water and 
5% (w/w) ethanol. For analytical purposes, the solubility in pure water could not be 
measured. Indeed, the low concentration of a solid in solution, that should lead to 
analytical results unreliable, that can be not quantified due to sensitivity of the 
quantification method.  
Concentration measurements have made as function of time and are shown in 
Tables 3.1 and 3.2. 
The standard deviation obtained (± 5 %), is mainly due to evaporation losses of 
solvent after sampling, but also closely related to systematic error (analytical method), 
like dilution and calibration curve. 
For the two mass ratios, the concentrations measured at 24, 48, 72 h are identical 
(Tables 3.1 and 3.2). Subsequently we have considered, for all solutions, the liquid-solid 
system has reached equilibrium after 24 h of stirring at a controlled temperature ± 
0.5°C. Thereafter, all the experimental results are the average of the three 
concentrations measured respectively at 24, 48 and 72 h (Table 3.1 and Table 3.2).  
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As shown in Table 3.1, the solubility of CRS 74 in pure ethanol was enhanced 
by temperature rise above 15oC, whereas the solubility in the mixed aqueous system 
containing 95% (w/w) water - 5% (w/w) ethanol was not affected by the temperature in 
all studied temperature range. With this last ratio, the solubility of CRS 74 is equal to 
0.0040 ± 0.0001 mg/g solution.  
The solubility of in different water-ethanol mixtures at 30oC was listed in 
Table 3.3. 
 
 
Table 3.1. Solubility of CRS 74 in ethanol as function of sample time in 
temperature range (5-30°C). 
T (°C) 
C (mg/g) 
24h 
C (mg/g) 
48h 
C (mg/g) 
72h 
 
(mg/g) 
SD 
(mg/g) 
5 
10 
15 
20 
25 
30 
68.1 
67. 5 
66.4 
72.0 
78.3 
90.6 
65.3 
67.8 
69.7 
74.8 
82.7 
93.0 
73.4 
68.9 
61.4 
77.7 
81.6 
94.3 
68.9 
68.1 
65.8 
74.8 
80.9 
92.6 
4.1 
0.8 
4.1 
2.8 
2.3 
1.9 
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Table 3.2. Solubility of CRS 74 in 95% (w/w) water - 5% (w/w) ethanol mixture 
as function of sample time in temperature range (5-30°C). 
T (°C) 
C (mg/g) 
24h 
C (mg/g) 
48h 
C (mg/g) 
72h 
 
(mg/g) 
SD 
(mg/g) 
5 
10 
15 
20 
25 
30 
0.0042 0.0048 0.0036 0.0042 0.0006 
0.0042 0.0041 0.0038 0.0040 0.0002 
0.0042 0.0041 0.0038 0.0040 0.0002 
0.0036 0.0036 0.0036 0.0036 0.0000 
0.0039 0.0041 0.0039 0.0040 0.0001 
0.0041 0.0041 0.0040 0.0041 0.0001 
 
 
The results revealed that this molecule exhibited a very poor solubility in water 
(not detected by HPLC analysis) and a solubility of 92.6 mg/gsolution in pure ethanol. On 
the one hand, Table 3.3 shows that the addition of ethanol to water at 30°C changed the 
solubility of 	 and that ethanol could be used as an organic co-solvent to change 
its solubility in aqueous media. It is well-known that the addition of an organic co-
solvent to water can dramatically change the solubility of drugs (YALKOWSKY and 
ROSEMAN, 1981) as observed here for more than 40
(w/w) . It is reported 
that a solvent is sufficient for pharmaceutical processing when the solubility exceeds 1 
mg/mL (LEE et al., 2006; SMITH et al., 2011).  On the other hand, combinations 
containing more than 60% (w/w) water as an anti-solvent are favourable for further 
crystallization studies.  
 
 
C
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Table 3.3. Solubility of CRS 74 in Ethanol/water mixtures at 30 °C. 
Solvent Mean Solubility (mg/gsolution) ± SD 
Water not detected by HPLC analysis 
95%(w/w) water - 5%(w/w) ethanol 0.004±0.0001 
85%(w/w) water - 15%(w/w) ethanol 0.010±0.0004 
80%(w/w) water - 20%(w/w) ethanol 0.020±0.0020 
75%(w/w) water - 25%(w/w) ethanol 0.030±0.0020 
70%(w/w) water - 30%(w/w) ethanol 0.070±0.0030 
60%(w/w) water - 40%(w/w) ethanol 2.290±0.0900 
50%(w/w) water - 50%(w/w) ethanol 12.300±1.4100 
40%(w/w) water - 60%(w/w) ethanol 60.960±5.2400 
30%(w/w) water - 70%(w/w) ethanol 87.890±4.0000 
Ethanol 92.600±1.9000 
 
 Correlation of solubility data by a UNIQUAC model 3.3.2.
At the liquid-solid equilibrium, the chemical potential of the constituent CRS 74 
in solid phase is equal to the chemical potential of the constituent CRS 74 in liquid-
phase at constant temperature and pressure. From this equality of chemical potential, we 
can show that the activity of the solute CRS 74 in liquid-phase (
) is a function of melting enthalpy of CRS 74, 
∆Hm, melting temperature Tm and solution temperature T (WALAS, 1985): 
 (3.3) 
    
     








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xCRS 74 solute being the molar fraction of the solute at saturation, γCRS 74 solute the 
activity coefficient of solute.  
The model UNIQUAC (UNIversal QUASI Chemical) is chosen to calculate the 
activity coefficient of solute. 
For a ternary system, twelve parameters are necessary: six parameters 
concerning the geometry of molecules and six binary interaction parameters. The first 
parameters, Rk and Qk, are estimated from the molecular formula of component. The 
second parameters, binary interaction parameter water/CRS 74 and ethanol/CRS 74, 
will be identified from solubilities measurement. Binary interaction parameters 
water/ethanol are available in DIPPR table. 
The volume and surface area parameters Rk and Qk of three components are 
given in Table 3.4.  
Table 3.4. Parameter Rk and Qk. 
Molecule Water (DIPPR) Ethanol (DIPPR) CRS 74 
Rk (cm3/mol) 0.9200 2.1055 37.4015 
Qk (cm3/mol) 1.4000 1.9720 29.4640 
 
The binary interaction parameters of the UNIQUAC model have been identified 
in two steps. Initially, solubility data on the binary ethanol/CRS 74 as function of 
temperature were considered to estimate the two binary interaction parameters 
ethanol/CRS 74 from the activity coefficient of the solute calculated by the equation 
(3.3) (Table 3.5).  
In a second stage, the binary interaction parameters of water/CRS 74 were 
calculated from experimental data over the ternary water/ethanol/CRS 74 with a mass 
ratio ethanol/(ethanol-water) of 5% and variable temperature (Table 3.5). A ternary 
mixture has been chosen because the solubility data in water as a function of 
temperature are not available.  
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In both cases, the minimized function fmin used for parameter estimation is 
calculated the following relation:  
  (3.4) 
Table 3.5. Binary interaction parameters. 
Binary Systems i-j uij (cal/mol) 
Water-CRS 74 1-3 
3-1 
-400.55 
22 132.13 
Ethanol-CRS 74 2-3 
3-2 
-381.47 
23 701.66 
Water-Ethanol 
(database Simulis) 
1-2 
2-1 
-96.4730 + 0.6843 * T(K) 
31.6290 + 0.4759 * T(K) 
  
The experimental and calculated activity coefficients ( 

and 


) for the two systems are reported in Table 3.6. The means of standard 
deviation (equation 3.5) for the binary system ethanol/CRS 74 and for the ternary 
system water/ethanol/CRS 74 are respectively 0.123 and 0.196 on the ternary system. 
 
      (3.5) 

 


  
  



		 

 		
 

		 

 		
 
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 Table 3.7 gives the solubilities calculated in pure ethanol as a function of 
temperature. The calculated concentrations are in good agreement with experimental 
values for temperatures above 15°C. Below this temperature, the calculated 
concentrations are significantly underestimated.  
Figure 3.4 shows the calculated solubility at 30°C as a function of the ethanol 
mass proportion in the mixture ethanol-water with the identified parameters. The 
calculated data showed good agreement with experimental results and revealed a 
maximum solubility of CRS 74 of 130.20 mg/gsolution for a mass ratio of 17%(w/w) 
water - 83%(w/w) ethanol. The maximum solubility for a solute in a mixed solvent 
system has been observed experimentally for other systems (water/acetone/ketoprofen-
ESPITALIER et al., 1995; water /ethanol /paracetamol and water/dioxane/phenacetin-
RUCKENSTEIN and SHULGIN, 2003; water/ethanol /hydrocortisone- ALI et al., 2009 
and n-heptane/ethanol/eflucimide - TEYCHENE and BISCANS, 2011). Different 
studies on Hidelbrand solubility approach have shown that the location and the height of 
the peaks could be linked with the polariry of the solute (JOUYBAN-GHARAMALEKI 
et al., 2000, PEÑA et al. 2006). Hydroxyl and amine groups of solute give a polar 
character to this molecule that could explain the maximum of solubility calculated for a 
high ratio of ethanol in the mixture. 
 
Figure 3.4. Experimental (characters) and calculated CRS 74 solubilities (__) in 
different ethanol-water mixtures at 30 ± 0.5oC. 
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Table 3.6. Experimental and calculated activity coefficients for ethanol/CRS 74 
and ethanol/water/CRS 74. 
 System ethanol/CRS 74 
SD = 0.123 
System water/ethanol/CRS 74 
Ethanol/(Ethanol+water) = 0.05 
SD = 0.196 
T (°C) 
    
  
10-4 

  
10-4 
5 
10 
15 
20 
25 
30 
0.0957 
0.1765 
0.3261 
0.4965 
0.7829 
1.1373 
0.1842 
0.2562 
0.3475 
0.5200 
0.7449 
1.1081 
0.4165 
0.7947 
1.4161 
2.7487 
4.2884 
6.9886 
1.0533 
1.5338 
2.2045 
3.1296 
4.3908 
6.0919 
 
Table 3.7. Solubility of CRS 74 in pure ethanol at different temperatures. 
T (°C) 
 
(mg/g) 
SD 
(mg/g) 
Ccalc 
(mg/g) 
5 
10 
15 
20 
25 
30 
68.9 
68.1 
65.8 
74.8 
80.9 
92.6 
4.1 
0.8 
4.1 
2.8 
2.3 
1.9 
46.4 
54.6 
63.4 
72.9 
83.1 
93.9 
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Theoritical yield of solid obtained by LAS crystallization 3.3.3.
Measurements and correlation of solubility of CRS 74 in different ethanol/water 
mixtures provided useful data for a better understanding of the solubility phenomenon 
in these media and to estimate the theoretical efficiency of the LAS recrystallization 
process as a function of ethanol/water mass ratios. Theoretical solid efficiency is the 
theoretical solid yield of crystallization based on the drug solubility in the liquid media, 
calculated from the ratio of weight particles obtained by assuming solid-liquid 
equilibrium attained and the initial weight of solute. Figure 3.5 depicts the theoretical 
solid efficiency of the LAS crystallization for the drug. It can also be seen that an 
ethanol concentration up to 50%(w/w) in ethanol/water mixtures is still favorable for 
the crystallization process, resulting in recovery of 82.6% (50 %Ethanol) of CRS 74 
based on the drug solubility in the liquid media. 
In an attempt to improve its dissolution properties, CRS 74 can be recrystallized 
by using a Liquid Anti-solvent (LAS) crystallization process and the data generated 
here can represent a useful tool to define the mass proportion between solvent (ethanol) 
and anti-solvent (water) for LAS crystallization studies. 
 
Figure 3.5. Theoretical yield of CRS 74 in different ethanol/(ethanol-water) mass 
ratios.  
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3.4. RESULTS AND DISCUSSION ON CRYSTALLIZATION 
STUDY 
After determining the solubility of the active ingredient in ethanol (solvent)- 
water (anti-solvent), it was developped an experimental system to study CRS 74 
recrystallization solvent. The crystals of CRS 74 were prepared by LAS crystallization 
from an ethanolic saturated solution at 30 °C (90 mg/gsolution) and water, used like anti-
solvent. The crystals suspension obtained after the crystallization process had a milky 
aspect that changed into a clear solution, after some seconds under magnetic stirring. 
This phenomenon can indicate the growth and the subsequent agglomeration of the 
crystals in solution. That can be observed in the form of long and big macroscopically 
visible agglomerates.  
Two different rapid mixing devices for controlling the properties of CRS 74 
particles produced by LAS crystallization were used. Two process parameters were 
tested: type of mixer and flow rate, which will be discussed here. For all essays at least 
two replicates were realized to evaluate the repeatability of the process and particle size 
measure method. The process conditions are given in the Table 3.8. 
The solid has been characterized after crystallization (still in suspension) and after 
crystallization, filtration and drying. The characterization step concerns the particle size 
measurement at the outlet tube of the mixer and the characterization of dried powder by 
particle size measurement, morphology, crystalline structure and dissolution properties. 
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Table 3.8 Experimental LAS crystallization process conditions 
Experiment Solvent flow rate (g/min) 
Antisolvent 
flow rate 
(g/min) 
Total flow 
(g/min) 
Type of 
mixer 
1 11.29 33.22 44.51 Roughton 
2 11.29 33.22 44.51 T 
3 6.77 20.32 27.09 T 
4 17.46 52.1 69.56 T 
 
 Characterization of particles in suspension 3.4.1.
3.4.1.1. Influence of the type of mixer on mixing 
In order to compare the efficiency of both mixers parameters such as residence 
time (τ), Reynolds number (Re) and energy dissipation rate (ED) were calculated for 
each mixer and for each flow rate tested.  
The residence time τ in the mixer is calculated  from V the volume of the mixer 
(mL) and Q the volume flow rate (mL/s): 
 (3.6) 
In our system, the Reynolds number can be calculated as follows (FOX et al., 
2004). 
 (3.7) 
with Re = Reynolds number,  = density of the mixture (kg/m3), u = velocity of the 
mixture (m/s), = flow rate of the mixture (m3/s), D = diameter of the outlet tube (m), 
µ = viscosity of the mixture (N.s/m2), A = cross sectional area of the outlet tube (m2). 
   
 





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It has been described that for Reynolds number above 1600, the mixing process 
is completed in the main mixing chamber. On the other hand, for low Reynolds number, 
this process continues at the outlet tube. Therefore, the larger the Reynolds number, the 
faster the mixing process and, consequently, a uniform composition in the mixer will be 
faster achieved.  
 The energy dissipation is a factor that strongly influences the quality of mixing. 
The purpose of the mechanical energy dissipated by the moving fluid is to homogenize 
fields of concentrations by displacement of fluid portions. The perfect mixing at the 
molecular level is sometimes achieved so late that the solute molecules are already 
chemically transformed or in phase change. The energy dissipated can be calculated as 
follow. 
 (3.8) 
where ED = energy dissipated (W/kg), f = friction factor, V = velocity of the fluid at the 
outlet tube (m/s), D = diameter of the outlet tube (m).  
By generating homogenized fields of concentration in the solution, the energy 
dissipation influences the mean velocity convection, the turbulent diffusion and the 
viscous-convective deformation (LINDENBERG and al, 2008). The improvement of 
these factors means an improved mixing. 
Properties of solvent mixture used, like density (ρ) and viscosity (µ) were 
calculated as shown in Table 3.9. These values were determined for the solvents 
mixture composed by ethanol (25%, w/w) and water (75%, w/w) at 30°C, without 
taking into account the influence of the solid (KHATTAB et al., 2012).  
 
 
 
 


 
CHAPTER 3 
 
 148 
Table 3.9 Density (ρ) and viscosity (µ) of ethanol/water mixtures at 30°C 
(KHATTAB et al., 2012). 
ρmixture (kg/m3) µmixture (N.s/m2) 
955.4 0.0017 
 
According to Table 3.10, Reynolds numbers were lower than 1600, so the 
mixing process continues at the outlet tube. Moreover, Roughton mixer shows better 
mixing efficiency when compared to the T-mixer. For the same flow rate, the Roughton 
mixer presents lower mixing time, which is required in order to have a uniform 
concentration distribution in the mixer, wide causes particle size distribution (ZHAO et 
al., 2011). It also shows higher Reynolds numbers and energy dissipation rates. It means 
a greater turbulence in the system that favours a closer contact between the fluid for 
total flow rate higher than 7 g/min and, consequently, results in improved mixing.  
Table 3.10. Calculated mixers parameters for: Roughton mixer (a) and T-mixer 
(b). 
QEtOH (g/min) QH2O (g/min) Qtotal (g/min) τ (s) Re ED (W/Kg) 
6.77 20.32 27 09 0.08 195 0.7 
11.29 33.22 44 .51  0.05 321 2 
17.46 52.1 69.56 0.03 503 4.9 
 
(a) 
QEtOH (g/min) QH2O (g/min) Qtotal (g/min) τ (s) Re ED (W/Kg) 
6.77 20.32 27.09 0.11 171 0.3 
11.29 33.22 44.51 0.07 281 0.9 
17.46 52.1  9.56 0.04 440 2.2 
 
(b) 
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3.4.1.2. Influence of the type of mixer on particle size 
For CRS 74 LAS crystallization the proportion ethanol:water equal to 25%:75% 
(w/w) and total flow rate of 44.51 g/min, were used, as given in Table 3.8. Results 
obtained by PCS and laser granulometry are presented. 
 
PCS results 
In a first time the influence of the type of mixer on particle size (PSD) by PCS 
was evaluated. Different essays using Roughton and T mixers at the same process 
conditions were realized. In order to follow the evolution of particle size and understand 
the influence of each mixer on the size of the final product.  
It was clear observed, that the particle size at 0 s for both mixers is small 
(nanoscale), but they evolved very fast inside the equipment during the measurement 
time (150 s), as shown in Table 3.11. This fast evolution of size could be explained by 
two phenomena: growth or aggregation/agglomeration. A certain variation of size value 
for the same essay was noticed as well. This difference of the measures values can be 
acceptable due to the high growth or agglomeration rates of the particles produced, 
which complicates the measurement accuracy. This variation among the measures was 
noted at 0 and 150 s for both mixers. 
It was noted, that the mean size of particle obtained with Roughton mixer seems 
to be smaller than that obtained with T-mixer at t0 = 0 s. After tf =150 s, none difference 
is observed. This behaviour can be explained by the fact that it provokes a better mixing 
when compared to the T-mixer, as showed before in Table 3.10 of this chapter.   
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Table 3.11. Evolution of crystallized particle size by PCS in different mixers, 
Roughton mixer (a) and T-mixer (b) at total flow rate of 44.51 g/min and ethanol-water 
ratio of 25-75 % (w/w). 
Experiment Size (nm) at t0 = 0 s Size (nm) at tf = 150 s  
1A 224 778 
1B 153 926 
1C 120 655 
Average 166± 54 787± 136 
 
(a) 
 
Experiment Size (nm) at t0 = 0 s Size (nm) at tf = 150s 
2A 269 845 
2B 393 815 
Average 331± 88 830± 21 
(b) 
 
Laser granulometry results 
 
The evolution of the particle size was still followed by laser granulometry, from 
the outlet of the mixer, until size stabilization of crystals during 10 minutes, in which 
each measure lasts around one minute. The first and the last measure of this period of 10 
minutes were shown in Figures 3.6 and 3.7. 
Analysing the results for each mixer separately, it was noted the fast crystal 
growth or agglomeration. During the 10 minutes analysis the particle size increased 30 
times of its initial size of 2 µm, i.e. almost a mean growth rate of 7 µm/min. This 
behaviour is due to tendency of the molecule to grow quickly and/or to form larger 
agglomerates. 
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In figure 3.7 it was noted that T-mixer presents particles with smaller sizes at the 
end of the measure (10 min) when compared with the size particle distribution of the 
particles crystallized in the Roughton mixer (see Figure 3.6).  
Optical microscopy photos can confirm the agglomeration phenomenon in the 
cell of laser granulometer. However, as shown in Table 3.12, the particles obtained 
using the Roughton mixer presented an agglomeration state of particles more 
significant, when compared to the particles obtained using the T-mixer. The presence of 
these agglomerates was observed too in Figure 3.6, where a family of particles was 
noticed at 500 µm.  
Table 3.12. Crystals at tf =10 min in suspension observed by optical microscopy  
Experiment Type of mixer Total Flow rate
 
500 µm 
1A Roughton 44.51 g/min 
 
2A T 44.51 g/min 
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t0 = 0 min 
 
tf = 10 min 
Figure 3.6. Particle size distributions by laser granulometry for Roughton mixer 
at t0 = 0 min and tf = 10 min at total flow rate of 44.51 g/min and ethanol-water ratio of 
25-75 % (w/w). 
 
Experiment D[4;3] (µm) Span 
1A 3 1.8 
1B 1 1.2 
1C 2 1.4 
Average 2±1.0 1.5±0.3 
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t0 = 0 s 
 
tf = 10 min 
Figure 3.7. Particle size distribution by laser granulometry for T-mixer at t0 = 0 
min and tf = 10 min at total flow rate of 44.51 g/min and ethanol-water ratio of 25-75 % 
(w/w). 
Experiment D[4;3] (µm) Span 
2A 2 1.3 
2B 2 2.6 
Average 2±0.0 1.9±0.9 
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3.4.1.3. Influence of flow rate in the T- mixer on particle size 
In this section the influence of the flow rate on particle size was analyzed using 
the T-mixer. Three different experiments varying the flow rate were performed (Table 
3.8) and the particle size was measured with the same experimental procedure.  
 
PCS results 
Analyzing the results for initial size and final size in different flow rates by PCS 
in Table 3.13. It was noted that there is no a great influence of flow rate on the particle 
size.  
Laser granulometry results 
The evolution of the particle size was still followed by laser granulometry during 
10 minutes. Like it was made in previous section. 
For all experiments the quickly grow or agglomeration rates of crystals was 
observed as illustrate in Figures 3.8, 3.9 and 3.10. During the 10 minutes analysis the 
particle size increased between 20 and 30 times of its initial size of 2 and 4 µm, i.e. 
almost a mean growth rate between 9 and 7 µm/min. 
According these results, the particles still continue to grow fast and/or to form 
larger agglomerates, which means that the flow rate does not influence the growth of the 
particle size after the mixing. The average flow (44.51 g/min) was chosen in the 
following essays. 
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Table 3.13. Evolution of crystallized particle growth by PCS in different total 
flow rate: a) 27.09 g/min; b) 44.51 g/min; c) 69.56 g/min and ethanol-water ratio of 25-
75 % (w/w). 
 
 
Experiment Total flow (g/min) Size (nm) at t0 = 0 s Size (nm) at tf = 150 s 
3A 27.09 354 942 
3B 27.09 350 1195 
Average  352 ± 3 1068 ± 179 
(a) 
 
Experiment Total flow (g/min) Size (nm) at t0=0s Size (nm) at tf=150s 
2A 44.51 269 845 
2B 44.51 393 815 
Average  331 ± 88 830 ± 22 
(b) 
 
Experiment Total flow (g/min) Size (nm) at t0 = 0 s Size (nm) at tf = 150 s 
4A 69.56 385  1241 
4B 69.56 257 963 
Average  321 ± 63 1102 ± 197 
(c) 
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t0=0s 
 
tf=10min 
Figure 3.8. Particle size distribution by laser granulometry for T-mixer at total 
flow rate of 27.09 g/min and ethanol-water ratio of 25-75 % (w/w)., at t0 = 0 min and tf 
= 10 min. 
Experiment D[4;3] (µm) Span 
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3B 4 2.1 
Average 4±0.0 1.9±0.3 
0
1
2
3
4
5
6
7
8
9
0.01 0.1 1 10 100 1000 10000
Vo
lu
m
e (
%
)
Size (µm)
3A
3B
Experiment D[4;3] (µm) Span 
3A 92 1.2 
3B 97 1.3 
Average 94±3.0 1.2±0.1 
0
2
4
6
8
10
12
0.01 0.1 1 10 100 1000 10000
Vo
lu
m
e (
%
)
Size (µm)
3A
3B
Solubility study and experimental design 
 
 
 
157
 
t0 = 0 s 
 
tf = 10 min 
 
Figure 3.9. Particle size distribution by laser granulometry for T-mixer at total flow rate 
of 44.51 g/min and ethanol-water ratio of 25-75 % (w/w), at t0 = 0 min and tf = 10 min. 
Experiment D[4;3] (µm) Span 
2A 2 1.3 
2B 2 2.6 
Average 2±0 1.9±0 
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t0 = 0 s 
 
tf = 10 min 
Figure 3.10. Particle size distribution by laser granulometry for T-mixer at total 
flow rate of 69.56 g/min and ethanol-water ratio of 25-75 % (w/w), at t0 = 0 min and tf = 
10 min. 
 
Experiment D[4;3] (µm) Span 
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3.4.1.4. Influence of addition time and steady state  
From the previous section, for all experiments the particle size average (PCS) 
presented a nanometric range right after crystallization. But the crystals size has evolved 
quickly until stabilization, i.e. micrometric range.  
In the case of uncontrolled crystallization, the size evolution of crystals can be 
due to growth or agglomeration mechanism. To know which crystallization 
phenomenon control the increase of size crystal, the population balance was proposed. 
For this simple calculation the steady state must be achieved, i.e. particle of size 
constant. 
An experiment over the time under the best crystallization condition was 
realized. The ethanol-water ratio equal to 25-75 % (w/w) and total flow rate of 44.51 
g/min, were chosen, based on previous results.  
The experiment does not last very long, only 6 min. This is due to problems of 
blockage, caused by affixation of solid on the surface of the mixer, as shown in Figure 
3.11. This problem can be caused by the affinity of the molecule with the material, 
which constitutes the surface of the mixer. It precludes the system from reaching the 
steady state and consequently, it prevents to calculate the growth and nucleation rates 
from population balance.  
 
Figure 3.11. Blockage and affixation of CRS 74 crystals on surface of the T-
mixer. 
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The blockage problem can be related to high saturation (S) of the alcoholic 
solution. In order to prevent the blockage problem, a second experiment with a low flow 
rate and a low supersaturation was performed, as shown in Table 3.14. In this 
experiment, different samplings from the outlet of the mixer as a function of time were 
realized. 
 
Table 3.14. Experimental LAS crystallization process conditions 
Experiment 
Total flow 
(g/min) 
ethanol-water ratio 
(w/w) 
S* 
5 44.51 25-75 % 894.0 
6 27.09 25-75 % 15.4 
*S= C /Ceq, - C is concentration after dilution with anti-solvent by assuming no crystallization 
(mg/g) and Ceq is the equilibrium concentration of the pharmaceutical active in the solution water+ethanol 
(mg/g) 
 
Comparing the results of both supersaturations at the same time, it was perceived 
that there is no big difference between the size particles values, as a function of time, as 
given in Table 3.15. It means that the supersaturation does not have a great influence on 
the particle size. It can be noted too, that the particle size for both experiments increases 
as a function of time. It means that, the steady state was not achieved for population 
balance calculus. 
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Table 3.15. Particle size distribution by PCS: S = 894.04 and S = 15.4.  
 S= 894.0 S= 15.4 
t (min) Size (nm) at t0 = 0s Size (nm) at t0 = 0s 
0 438 421 
2 455 491 
4 503 579 
6 688 x 
 
For both experiments, the particle size measurement as a function of time does 
not last very long (t < 6 min) due to problems of blockage. 
The essay with the lower supersaturation and flow rate lasted less than the other 
one, only 4 minutes. In this process condition the residence time of the crystals is 
bigger, as shown in Table 3.10 (0.11 s for 27.09 g/min and 0.07 for 44.51 g/min). It 
means, that the crystals have more time to be in contact with the surface of mixer, 
causing problems of blockage. Furthermore, the particles in nanometric range have a 
high-energy surface; this property can potentiate the high affinity of CRS 74 on the 
surface material. 
Because of this drug behaviour, which precluded the realization of essays over 
time, it was not possible to simply calculate the nucleation and agglomeration rates. In 
addition this drug behaviour prevent the use of this crystallization proceeding in 
industrial applications. 
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 Characterization of solid particles obtained in experimental design 3.4.2.
 
By comparing the SEM photos of raw material and the synthetized powders, a 
decrease of the crystal size (elementary particles and agglomerates) and no shape 
changes can be observed in Table 3.16. This size reduction can indicate an influence of 
the crystallization process on the size particle. On the other hand, the presence of 
powder compact agglomerates was noted. This agglomeration phenomenon may be due 
to the crystallization process (particle surface state) and to the powder recuperation 
process (filtration and drying). 
 
The powder obtained were characterized by purity ranging from 97.00% ± 2.76 
%. This value can prove that the experimental proceeding does not induce the product 
contamination by germs in tubing elements of pump or in mixer device. 
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 Comparative study of original CRS 74 and LAS recrystallized drug with T-3.4.3.
mixer
According to experimental result (see section 3.4.1.2) the T-mixer was chosen for the 
following steps. The original CRS 74 (raw material) and recrystallized powder using T-mixer 
using the best experimental conditions was characterized in order to verify physicochemical 
changes, among the products after recrystallization process. 
3.4.3.1. Particle size and morphology  
Laser diffractometry yields the volume-weighted diameters. The dv10%,dv50% and 
dv90% represent the sizes in which 10%, 50% and 90% of the particles are below the given 
sizes, respectively. From Figure 3.12, it can be seen that the particle size distribution changed 
as follows: the original CRS 74 with 90%, 50% and 10% of the particles smaller than 515 µm, 
101 µm and 4.3 µm were reduced respectively to 138 µm (dv90%), 34 µm (dv50%) and 4.4 µm 
(dv10%) after LAS recrystallization.  
 
Figure 3.12. Particle size (laser diffraction data) of CRS 74, before and after the LAS 
recrystallization process. 
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These results are supported by the powder morphology observed by SEM (Figure 3.13). 
The particles of the original powder were found to be larger and exhibiting a broad particle 
size distribution compared to the LAS recrystallized drug.   
  
(a) (b) 
  
(c) (d) 
Figure 3.13. SEM micrographs of the original (a, b) and LAS recrystallized CRS 74 (c, 
d). 
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3.4.3.2. XRD analysis 
XRD analysis was performed to detect the changes in the physical state and crystalline 
phases of the drug, before and after LAS recrystallization. Figure 3.14 shows the XRD 
patterns for the two studied samples. CRS 74 shows peaks at approximately 8.5, 14, 16.9, 
18.7, 19.4 and 21.3°, indicating that the drug was a crystalline powder. Comparing the DRX 
diffractograms of LAS recrystallized drug to the original CRS 74 it can be seen that the 
crystalline phases were preserved. 
 
 
Figure 3.14.  X-Ray diffractograms of the original and LAS recrystallized drug 
powders. 
3.4.3.3. DSC analysis 
The DSC thermograms of original and LAS recrystallized drug are presented in Figure 
3.15. The onset melting point and fusion enthalpy obtained from the DSC study are 
summarized in Table 3.17. Relative enthalpy is calculated by taking the fusion enthalpy of 
original CRS 74 powder as 100%.  
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From DSC data, it was concluded that LAS recrystallization changed marginally the 
thermal properties of the drug.  
 
(a) 
(b) 
Figure 3.15. a) DSC thermograms of original CRS 74 (first heating), which consists of 
a melting endotherm (peak onset temperature Tm(Onset) = 188.64oC) and LAS recrystallized 
drug, which consists of a melting endotherm (peak onset temperature Tm(Onset) = 187.79oC); b) 
DSC thermograms of original CRS 74 (cooling after first heating), which consists of a 
crystallization exotherm (peak onset temperature Tc(Onset) = 132.12oC) and LAS recrystallized 
drug, which consists of a crystallization exotherm (peak onset temperature Tc(Onset) = 
138.43oC). 
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The observed reduction of the fusion enthalpy (Table 3.17) may be caused by the 
higher surface/volume ratio exhibited by the LAS recrystallized powder, needing lower 
energy for melting. Crystal energy is known to correlate with Tm(Onset) (onset melting point) 
and ∆hf (enthalpy of fusion), which refers to the energy a compound must overcome to 
dissolve (VIPPAGUNTA et al., 2007). 
 
Table 3.17. Melting Temperature (Tm(Onset)), Heat of Fusion (Δhm) for the original and 
LAS recrystallized drug. 
Thermal and dissolution 
parameters 
Original 
CRS 74 
LAS recrystallized 
CRS 74 
Tm(Onset)(°C) 188.6 187.8 
Δhm (J/g) 86.6 79.2 
Relative enthalpy(%) 100 91.5 
 
3.4.3.4. Dissolution studies 
Figure 3.16 shows the dissolution profiles of original and LAS recrystallized CRS 74 
in 0.1 M HCl (pH 1.2). It can be seen from Figure 3.13 that both drug samples did not even 
reach 50% dissolution within 3 h. 
The dissolution profiles were compared through the model-independent simple 
method. The model-independent simple method includes the difference factor (f1) and the 
similarity factor (f2), calculated by using the following equations (3.7) and (3.8) (MOORE 
and FLANNER, 1996; COSTA and LOBO, 2001).  
  
  

   (3.9) 
     


  



   (3.10) 
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where Rt and Tt are the percentage of drug dissolved at each time point for the reference and 
test products, respectively; n is the number of dissolution sample times and t is the time points 
for collecting dissolution samples. 
The f1 factor measures the percentage of the error between two curves over all time 
points. This percentage is zero when the test and drug reference profiles are identical and 
increases proportionally with the dissimilarity between the two dissolution profiles. The f2 
factor is a logarithmic transformation of the sum-squared error of differences between the test 
and the reference products over all time points. When the two profiles are identical, f2=100. 
An average difference of 10% at all measured time point results in a f2 value of 50. FDA has 
set a public standard of f2 value in the range 50-100 to indicate similarity between two 
dissolution profiles.  
Since original CRS 74 is the reference, the factors f1 and f2 are calculated between this 
product and the LAS recrystallized powder. The results of f1 and f2, 24.8 and 98.8, 
respectively, showed that the profiles of original CRS 74 and LAS recrystallized drug are 
almost similar.  
 
Figure 3.16. Dissolution profiles of CRS 74, before and after LAS recrystallization (in 
0.1 M HCl at 37 °C, n = 4). 
0 
10 
20 
30 
40 
50 
60 
70 
80 
0 20 40 60 80 100 120 140 160 180 200 
D
is
so
lv
el
d 
D
ru
g 
(%
) 
Time (min) 
LAS recrystallized drug 
Original CRS 74 
Solubility study and experimental design 
 
 171 
3.4.3.5. Determination of surface properties  
The surface properties of drug samples were investigated to find a possible relation 
between surface properties and dissolution. Sessile drop contact is most commonly measured 
on compacted powder disc surface. However, compaction of the material can alter the particle 
morphology and surface energy (BUCKTON, 1955). Alternatively, some of the authors 
(AHFAT et al, 2000; HE et al, 2008) have reported the use of powder layer adhered to an 
inert support. The powder layer was adopted for the present work as it allows the study of “as 
is” powder properties. This method gave reproducible values.  It has been seen that contact 
angle measurements can vary with experimental methodology, however the technique was 
used for comparative evaluation between LAS recrystallized samples and the original drug 
powder.  
The contact angle of drop deposited on powder surface was plotted as a function of 
time from 0 to 10 s, beyond which there was no significant change in the contact angle. With 
water as the wetting liquid, original drug crystals exhibited a contact angle almost unchanged 
with time from 136.4 ± 0.8° (0 s) to 136.6 ± 0.6°(10 s), as shown in Figure 3.17. In turn, LAS 
recrystallized drug exhibited an initial contact angle of 133.5 ± 1.8° which changed 
marginally to 132.9 ± 1.7° over the 10 s period.  
The wetting process with water was quantified for the work of adhesion (Wa), 
cohesion (WCL) and the spreading coefficient (λLS), as already calculated in Chapter 2, 
section 2.3.5.  
The contact angle made at 0 s was considered as the initial contact angle and the surface 
tension of water was taken from the literature (72.8 mN/m; PURI et al., 2010). These values 
were used to determine Wa, WCL and λLS from equations (2.2), (2.3) and (2.4) for the drug 
powders (Table 3.18). 
The thermodynamic driving force for each process is indicated by the work value, 
where a negative value denotes the spontaneity of the process (Young and Buckton, 1990). 
The positive Wa and WCL obtained for both drug powders indicated that the adhesion and the 
cohesion processes are not spontaneous in both cases. Further, a negative spreading 
coefficient (λLS < 0) means that the original CRS 74 displayed an unfavorable spreading of 
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water (NGUYEN and HAPGOOD et al., 2010), characteristic which remained unchangeable 
after LAS recrystallization of the drug. This poor wettability can be related to the poor 
dissolution rates measured. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17. Contact angle (o) of water as a function of time for: a) original CRS 74; b) 
LAS recrystallized drug.  
 
(a) 
 
(b) 
100 
105 
110 
115 
120 
125 
130 
135 
140 
145 
150 
0 1 2 3 4 5 6 7 8 9 10 
C
on
ta
ct
 A
ng
le
 (°
) 
Time (seconds) 
θ=136.4°±0.85  θ= 136.6°±0.57 
Solubility study and experimental design 
 
 173 
Table 3.18. Work of adhesion (WA), cohesion (WCL) and spreading coefficient (λLS) 
for CRS 74. 
Sample WA (mN/m) WCL (mN/m) λLS (mN/m) 
CRS 74 20.08 145.6 -125.6 
LAS recrystallized powder 22.69 145.6 -122.9 
 
 
3.5. CONCLUSIONS 
The present chapter had the purpose to determine the solubility of CRS 74 in binary 
solvent mixture (ethanol-water) and to study the influence of operational parameters on the 
synthesis of a pharmaceutical drug. 
The CRS 74 is soluble in ethanol (92.6 mg/gsolution) and seems to present a maximum 
in solubility in ethanol-water mixtures as determined in this study using UNIQUAC-based 
model at 30°C. To the best of our knowledge, there are no published data of the solubility of 
such given solute in ethanol-water mixtures to compare with. 
The synthesis process should result in a powder with small crystal size with the view 
to improve the bioavailability of the drug. 
According to two main parameters tested, type of mixer and flow rate, uncontrolled 
crystal growth and no change on the final product was observed, i.e. the operational 
parameters do not have influence on recrystallized particles. These experiments proved to be 
quite laborious due to the rapid growth and agglomeration of the produced particles and 
problems of blockage of the mixer. Because of this drug behaviour, which precluded the 
realization of essays over time, it was not possible to simply calculate the nucleation and 
agglomeration rates. In addition this drug behaviour prevent the use of this crystallization 
proceeding in industrial applications. 
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After setting process conditions, a solid crystallized by LAS crystallization (operating 
conditions) was compared (or has been compared) to the raw material. After crystallization 
process the synthesized product do not present any crystallinity changes. However, a decrease 
of particle size was observed and consequently a considerable agglomeration of crystals. 
Furthermore, in the case of CRS 74 LAS crystallization does not have a real impact on the 
dissolution rate of synthesized powder. 
In an attempt to improve its dissolution properties, CRS 74 can be recrystallized by 
using a Liquid Anti-solvent (LAS) crystallization process and the data generated here can 
represent a useful tool to define the mass proportion between solvent (ethanol) and anti-
solvent (water) for LAS crystallization studies. However, to improve its dissolution kinetics, 
smaller particles with a more hydrophilic surface need to be produced. This research is going 
on and our specific aims are to consider the feasibility of the LAS crystallization using 
different excipients to optimize process and formulation parameters. 
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Résumé Chapitre 4- Etude de la recristallisation par effet anti-solvant en 
présence d’additifs 
En vue d’améliorer sa dissolution en milieux aqueux, le CRS 74 a été recristallisé en 
utilisant une opération de cristallisation par effet anti-solvant en présence d’additifs.  
Des additifs ont donc été utilisés en vue de modifier les propriétés de dissolution des 
cristaux, et les vitesses de cristallisation (nucléation, agglomération, croissance). 
L'effet des additifs sur la taille des cristaux, la cinétique de dissolution et la 
mouillabilité du solide synthétisé a été étudié.  
Les additifs ont été choisis en accord avec des applications pharmaceutiques futures de 
cette molécule. Ils sont de quatre types 
-des tensio-actifs non ioniques : Tween 20 (ester de sorbitan polyoxyéthylénique) et 
HPMC (Hydroxypropylméthylcellulose) pour une stabilisation stérique, 
- un copolymère à bloc, le poloxamer 407 (P-407) pour une stabilisation stérique, 
-un tensio-actif anionique, le dodécylsulfate de sodium (SDS) pour une répulsion 
électrostatique, 
-un copolymère composé de D-glucosamine et de N-acétyl-D-glucosamine (chitosane) 
pour un effet combiné de stabilisation stérique et répulsion électrostatique. 
Ils ont été introduits dans le solvant (éthanol) ou dans l'anti-solvant (eau), ou dans les 
deux phases.  
Par rapport aux additifs testés, des changements des propriétés de surface ont été 
constatés. Une diminution remarquable de l'angle de contact a été observée pour deux 
formulations, une avec le copolymère  à bloc P-407 (concentration de 0,02 %, > CMC dans la 
phase organique) et l'autre avec ce dernier combiné avec du chitosane (P-407 concentration de 
0.02 %, > CMC dans la phase organique et le chitosane avec une concentration de 0,5 % dans 
la phase aqueuse). De plus, la dissolution a été améliorée de façon très notable : à 20 min de 
dissolution, le pourcentage dissous du principe actif est de 4% avec la poudre initiale et de 
l’ordre 40% pour la poudre recristallisée avec ces deux formulations.
  
Dans l'ensemble, les résultats ont montré de façon concluante que la technique de 
cristallisation par effet anti-solvant en présence d'additifs a permis de produire des 
microcristaux présentant des profils de dissolution nettement plus rapide que la poudre 
originale. L’amélioration de la dissolution peut-être due à la réduction de la taille des 
particules des cristaux du principe actif mais aussi à l'amélioration des propriétés de 
mouillage due aux interactions spécifiques entre le principe actif, les additifs et le milieu 
aqueux de dissolution. Il est important de noter qu’aucun colmatage n’a été observé avec la 
formulation combinant les additifs P-407 et chitosane. 
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4.1.INTRODUCTION  
Up to now, we could demonstrate that LAS recrystallization process reduced the mean 
particle size and particle size distribution of the CRS 74 crystals. However, this particle size 
reduction did not change the dissolution rate as it could be expected with the increased 
surface area of the powder. In fact, the powder is characterized by a very high hydrophobicity 
as confirmed experimentally, and the particles once formed in a nanometric size range grew 
up very fast and finally agglomerated, reducing the powder surface area in contact with the 
dissolution medium. In addition, a very strong attraction between the drug particles and the 
metallic surface of the rapid mixers used in the process led to a retention of the solid inside 
the mixers and to the interruption of the continuous process.  
In this last part of the work, we investigated the effect of organic additives in the CRS 
74 recrystallization using the LAS process. Changes in drug-crystal properties were evaluated 
for particle size and shape, crystal structure, surface characteristics such as wettability and 
dissolution rate. The methodology and the results obtained are presented in this Chapter. 
Considerations for selection of stabilizers 
In LAS crystallization, the mixing process and the control of supersaturation are crucial 
factors to control the production of uniform and small solid drug particles. However, as 
already discussed in Chapter 1, the addition of stabilizers  in the process in order to inhibit 
excess crystal growth or particle aggregation has been related by a great number of scientific 
publications (ALI et al., 2011, GHOSH et al., 2011, SU et al., 2011).  
Stabilizers can be added either in solvent or anti-solvent, acting as surface modifiers. 
Polymers are often used for steric stabilization, while surfactants are often used for 
electrostatic stabilization. The suitable stabilization depends on properties of the substance 
that should crystallize. Charge and hydrophilicity are some important properties to consider. 
The stabilizer must of course have sufficient affinity for the particles surface, and it must also 
have a rather high diffusion rate in order to rapidly cover the generated surface. 
Unfortunately, there exists no systematic technique to determine the effectiveness of additives 
a priori. Stabilizing agents are chosen from the list of pharmaceutically acceptable substances, 
with surface active properties capable to provide steric and/or ionic stabilization against 
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growth and agglomeration of drug particles, during LAS crystallization. In this study, 
stabilizers were screened and introduced in the solvent, or in the anti-solvent, or in both 
phases. 
Two main mechanisms of stabilization were tested: steric stabilization and electrostatic 
repulsion. 
For steric stabilization, we used non ionic polymers and amphiphilic block 
copolymers:  
• Polyoxyethylene sorbitan monooleate (Tween 20), a nonionic surfactant.  
If this additive is adsorbed on the surface of a hydrophobic drug like CRS 74, we could 
expect that a mechanical barrier would be formed against crystal growth and agglomeration. 
The additive would occupy the adsorption sites on the surface of freshly formed CRS 74 
crystals during LAS crystallization, and inhibits subsequent growth by inhibiting the 
incorporation of drug molecules from solution into crystal lattices, as already observed for 
other drugs such as Fenofibrate and Acid Folic (WU et al. 2011; PARDEIKE et al., 2011); In 
addition, Tween 20 was selected because it is also very well tolerated in pharmaceutical 
formulations, being accepted even for intravenous injection (FDA, 2007). 
• Hydroxypropylmethylcellulose (HPMC), a neutral polymer. 
It could be expected that this polymer adsorbs on the hydrophobic CRS 74 surface and 
the portions of polymer chain extending in solution provides steric protection. HPMC is a 
stabilizer frequently used in LAS crystallization studies due to its characteristic of good 
solubility in water and not being toxic (DONG et al., 2009). 
• Poloxamer 407 (P-407) copolymer (ethylene oxide and propylene oxide blocks), a 
hydrophilic non-ionic surfactant of the more general class of copolymers known as 
poloxamers.  
Poloxamer-407 can induce the steric stabilization and its use in pharmaceutical 
formulations is approved (oral solutions, ophthalmic solutions, periodontal gels and 
topical emulsions (REHMAN, 2011).  
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For electrostatic repulsion, the anionic surfactant Sodium dodecyl sulfate (SDS) was 
chosen. This surfactant has been used as an electrostatic stabilizer with high affinity to absorb 
onto particle surfaces leading to high zeta potentials. It is a regulatory accepted stabilizer for 
oral dosage forms (e.g. tablets and capsules), and is therefore suitable to be used in 
nanosuspensions (HU et al., 2011). 
For a combined effect of steric stabilization and electrostatic repulsion, we tested 
Chitosan, a copolymer of glucosamine and N-acetyl glucosamine, a polycationic, 
biocompatible and biodegradable polymer.  
Chitosan is a compound which combines the electrostatic stabilization due to its 
positive charge in acidic medium, and the steric stabilization because of its polymeric nature. 
Theoretically, that means that if the polyelectrolyte adsorbs onto the surface of small embryo 
drug particles surface, it should be the ideal stabilizer because it combines electrostatic and 
steric stabilization, it forms a strong double layer around hydrophobic drug particle. In 
addition, the chitosan can increase the drug bioavailability due to mucoadhesion, that is able 
to increase cellular permeability (BOWMAN and LEONG, 2006). 
Concerning surfactants, in aqueous solution, dilute concentrations of surfactant act 
much as normal electrolytes, but at higher concentrations a very different behavior is 
observed. This behavior is explained in terms of formation of organized aggregates of large 
numbers of molecules called micelles, in which the lipophilic parts of the surfactants associate 
in the interior of the aggregate leaving hydrophilic parts to face the aqueous medium. 
The physico-chemical properties of surfactants vary markedly above and below the 
CMC value. As an example, below the CMC value, the physico-chemical properties of ionic 
surfactants like sodium dodecylsulfate, SDS, (e.g., conductivities, electromotive force 
measurements) resemble those of a strong electrolyte. Above the CMC value, these properties 
change dramatically, indicating a highly cooperative association process is taking place, This 
is illustrated in Figure 4.1. ( LAURIER et al., 2003). 
Based on this discussion, the CMC values can be important in our additives study, and 
the additive concentration for the surfactants Tween 20, SDS and Poloxamer 407 were varied 
from below to above their CMC. The CMC is also of interest because at concentrations above 
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this value, the adsorption of surfactant at interfaces usually increases very little. This means 
that the CMC frequently represents the solution concentration of surfactant from which nearly 
maximum adsorption occurs (LAURIER et al., 2003). 
 
Figure 4.1. Variation in physical properties of   	
 (or SDS) 
surfactant solutions below and above the CMC value (from Laurier et al, 2003). 
To sum up, Tween 20, SDS, Poloxamer 407, HPMC and Chitosan are the chosen 
additives expected to improve particle size control during the LAS crystallization process of 
CRS 74, and they were introduced in the solvent (Poloxamer 407) or in the anti-solvent (all 
the other ones) in our CRS 74-ethanol-water system. 
 
4.2. Materials and methods 
 Materials 4.2.1.
The additives used are shown in Table 4.1. 
CMCs of Tween 20, SDS and Poloxamer 407 are given in Table 4.2. The CMC values 
for Tween 20 and SDS were found in the literature (Silva and Volpato, 2002).The CMC for P-
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407 was measured in the laboratory, using a tensiometer 3S ILMS (GBX Instruments, 
France).  
Table 4.1. Different additives used in LAS crystallization of CRS 74. 
Additives Chemical structure Supplier 
  
Sodium dodecyl sulfate (SDS) 
M.W. : 288 g/mol  
Fluka, France. 
Polyoxyethylene sorbitan 
monolaurate 
 (Tween 20) 
M.W. : 1228 g/mol 
 
Sigma–Aldrich, France. 
Poloxamer 407 or Pluronic 
F127 M.W. : 8400 g/mol
 
Basf, France. 
Hydroxypropylmethylcellulose 
(HPMC) 
M.W. : 22000 g/mol 
 
Sigma–Aldrich, France. 
Chitosan 
Low molecular weight 
M.W . : 227000 g/mol 
 
Sigma–Aldrich, France. 
M.W.: Molecular weight 
 
A maximum concentration was fixed for all additives to give a mass ratio of 1:4 
(additive:drug). This corresponds to 0.5%w/w for HPMC, Chitosan, Tween 20 and SDS in 
water and 0.02% (w/w) for P-407 in ethanol. 
  
H3C O 
SO3Na 
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Table 4.2. Critical micelle concentration of additives used in LAS crystallization at 25°C. 
Addtive CMC value (w/w) Reference 
Tween 20 0.05 % SILVA and VOLPATO, 2002 
SDS 0.1 % SILVA and VOLPATO, 2002 
Poloxamer P-407 0.0008 % Measured experimentally 
 
 Methods  4.2.2.
4.2.2.1. Production of particles by LAS crystallization in presence of additives 
The original CRS 74 crystals were recrystallized by the LAS crystallization method 
already described in Chapter 3, using the same experimental set-up. Briefly, a certain amount 
of original CRS 74 samples was completely dissolved in ethanol at 30 ± 0.5°C at definite 
concentration (90 mgCRS 74/gsolution). The solution was filtrated through 0.22 µm pore size 
membranes to remove the possible particulate impurities. The drug was then recrystallized via 
the concurrent introduction of the CRS 74 ethanol solution and an anti-solvent stream of 
water in the T-mixer. The freshly formed crystals were collected in a vessel under magnetic 
stirring and then filtered and dried under vacuum at 50 ± 1°C for 24 h. The dried samples 
produced in the process were characterized by laser diffractometry, differential scanning 
calorimetric analysis, X-ray diffraction analysis, scanning electron microscopy analysis, 
sessile drop method and dissolution testing. 
The experimental conditions are summarized in Table 4.3. The studied parameters were:  
1. Phase for incorporation of the additive (organic solution, aqueous solution or both 
solutions); 
2. Additive concentration  (above and below CMC); 
3. Drug concentration in the organic phase; 
4. Re-structured organic phase containing P-407: Poloxamer 407 was introduced in a 
dilute ethanol solution (concentration below its CMC), before the drug. The resulting 
solution was then heated under controlled conditions (rotoevaporator) to promote a 
partial evaporation of the solvent and concentrate the solution to a surfactant 
concentration above its CMC. 
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Table 4.3. Experimental conditions for LAS crystallization in presence of additives. 
Experiment 
 
AdditiveOrganic phase 
 
 
Ratioaddit.org.:drug 
 
AdditiveAqueous phase 
 
Ratioaddit.aqu.:drug 
  
S 
(S=C/Ceq) 
1 X X X X 894.04 
Additive in the aqueous phase  
2 X X HPMC 0.5% w/w 1:6 445.63 
3 X X 
SDS < CMC 
(0.008% w/w) 1:4000 391.85 
4 X X SDS 0.5% w/w 1:6 150.51 
5 X X 
Tween 20 < CMC 
(0.008% w/w) 1:4000 541.13 
6 X 
X Tween 20 
0.5% w/w 1:6 398.72 
7 X 
X Chitosan  
0.5% w/w 1:6 * 
Additive in the organic phase 
8 
P-407 < CMC 
(0.0003%w/w) 1:8000 X X 901.97 
9 
P-407> CMC 
(0.02% w/w) 1:4 X X 673.40 
Additive in both, organic and aqueous phases 
10 
P-407 < CMC 
(0.0003%w/w) 
1 :10000 SDS  
0.5% w/w 1:6 217.11 
11 
P-407> CMC 
(0.02% w/w) 
1:4 SDS  
0.5% w/w 1:6 194.93 
12 
P-407 < CMC 
(0.0003% w/w) 
1 :10000 Chitosan  
0.5% w/w 1:6 * 
13 
P-407 > CMC 
(0.02% w/w) 
1:4 
Chitosan  
0.5% w/w 
1:6 * 
Drug concentration in the organic phase 
14 
P-407 > CMC 
(0.02% w/w) 
1:4 X X 374.51 
15 
P-407 > CMC 
(0.02% w/w) 
1:4 X X 156.41 
16 
P-407 > CMC 
(0.02% w/w) 
1:4 SDS 0.5% w/w 1:3 104.50 
17 
P-407 > CMC 
(0.02% w/w) 
1:4 SDS 0.5% w/w 1:1.5 43.25 
18 
P-407 > CMC 
(0.02% w/w) 
1:4 Chitosan 0.5% w/w 1:3 * 
19 
P-407 > CMC 
(0.02% w/w) 
1:4 Chitosan 0.5% w/w 1:1.5 * 
Reorganized organic phase containing P-407 
20 
P-407 < CMC 
(0.0003% w/w) 
1:4 X X 77.59 
21 
P-407 < CMC 
(0.0003% w/w) 
1:4 Chitosan 0.5% w/w X * 
*Data not determined  
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4.2.2.2. Determination of solubility in presence of additive 
The equilibrium concentration (Ceq) for the CRS 74-ethanol-water system was 
previously measured and presented in Chapter 3. The presence of additives can modify the 
drug saturation concentration in this system. The solubility of CRS 74 was then determined in 
presence of additives, for a mass proportion of 1 ( 25% solvent) to 3 ( 75% anti-solvent) using 
the same procedure as described previously. The new solubility data were used to estimate the 
theoretical efficiency of the process as a function of the additive used. 
4.2.2.3. Characterization methods  
 Measurements of particle size during the crystallization process 4.2.2.3.1.
Particle size was measured during the crystallization process and at the end of the 
process, after product drying. 
In a first step, at the exit of the T-mixer, the mixed phases were poured into a vessel 
under agitation and a sample was immediately submitted to a particle size analysis in a 
Zetasizer Nano Zs (Malvern Instruments, United Kingdom) to follow the growth of small 
embryo particles in the crystallization medium during 150 seconds. To achieve appropriate 
measurement concentration for analysis, the sample was diluted 5 times using a saturated 
solution composed of water, ethanol, drug and the additive. 
At the end of the process (2 min), the final suspension was filtered and the solids were 
dried under vacuum at 50 ± 1°C for 24h. The dry powder was then analyzed by laser 
granulometry, using a MasterSizer 3000 (Malvern Instruments, United Kingdom). All 
samples were firstly mixed with Tween 20 to increase the powder dispersion in dispersive 
media, and then dispersed in water until achievement of the good obscuration. The sampling 
procedure is schematized in Figure 4.2. 
 
Zeta potential  
The zeta potential was also determined in the Zetasizer Nano Zs (Malvern 
Instruments, United Kingdom) by measuring the electrophoretic mobility of the particles. The 
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measurements were performed on the same sample taken at the exit of the T-mixer 
immediately diluted with the saturated solution. 
 
 
Figure 4.2. Particle size analysis using Zetasizer Nano Zs (particles in suspension) and 
MasterSizer 3000 (dried powders).  
 
Powder physicochemical properties  4.2.2.3.2.
Size distribution, surface properties, morphology, drug purity and dissolution kinetics 
of recrystallized powders were determined as previously described in Chapter 3.   
 
Final drug suspension 
in the water-ethanol 
solution 
Sampling 
Dilution  
Measure time (s) 
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150 
Particle size evolution 
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Particle size distribution 
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4.3. RESULTS AND DISCUSSION 
 CRS 74 solubility in presence of additives 4.3.1.
The results obtained for the solubility of CRS 74 in presence of additives are presented 
in Table 4.4.  Figure 4.3 displays the same data graphically. It can be seen that the effect of 
additives on the drug solubility in the ethanol-water mixture depended on the type and the 
concentration of the additive used. 
Surfactants in solution below their critical micelle concentration (CMC) improve drug 
solubility by providing regions for hydrophobic drug interactions in solution (NARANG et al, 
2007). It can be seen that the presence of the three additives used here in a concentration 
below their CMC (Tween 20, SDS and P-407) improved only modestly the drug solubility in 
the ethanol-water mixture (0.025-0.05 mg/gsolution ). 
Above the CMC, surfactants self-aggregate in defined orientation to form micelles with 
a hydrophobic core and a hydrophilic surface. The hydrophobic core enhances the entrapment 
of drug, thus increasing its solubility (RANGEL-YAGUI et al., 2005), which probably 
happened to CRS 74 but the effect is still marginal with Tween 20 and P-407 (0.025-0.057 
mg/gsolution).  
The extent of CRS 74 solubility in the micelle cores formed with the different additives 
is probably dependent on the compatibility between the drug and the micelle core. In contrast, 
SDS in concentration above its CMC increased the Ceq from 0.025 to 0.151 mg/gsolution. The 
highest solubilization capacity of SDS can be attributed in part to its anionic charge. 
According to the literature, the solubilizing powers of the surfactants is in the order of anionic 
< cationic < nonionic (TOKIWA, 1968). 
Finally, the presence of HPMC did not have a significant influence on the Ceq.   
The solubility of CRS 74 in presence of chitosan could not be measured because any 
drug peak was detected by HPLC analysis. 
 
Effect of Additives in LAS crystallization
 
 189 
Table 4.4. CRS 74 solubility in ethanol-water mixture with a ratio of 25-75 % (ww) at 
30°C. 
Additive Solubility (mg/gsolution) ±SD 
No additive (original CRS 74) 0.025±0.000 
No additive (recrystallized CRS 74) 0.025±0.000 
P407< CMC (0.0003%w/w) 0.025±0.000 
P407> CMC (0.02%w/w) 0.033±0.002 
HPMC 0.5%w/w 0.051±0.002 
Tween 20 < CMC (0.008%w/w) 0.042±0.000 
Tween 20 0.5%w/w 0.057±0.001 
SDS<CMC (0.008%w/w) 0.058±0.003 
SDS 0.5%w/w 0.151±0.003 
SDS 0.5% +P407< CMC (0.0003%w/w) 0.106±0.001 
SDS 05%+P407> CMC (0.02%w/w) 0.114±0.003 
 
 
Figure 4.3. CRS 74 solubility in ethanol-water mixture with a ratio of 25-75 % (w/w) at 
30oC, in presence of different additives. 
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 Effect of additives on yields of production of CRS 74 crystals 4.3.2.
The crystals suspension obtained immediately after the crystallization process, in 
absence of additives, had a milky aspect, which changed into a clear solution after several 
minutes. In contrast, for the particles crystallized in presence of additives, this phenomenon 
was not observed. The crystal suspension maintained a milky appearance until the filtration 
step, which could represent a first indication on the additive effect for covering the CRS drug 
crystal surfaces and inducing steric or electrostatic hindrance to prevent crystal growth or/and 
agglomeration.  
Theoretical yield is the maximum amount of recrystallized dry crystals that can be 
created by the given amount of initial mass of raw crystals. The yields of production  were 
calculated as the weight percentage of the crystal powder after drying with respect to the 
initial total amount of drug used for recrystallization. Table 4.5 shows that the percent yield of 
production that was obtained from the LAS crystallization ranged from approximate 50 to 
87%. Tween 20 0.5% was proven to be the most effective stabilizer to improve the percent 
yield of crystals. 
There are some unavoidable errors that prevented the experiments from achieving 
100% yield. Probably the most common error was mass losses in all experiments due to 
operation of solid and liquid transfer. The filtration process may allow some of the product to 
pass through. Also during recovery there was some product lost. For instance, some of the 
product was stuck inside the T-mixer and could not be completely removed.   
The next sections will present and discuss experimental data related to the solid 
properties when additives were placed respectively in the aqueous phase, in the organic phase 
and in both phases. 
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Table 4.5. Theoretical and Practical Yield (%) of CRS 74 crystals obtained by LAS 
crystallization process.  
Experiment Additive 
Theoretical 
Yield (%) 
Yield of 
production 
(%) 
1 X 99.67 79.44 
Additive in aqueous phase 
2 HPMC 0.5% w/w 99.84 50.23 
3 SDS<CMC (0.008%w/w) 99.86 76.61 
4 SDS 0.5% w/w 99.95 75.56 
5 Tween 20<CMC (0.008%w/w) 99.80 47.15 
6 Tween 20 0.5% w/w 99.86 86.77 
7 Chitosan 0.5% w/w * 64.78 
Additive in organic phase 
8 P-407<CMC (0.0003%w/w) 99.67 65.63 
9 P-407>CMC (0.02%w/w) 99.75 70.96 
Additive in both, organic and aqueous phase 
10 P-407<CMC (0.0003%w/w)+ SDS 0.5% w/w 99.92 72.74 
11 P-407>CMC(0.02%w/w)+ SDS 0.5% w/w 99.91 87.83 
12 P-407<CMC(0.0003%w/w)+Chitosan 0.5% w/w * 76.43 
13 P-407>CMC(0.02%w/w)+Chitosan 0.5% w/w * 83.74 
Drug concentration in the organic phase 
14 P-407>CMC (0.0003%w/w) 99.75 52.81 
15 P-407>CMC(0.02%w/w) 99.75 74.55 
16 P-407>CMC(0.02%w/w)+ SDS 0.5% w/w 99.91 72.48 
17 P-407>CMC(0.02%w/w)+ SDS 0.5% w/w 99.91 65.43 
18 P-407>CMC(0.02%w/w)+Chitosan 0.5% w/w * 65.00 
19 P-407>CMC(0.02%w/w)+Chitosan 0.5% w/w * 60.19 
Reorganized organic phase 
20 P-407<CMC(0.0003%w/w)       99.75 57.56 
21 P-407<CMC(0.0003%w/w)+Chitosan 0.5% w/w * 57.92 
*Data not determined     
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Effect of presence of the additive in the aqueous phase on physical and 4.3.3.
surface properties of recrystallized powders 
Table 4.6 summarizes the results related to the particle size evolution of the small 
embryo particles formed at the exit of the T-mixer, when the additive was added in the 
aqueous phase (HPMC, SDS, Tween 20 and Chitosan). As it can be seen, in all studied 
systems, the drug particles presented almost the same size (140 - 240 nm), regardless of the 
type of additive used. However, these particles grew fast reaching in 150 s (t150) almost 2 times 
their initial particle size (t0). 
 
Table 4.6. Initial average particle size (APS) and characteristics of  CRS 74 crystals in 
suspension in presence of different additives in the aqueous phase  
Experiment Additive Time (s) APS(nm) 
Zeta potential 
(mV) 
pH suspension 
1 X 
t0  248 * * 
t150 417 -2.11± 0.28 3.28 
2 HPMC 0.5% w/w 
t0 245 * * 
t150 459 -2.44±0.27 4.88 
3 SDS<CMC(0.008%w/w) 
t0 174 * * 
t150 325 -18.57±0.31 4.48 
4 SDS 0.5% w/w 
t0 161 * * 
t150 358 -38.90±2.12 4.44 
5 
Tween 20<CMC 
(0.008%w/w) 
t0 138 * * 
t150 411 -8.67±1.27 4.53 
6 Tween 20 0.5% w/w 
t0 154 * * 
t150 308 -6.77±1.12 4.45 
7 Chitosan 0.5% w/w 
t0 204 * * 
t150 653 +35.20±1.40 4.44 
 
The particle charge was quantified as the so-called zeta potential, which was measured 
via the electrophoretic mobility of the particles in an electrical field. The zeta potential theory 
is described in very detail in the literature (HUNTER, 1981), here only a brief explanation is 
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given. In general, particles possess a surface charge which occurs due to the dissociation of 
surface functional groups, the so-called Nernst potential. Of course, the degree of dissociation 
of the functional groups depends on the pH of the suspension; therefore the zeta potential is 
pH dependent.  
Table 4.6 shows the changes on the zeta potential of the particles in presence of 
additives. When the crystals were synthesized without additives, they possessed a low 
negative surface charge (-2.1mV). The zeta potential remained almost unchanged when 
nonionic stabilizers, i.e. HPMC (-2.4mV) and Tween 20 (-8.7/-6.8mV) were used.  However, 
charged additives like SDS (negatively charged) and Chitosan (positively charged) adsorbed 
with the charged parts of the respective molecules onto the drug particle surface. The surface 
coverage increased with the increase in SDS concentration, leading subsequently to an 
increase of the zeta potential (-18.6/-38.9mV). The higher particles are equally charged, the 
higher is the electrostatic repulsion between particles.  
As a rule of thumb, suspensions with zeta potential above |30| mV are physically stable. 
Suspensions with a potential above |60| mV show excellent stability. Suspensions below 
|20|mV are of limited stability; below |5| mV they undergo pronounced aggregation (LEE et 
al., 2008; PATEL and AGRAWAL, 2011). Chitosan and SDS 0.5% were proven to be the 
best additives to ensure an electrostatic repulsion between freshly CRS 74 crystal formed in 
the LAS process. 
Table 4.7 summarizes some properties of the dried powder obtained at the end of the 
LAS crystallization process e.g., particle size, SEM images, contact angle and composition 
(drug content and residual solvent). For easier comparaison, the dv10%, dv50% and dv90% for the 
dried powders produced in presence of all additives tested in this study are gathered in Figure 
4.4. The corresponding particle size distributions are graphically presented in Appendix III. 
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Figure 4.4. Particle size of the drug powders synthesized in presence of additives in the 
aqueous phase (laser diffraction data).  
The primary role of stabilizers is to inhibit excessive crystal growth. In a general way, 
Figure 4.4 shows that most CRS 74 crystals produced in presence of additives had a smaller 
particle size compared to original or recrystallized powder without additives. Additives such 
as HPMC and Tween 20 (concentration below CMC) were less effectives to inhibit 
agglomeration, while a higher concentration of Tween 20 (above CMC) had a very positive 
effect on particle size control. 
Concerning particle morphology (see Table 4.7), the SEM images revealed that in the 
case of SDS, Tween 20 and Chitosan there was not particle shape changes on the columnar 
crystals or very little; Contrarily, clusters of thinner (predominantly needle-shaped) primary 
particles forming agglomerates or aggregates were obtained in presence of HPMC. This effect 
can be also confirmed by light microscopy (Appendix V) revealing agglomerates or particle 
assemblies composed of a large number of individual needle-shaped crystals). In this case, a 
possible explanation could be an inappropriate diffusion (too slow) of the solvent toward the 
anti-solvent caused by a high viscosity of the anti-solvent containing 0.5%w/w HPMC. A 
high viscosity could prevent diffusion between solution and anti-solvent and resulted in 
nonuniform supersaturation and agglomeration. 
0 
100 
200 
300 
400 
500 
600 
700 
800 
Or
igi
na
l C
RS
 74
 
 LA
S r
ecr
yst
all
ize
d d
rug
  
HP
MC
 0.
5%
 (w
/w
) 
SD
S<
CM
C 
SD
S 0
.5%
 (w
/w
) 
Tw
een
 20
<C
MC
 
Tw
een
 20
 0.
5%
 (w
/w
) 
Ch
ito
san
 0.
5%
 (w
/w
) 
4.29 
4.37 2.51 
3.55 3.27 5.76 
2.15 4.26 
101 
33.8 
134 
16.6 
12 
77.9 
7.55 23.6 
515 
138 
767 
81.4 
52.7 
226 
20.2 
132 
Pa
rt
ic
le
 si
ze
 (µ
m
) 
dv10% 
dv50% 
dv90% 
Effect of Additives in LAS crystallization
 
 195 
XRD analysis was performed to detect the changes in the physical state and crystalline 
phases of the drug due to the presence of additives in the aqueous phase. Figure 4.5 shows the 
XRD patterns for all powder samples. Comparing the DRX diffractograms of recrystallized 
drug in presence of HPMC, Tween 20 (below and above CMC), SDS (below and above 
CMC) and Chitosan, it can be seen that the crystalline phases were preserved (the peaks at 
8.5, 14, 16.9, 18.7, 19.4 and 21.3° detected for the original drug remained unchanged after 
recrystallization in presence of these additives). 
 
(a) (b) 
 
(c) (d) 
Figure 4.5. X-Ray diffractograms of the drug powders synthesized with additives in the 
aqueous phase: a) HPMC 0.5% (w/w); b) Tween 20 <CMC and 0.5% (w/w); c) SDS<CMC 
and 0.5% (w/w); d) Chitosan 0.5% (w/w). 
Original CRS 74 
LAS recrystallized drug 
HPMC 0.5% (w/w) 
Original CRS 74 
LAS recrystallized drug 
Tween 20<CMC  
Tween 20 0.5% (w/w)  
Original CRS 74 
LAS recrystallized drug 
SDS<CMC  
SDS 0.5% (w/w)  
Original CRS 74 
LAS recrystallized drug 
Chitosan 0.5% (w/w)  
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The contact angle measurements were employed to describe the effect of the presence 
of additives in the aqueous phase on the wettability of the recrystallized powders compared to 
original CRS 74. The contact angle of drop deposited on all powders surface was plotted as a 
function of time from 0 to 10 s, and the results are given in Appendix IV. Table 4.6 presents 
the initial contact angle made at 0 s for all powders. The original powder and the powder 
recrystallized without additives were strongly hydrophobic (θ >132°) as already discussed in 
Chapter 3. This surface characteristic remains practically unchanged after recrystallization in 
presence of most of additives tested up to here. It can be observed that the powder produced 
in presence of Chitosan possessed a contact angle higher than the contact angle for the 
original drug (θ = 140.9°± 0.4). In fact, the measure is not totally effective as it became 
difficult to measure experimentally liquid contact angles on high charged surfaces. To sum 
up, the unique additive that was able to reduce consistently the contact angle of this drug with 
water to approximately 100° was Tween 20 0.5 % (w/w). 
Finally, Table 4.7 also gives the powder composition in terms of drug content and 
residual solvent. The drug contents of the CRS 74 microcrystals were above 98% for all CRS 
74 recrystallized samples. These results show that almost all of the additives were removed by 
washing. 
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 Effect of the presence of the additive in the organic phase on physical and 4.3.1.
surface properties of recrystallized powders 
 
In the second part of the additive screening study, P-407 was incorporated in the 
organic phase (ethanol + drug + P-407).   
Block co-polymeric surfactants such as P-407, consist of ethyleneglycol and propylene 
glycol, and are very efficient non-ionic stabilizers owing to multiple attachments of 
hydrophobic domains at the drug particle surface (KIPP, 2004; CHO et al, 2010). Because P-
407 has hydrophobic moieties that adsorb onto hydrophobic drug particle surface and two 
hydrophilic blocks, the adsorption of P-407 onto CRS 74 drug particle surface could provide 
an effective steric barrier against crystal growth. From the polymer screening, P-407 was 
selected as an additive for this part of the work. The effect of the polymer concentration was 
investigated by incorporating the additive in ethanol in two different concentrations (Table 
4.4): 0.0003%w/w (<CMC) and 0.02%w/w (> CMC), before the incorporation of the drug. 
Following the same experimental procedure already described, Table 4.8 shows the 
particle size evolution of the small embryo particles formed in presence of P-407 when the 
mixed phases exiting the T-mixer were poured into a vessel and immediately sampling for 
analysis. From the results, it can be observed that nanometric particles were obtained, which 
continued to grow to reach an approximate particle size average of 350 nm at the end of the 
measure time (150 s), independently of the additive concentration. These particles were 
slightly more negative charged (-5.4/-7.5 mV) compared to those of drug suspension without 
additives (-2.1 mV). 
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Table 4.8. Initial particle size average (APS) and characteristics of  CRS 74 crystals in 
suspension in presence of P-407 in the organic phase  
Experiment Additive Time (s) APS (nm) 
Zeta potential 
(mV) 
pH suspension 
1 X 
t0  248 * * 
t150 417 -2.11± 0.28 3.28 
8 P-407<CMC(0.0003%w/w) 
t0 199 * * 
t150 351 -5.43±0.51 4.41 
9 P-407>CMC(0.02%w/w) 
t0 133 * * 
t150 341 -7.52±0.37 5.68 
 
Particle size, SEM micrographs, contact angle, drug content and residual solvent of 
recrystallized particles are given in Table 4.9. Dv10%, dv50% and dv90% for the dried powders 
produced are also presented in Figure 4.6. The corresponding particle size distributions are 
graphically presented in Appendix III. When compared to the original or the recrystallized 
powder without additives (Figure 4.6), a remarkable effect of reduction of particle size (dv50% 
and dv90%) was observed with P-407 at the higher concentration (> CMC). SEM images 
confirmed that the CRS 74 microcrystals crystals were clearly homogeneously distributed. 
Hardly any agglomerated or aggregated particles were found. This result confirmed that the 
microcrystals, which normally aggregate in order to lower the surface energy, could be 
stabilized sterically against crystal growth by a layer of protective polymer. 
The higher concentration of P-407 also modified the surface properties of the 
recrystallized powder (see Table 4.9). Contact angle of the powder with water was reduced 
from 133.5 ± 1.8° (without additive) to 85.3  ± 0.8° (P-407 0.5 %w/w). 
Table 4.9 also shows a drug content of 96 % for the recrystallized sample with the 
higher concentration of P-407. This results shows that all additive was probably not removed 
by washing. The remarkable effect on the contact angle can confirm this finding the additive 
probably remained attached to the hydrophobic drug particle surface lowering the interfacial 
tension. 
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Figure 4.6. Particle size of the drug powders synthesized in presence of P-407 in the 
organic phase.  
Figure 4.7 shows the XRD patterns for the powder samples obtained in presence of P-
407. It can be noted that the crystalline phases were preserved after recrystallization in 
presence of this additive. 
Figure 4.7. X-Ray diffractograms of the drug powders synthesized in presence of P-407 
in the organic phase. 
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 Effect of the presence of the additive in both, aqueous and organic phases   4.3.2.
Additives can be placed either in solvent or anti-solvent. The strength of adsorption of 
additive molecules on the drug surface depends on the nature of the additive and drug surface 
(THORAT and DALVI 2012). Additives are being introduced in the LAS crystallization of 
CRS 74 molecule, firstly, to inhibit particle growth and, subsequently, particle agglomeration. 
Factors controlling the amount of additive adsorbed on the CRS 74 will probably be related to 
the solubility of the additive in liquid phase, to the strength of additive-liquid phase 
interactions and to the strength of additive-drug particle interaction. The later can be complex 
function of parameters such as functional groups and surface energy as suggested by CHOI et 
al (2005).  
Stabilizing agents such as polymer and surfactant can be combined together to enhance 
the stabilization through synergistic effect (THORAT and DALVI 2012). In such cases the 
overall stabilization depends on the pair of the stabilizers used. For instance, synergistic effect 
have been reported in previous works combining ionic and non-ionic stabilizer (WU et al., 
2011) or neutral polymers (HPMC) with anionic surfactant (SDS) (DALVI and DAVE, 
2009).  
Effect of additives on the CRS 74 particles size were analysed by measuring the drug 
particles immediately after LAS crystallization. The same experimental sampling already 
described in previous sections was followed. It was found that the particles at 0 s were 
discrete with a size of approximate two hundred nanometers with SDS, however two times 
bigger with Chitosan (Table 4.10). These particles were also examined 150 s after LAS 
crystallization and found to be 2 times bigger but always in nanometric range of size. At the 
end of the process, after drying, they were examined and found to be several microns as given 
in Table 4.10 and graphically represented in Figure 4.8. Surprisingly, the dry particles 
produced in presence of Chitosan were not bigger than the other ones. Maybe, Chitosan was 
less effective than SDS in arresting the particle growth, but not less effective to prevent 
aggregation (high absolute zeta potential given in Table 4.10). 
Table 4.11 also shows that the association of additives in both aqueous and organic 
phases had a positive effect, reducing the contact angle of the drug powder with water to 
94.1°±4.3 with P-407/Chitosan and to 74.7°± 5 with P-407/SDS, in comparison to the original 
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drug (136.4°± 0.8). The powders were characterized by purity higher than 98.8% and residual 
solvent content ranged from 0.6% to 1.5% (see Table 4.11). 
Table 4.10. Initial particle size average (APS) of CRS 74 crystals in suspension in 
presence of additives in both, aqueous and organic phases.
Experiment Additive Time (s) APS (nm) 
Zeta potential 
(mV) 
pH suspension 
1 X 
t0  248 * * 
t150 417 -2.11± 0.28 3.28 
10 
P407< CMC 
(0.0003%w/w)+ 
SDS 0.5% w/w 
t0 150 * * 
t150 368 -17.53±4.77 4.73 
11 
P407> CMC (0.02%w/w)+  
SDS 0.5% w/w 
t0 234 * * 
t150 440 -3.96±0.17 4.27 
12
P407< CMC 
(0.0003%w/w)+
Chitosan 0.5% w/w 
t0 457 * * 
t150 990 +39.40±3.24 4.60 
13 
P407> CMC (0.02%w/w +
Chitosan 0.5% w/w 
t0 596 * * 
t150 918 +16.33±2.73 4.64 
 
 
Figure 4.8. Particle size (laser diffraction data) of the drug powders synthesized in 
presence of additives in both, organic and aqueous phases.  
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X-ray powder diffraction patterns shown in Figure 4.9 identical to original CRS 74 for 
crystals generated using P-407/Chitosan and P-407/SDS suggested that these additive are not 
within the crystal lattice but only adsorbed on the surface.
(a)
 
(b) 
Figure 4.9. X-Ray diffractograms of drug powders produced with additives in organic 
phase: a) P-407/SDS; b) P-407/Chitosan. 
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 Drug concentration in the organic phase 4.3.3.
At we known, an uniform and extremely high supersaturation is required to produce 
ultra-fine particles by LAS recrystallization. With the aim to improve control on particle size 
of the recrystallized powder, some additional experiments were made to investigate the effect 
of supersaturation on the properties of the drug recrystallized in presence of the pairs of 
stabilizers, P-407/Chitosan and P-407/SDS. Experiments were conducted with reduced initial 
drug concentration in the organic phase. The corresponding supersaturation values are given 
in Table 4.12. No remarkable effect of the supersaturation level was observed on the 
reduction of the drug particle size, as confirmed by Figure 4.10. The ability to achieve high 
particle concentrations without compromising the particle size significantly is of great interest 
for scaling up this process. Furthermore, the utilization of relatively concentrated organic 
solutions to reduce the amount of organic solvent is also beneficial. 
Table 4.12 also shows that drug particles recrystallized in presence of Chitosan were 
always positively charged. Powders presented high purity and low residual solvent content 
(Table  4.13). 
Table 4.12. Initial average particle size (APS) of the CRS 74 crystals in suspension in 
presence of different stabilizing systems into internal phase and external phase in different 
supersaturations.  
Experiment Additive S Time (s) APS (nm) 
Zeta 
potential 
(mV) 
pH 
suspension 
1 X 894.04 
t0  248 * * 
t150 417 -2.11± 0.28 3.28 
14 P-407>CMC(0.02%w/w) 374.51 
t0 199 * * 
t150 290 -9.70±0.85 4.97 
15 P-407>CMC(0.02%w/w) 156.41 t0 140 * * 
t150 301 * 4.96 
16 
P-407>CMC(0.02%w/w) 
+ SDS 0.5% w/w 
104.50 
t0 186 * * 
t150 404 -6.39±0.04 5.27 
17 
P-407>CMC(0.02%w/w) 
+ SDS0.5% w/w 
43.25 t0 125 * * 
t150 348 * 5.46 
18 P-407>CMC+ 
Chitosan 0.5% w/w 
* 
t0 489 * * 
t150 971 +23.87±1.07 4.64 
19 
P-407>CMC(0.02%w/w) 
+Chitosan 0.5% w/w 
* 
t0 453 * * 
t150 1649 +23.03±4.11 4.76 
*Data not determined 
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Figure 4.10. Particle size (laser diffraction data) of the drug powders synthesized in 
presence of additives in organic phase and in both (organic and aqueous) at different 
supersaturation degrees. 
 
Moreover, no changes on the powder crystallinity were observed as proved by the X-
ray diffractograms presented in Figure 4.11.  
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(a) (b) 
  
(c) 
Figure 4.11. X-Ray diffractograms of the drug powders synthesized in presence of 
additives in organic phase and in both (organic and aqueous) at different supersaturation 
degrees: a) P-407; b) P-407/SDS 07; c) P-407/Chitosan.  
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 Reorganized organic phase 4.3.4.
In the second part of the additive screening study, P-407 was incorporated into the 
organic phase (ethanol + drug + P-407).  Two concentrations were studied: 0.0003%w/w 
(<CMC) and 0.02%w/w (> CMC), before the incorporation of the drug.  
The results obtained already discussed in the previous section, showed that the higher 
concentration (> CMC) could prevent crystal growth and agglomeration, and modify the 
surface properties of the recrystallized powder. Contact angle of the powder with water was 
reduced from 133.5 ± 1.8° (without additive) to 85.3 ± 0.8° (P-407 0.5%w/w). These results 
were attributed to the probable attachment of the additive to the hydrophobic drug particle 
surface lowering the interfacial tension. However, CRS 74 crystals obtained are always 
micron-sized. 
Due to the molecular characteristics of CRS 74, we hypothesized the possibility of a 
molecular pre-organization of this drug in organic solution favoring uncontrolled growth of 
crystals after nuclei formation. This hypothesis is investigated in this section. 
In fact, a large number of drug molecules are amphiphilic, and self-associate in aqueous 
solution to form small aggregates. The self-assembly and self-organization are natural and 
spontaneous processes, occurring mainly through non-covalent interactions such as Van der 
Waals, hydrogen-bonding, hydrophilic/hydrophobic, electrostatic, donor and acceptor, and 
metal-ligand coordination networks (WHITESIDES and GRZYBOWSKI, 2002). 
Many molecules are amphiphilic, such as phenothiazines, tranquilizers, analgesics, 
peptides, antibiotics, tricyclic antidepressants, and self-associate in surfactant like-manner in 
aqueous environment, above a critical concentration value (ATTWOOD and FLORENCE, 
1983). It is known that the amphiphilic drug molecules in water form aggregates (MOHD et 
al., 2010), but it is described in the literature that the amphiphilic aggregates can be formed on 
nano- or micron-sized in selective solvents, like ethanol (LEE et al., 2008). 
Some amphiphilic drugs are well studied in the literature, among them Promethazine 
hydrochloride (PMT) and Imprimine chloride (IMP), both being used in clinics as 
antidepressant and antipsychotic drugs. These amphiphilic compounds possess a hydrophobic 
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nitrogen-containing heterocyclic bound to a short chain carrying a charged amino group 
(ALAM et al., 2008), as shown in Figure 4.12.  
PMT IMP 
Figure 4.12 Molecular Structure of Promethazine hydrochloride (PMT) and Imprimine 
chloride (IMP). (ALAM et al., 2008). 
 
Regarding the studied molecule CRS 74 (see Figure 4.13), it has the same chemical 
function responsible for the drug self-organization in the refered molecules. It possesses a 
hydrophobic nitrogen-containing heterocyclic bound to a short chain carrying a charged 
amino group, as discussed before for the PMT and IMP. It means that this molecule could 
have the same capacity to self-associate in solution above a critical concentration value. 
 
 
Figure 4.13. Chemical structure of CRS 74. 
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Some experiments were then carried out in our study to verify the effect of drug 
concentration in ethanol solution, by dynamic light scattering (PCS) measurements. This 
methodology has proved to be a useful tool in characterizing colloidal systems (MOHD et al., 
2010). The study was realized in order to verify the appearance of micelles depending on the 
concentration of drug in solution. Figure 4.14 confirms the appearance of drug micelles (1.6 – 
1.8 nm) in ethanol at drug concentrations above 0.001 mol/L.  
A micellar organization in solution could be the starting point of all LAS crystallization 
studies conducted up to here, as schematically represented on Figure 4.15. From a pre-
aggregated molecular organization, it could be difficult to stop growth after nucleation, which 
could maybe explain the strong difficulty to stop drug nuclei growth within a nanosize range, 
even in presence of different additives. 
 
Figure 4.14. Diameter of  drug micelles in ethanol as a function of drug concentration 
(PCS measurements). 
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Figure 4.15. Illustration of the effect of increasing concentration of drug in ethanolic 
media leading to a micellar organization. 
Keeping in mind the above hypothesis, complexes molecular aggregates of CRS 74 in 
organic solution can hinder the crystal size control during LAS crystallization. In order to 
perturb this molecular organization, some new experiments were carried out. The aim was to 
introduce the additive P-407 in the organic phase in a dilute system, in order to promote 
interaction between the additive and the CRS 74 molecule in concentrations below the drug 
critical micelle organization (0.001 mol/L), as represented on Figure 4.16. 
 
Figure 4.16. Possible schematic representation of drug self-assembled at molecular level in 
ethanolic solution. 
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The additive was added to ethanol in a concentration below its CMC (0.0002% w/w). In 
the following, the drug was added in a concentration below its critical micellar concentration 
(0.00036 mol/L) to prevent drug self-assembly. The organic phase was then concentrated by 
rotary evaporation under reduced pressure to a final more concentrated drug solution. Table 
4.14 summarizes the results of experiments conducted under the described conditions. A 
combined effect of Chitosan was also investigated as shown in the same table. Table 4.15 
shows SEM images drug and water contents of the powders obtained. Due to low 
supersaturation, the yield of production was too low and the amount of drug powder obtained 
was insufficient for further analysis (dry particle size, surface properties, XRD and DSC 
analysis). 
Compared to the previous experiments for which the drug was in contact with the 
additive in concentrations above its critical micelle concentration, no positive effect in particle 
size control within the first 150s during LAS crystallization was noted. 
  
Table 4.14. Initial average particle size (APS) of CRS 74 nanocrystals during LAS 
crystallization, in presence of P-407 in organic phase, which was concentrated by rotary 
evaporation.  
Experiment Additive S 
Time 
(s) 
APS 
(nm) 
Zeta 
potential 
(mV) 
pH 
suspension 
1 X 
894.0
4 
t0  248 * * 
t150 417 -2.11± 0.28 3.28 
19 
P-407<CMC 
(0.0003%w/w) 
77.59
* 
t0 203 * * 
t150 319 * 4.87 
20 
P407<CMC(0.0003%
w/w)+Chitosan 0.5% 
(w/w) 
* 
t0 687  * 
t150 1237 +19.93±0.25 4.64 
*Data not determined; * Supersaturation calculated after ethanol evaporation   
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 Improving process production  4.3.5.
Most of LAS recrystallizations realized up to here in order to investigate the influence 
of several processes or formulation parameters on the properties of the recrystallized drug 
powder were conducted during a short period of time of approximately 2- 6 min. Experiments 
in absence of additives, as described in Chapter 3, proved to be quite laborious due to the 
rapid growth of the produced particles and problems of blockage of the mixer, which 
precluded the realization of essays over time. This is not interesting for the industrial 
proceeding.  
It seemed that these problems were caused by the affinity of the drug molecule with the 
material which constitutes the surface of the rapid mixer. Furthermore, the nano-sized drug 
crystals, freshly formed, have a high-energy surface; this property can increase the high 
affinity for CRS 74 surface material adsorption reported in Chapter 3.  
To solve this blockage problem and to make the LAS crystallization process industrially 
viable, some studied systems were selected (Table 4.16). The criteria of choice was the 
surface properties of recrystallized drugs: low contact angle values (θ ≈ 90°), that means a 
decrease in surface hydrophobicity, and probably, a decrease in affinity of the molecule with 
the material which constitutes the hydrophobic surface of the mixer (stainless steel). 
Table 4.16. Stabilizing agents studied to solve the T-mixer blockage problem 
Experiment Additive θ  (°) 
9 P-407>CMC 85.3 
11 P-407>CMC+SDS 0.5% (w/w) 74.7 
13 P-407>CMC+Chitosan 0.5% (w/w) 94.1 
 
As shown in Table 4.16, all the stabilizing systems presented a significant reduction of 
contact angle value compared to recrystallized drug in absence of additives (136o). However, 
the better drug surface characteristics were not enough to prevent the affinity of the molecule 
with the surface material for Experiments 9 and 11 (see Table 4.17). On the contrary, drug 
particles highly negatively charged by SDS 0.5% showed a strong affinity to T-mixer material 
walls (blockage of the mixer operation after 2 min). On the other hand, the combined effect of 
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P-407 placed in the organic phase and Chitosan in the aqueous phase could solve this 
problem, ensuring a continuous process of production through the T-mixer. 
Table 4.17. Initial particle size average (APS) of the nanosuspensions and 
characteristics of CRS 74 nanocrystals in suspension. 
Experiment Additive APS (nm) Zeta potential (mV) pH suspension Blockage time (min) 
9 P-407>CMC 169.5 -3,94±0.37 4.51 6 
11 P-407>CMC+SDS 0.5% (w/w) 225.3 -5,26±0.35 4.78 2 
13 P-407>CMC+Chitosan 0.5% (w/w) 706.6 +23,80±2.12 4.65 
No blockage 
 
 
To explain this finding, it was necessary to consider the characteristics of the T-mixer 
material, i.e. stainless steel. Some materials can be ionized on specific pH;  among them, as 
reported in the literature, stainless steels can present different surface charge properties as a 
function of pH. The material surface is positively charged over the pH range of 2.5 to 5.0 
(TAKEHARA and FUKUZAKI, 2002). Because of this, the surface charge of stainless steel 
is believed to act as adsorption sites for negatively charged CRS 74, as schematically 
represented in Figure 4.17. 
 
 
(a) 
 
(b) 
Figure 4.17. The charge interaction between the negatively (a) and positively (b) 
charged CRS 74 nanocrystals and the negatively surface charged stainless steel (pH in the 
range 3-5). 
pH: 4-5 


pH: 4-5 



 


 










 
 


 
 


 
 


 
 


 

CHAPTER 4 
 
 224 
In conclusion, the combination of P-407 (organic phase) and Chitosan (aqueous phase) 
represented a key solution to a continuous production of recrystallized CRS 74 through 
stainless steel rapid mixers. 
 
 Dissolution behaviour of recrystallized powders in presence of additives 4.3.6.
In previous sections, it was observed changes on some powders properties, like: 
wettability, powder agglomeration state and size reduction. These properties will probably 
have a direct impact on dissolution profile, which will be verified in this section.  
In order to evaluate the impact of powders on dissolution kinetics, the powders for this 
section were selected according the lower agglomeration state and/or low contact angle value. 
The dissolution of each sample was determined under sink conditions, as discussed in Chapter 
2.  
Additives can change the drug solubility In the dissolution medium. To ensure sink 
conditions (maxium drug concentration << Ceq), the solubility of the recrystallized samples in 
presence of the different additives was firstly measured in 0.1M HCl at 37oC. The same 
experimental procedure described in Chapter 2, was used. The results are given in Table 4.18 
and represented graphically in Figure 4.18. It can be concluded that the probably association 
of additives to the drug in some cases did not change the drug solubility in the dissolution 
medium, or very little (Ceq < 0.2 mg/gsolution in all cases). To sum up, although additives can 
increase the solubility of poorly soluble compounds, the amounts adsorbed onto the CRS 74 
particles crystallized in the presence of additives in our study are probably too small to affect 
the solubility of the drug in bulk solution.  
To assess the differences between original drug and the generated samples, 0.1M HCl 
was chosen as a discriminatory dissolution medium (The dissolution method was developed 
and presented in Chapter 2).  
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Table 4.18. CRS 74 solubility and synthesized powders solubility in HCl 0.1M at 
37°C. 
Stabilizing system Solubility 
(mg/gsolution) ±SD 
Original CRS 74 0.102±0.008 
No additive (recrystallized CRS 74) 0.134±0.005 
P407> CMC (0.02%w/w) 0.117±0.006 
HPMC 0.5% w/w 0.144±0.008 
Tween>CMC 0.5%w/w 0.091±0.003 
SDS 0.5%/P-407< CMC (0.0003%w/w) 0.094±0.003 
SDS 0.5% /P-407 > CMC (0.02%w/w) 0.110±0.004 
Chitosan 0.5%/ P-407> CMC (0.02%w/w) 0.088±0.004 
P-407<CMC (0.0003%w/w) Reorganized 0.161±0.009 
Chitosan 0.5% / P-407(0.0003%w/w) Reorganized 0.121±0.006 
 
 
Figure 4.18. Solubility of CRS 74 samples in HCl 0.1M at 37°C  (samples 
recrystallized in presence of different additives; original drug also presented for comparison) 
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Figure 4.19 shows the dissolution profiles of CRS 74 crystallized in presence of the 
additives studied in this section. The dissolution profiles of original CRS 74 and the sample 
crystallized in the absence of additive are also included in this Figure. 
 
Figure 4.19. Dissolution profiles using 0.1M HCl as discriminatory dissolution medium 
at 37oC and paddle at 75 rpm. LAS recrystallized drug in presence of additive. Original CRS 
74 also included. 
 
The dissolution profiles of recrystallized samples in presence of additives and original 
CRS 74 were compared by calculating difference factor (f1) and similarity factor (f2) for each 
dissolution profile given in Figure 4.19. Table 4.19 shows the calculated f1 and f2 values. f1 
(>0) and f2 (50<f2 <85) values confirmed significant difference in dissolution profiles of 
recrystallized samples in presence of additives compared to the original drug. 
 
The percentage of drug dissolved within the first 20 min. was used to compare 
dissolution rate of various samples. The values are given in Table 4.20. The data indicates that 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
0 50 100 150 200 
D
iss
ol
ve
d 
dr
ug
 (%
) 
Time (min) 
Original CRS 74 
LAS recrystallized drug-No additive 
P-407>CMC 
HPMC 0.5% 
Tween>CMC 
P-407 > CMC+SDS 0.5%  
P-407< CMC+SDS 0.5% / 
 P-407> CMC+Chitosan 0.5% 
P-407<CMC Reorganized 
  P-407<CMCReorganized+Chitosan 0.5% 
Effect of Additives in LAS crystallization 
 
 227 
there is a marked increase in the dissolution rate of CRS 74 from the recrystallized samples in 
presence of additive compared to the original drug. The faster dissolution profile led to 80% 
of drug dissolved in 3 h of against approximate 20% for original drug or even the drug 
recrystallized whitout additives. 
 
Table 4.19. Comparison of dissolution profiles through the difference factor (f1) and the 
similarity factor (f2). Original CRS 74 is the reference product for test. 
    Experiment Additive f1  f2 
Original CRS 74 X * * 
1 No additive 24.8 98.8 
2 HPMC 0.5% w/w 389.92 64.18 
6 Tween 20 0.5% w/w 518.62 58.89 
9 P-407>CMC 749.52 50.50 
10 P-407<CMC+SDS 0.5% w/w 239.86 72.65 
11 P-407>CMC+ SDS 0.5% w/w 296.38 69.89 
13 P-407>CMC+Chitosan 0.5% w/w 659.33 53.54 
19 P-407<CMC Reorganized 130.4 84.49 
20 P-407<CMCReorganized+Chitosan 0.5% w/w 309.13 69.49 

Table 4.20. Percentage of drug dissolved within the first 20 min. 
Experiment Additive Percentage of drug 
dissolved in 20 min 
Original CRS 74 X 4.36 ± 0.75 
1 No additive 3.37 ± 1.86 
19 P-407<CMC Reorganized 11.45 ± 2.71 
10 P-407<CMC+SDS 0.5% w/w 12.53 ± 2.88 
11 P P-407>CMC+ SDS 0.5% w/w 16.40 ± 2.01 
2 HPMC 0.5% w/w 22.92 ± 3.79  
6 Tween 20 0.5% w/w 26.66 ± 1.04 
20 P-407<CMCReorganized+Chitosan 0.5% w/w 27.74 ± 0.64 
13 P-407>CMC+Chitosan 0.5% w/w 34.46±1.59 
9 P-407>CMC 39.96 ± 1.98 
 

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Drug release kinetics 
In order to describe the kinetics of the release process of drug from the different 
samples, two  equations were used: 
• The first-order equation, which describes the release from systems where dissolution 
rate is dependent on the concentration of the dissolving species (ISHI, 1996; SERRA, 
2007; RATNA et al., 2012): 
 
 (4.1) 
• The Hixson-Crowell cube root law, which describes the release the release from 
dosage forms which show dissolution rate limitation and which do not dramatically 
change during the release process. (HIXSON, 1931):  
 
 (4.2) 
 
The applicability of these two equations was tested for selected dissolution data giving 
the faster drug release rates. The dissolution data were plotted in accordance with the first-
order equation, i.e., the logarithm of the percent remained as a function of time between 10 
and 25 min (Figure 4.20) and were also plotted in accordance with the Hixson-Crowell cube 
root law, i.e., the cube root of the initial concentration minus the cube root of percent 
remained, as a function of time between 0 and 25 min (Figure 4.21). It is evident from Figures 
4.20 and 4.21 that a linear relationship was obtained with r2 values close to unity as shown in 
Table 4.21. 
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Figure 4.20. A linear plot for the dissolution data of CRS 74 powder samples in 
accordance with the first-order model equation. 
 
Figure 4.21. A linear plot for the dissolution data of CRS 74 powder samples in 
accordance with the Hixson-Crowell cube root law.  
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The first order model describes the release systems for which the dissolution rate is 
dependent on the concentration of the drug dissolved in the media, whereas the drug surface 
area remains constant. The Hixson-Crowell model has been used to describe a decrease of the 
drug particle surface as dissolution occurs. Table 4.21 shows that both mathematical models 
fitted well the experimental dissolution data probably because during 25 min the decrease of 
particle surface is very low. 
 
Table 4.21. Release parameters of CRS 74 powder samples recrystallized in presence of 
additives in comparison to original drug sample. 
 
Exp. 
First order Hixson-Crowell 
r2 k (min-1) Linear equation r2 k (min-1) Linear equation 
CRS 74 0.9846 -0.0024 y = -0.0024x + 4.6104 0.9847 0.0008 y = 0.0008x - 0.0017 
1 0.9973 -0.0014 y = -0.0014x + 4.598 0.9974 0.0005 y = 0.0005x + 0.0024 
9 0.9964 -0.0246 y = -0.0246x + 4.5899 0.9939 0.0071 y = 0.0071x + 0.0131 
13 0.9961 -0.0157 y = -0.0157x + 4.502 0.9945 0.0046 y = 0.0046x + 0.0371 
k = dissolution rate constant 
x = t- e y = ln % No dissolved 
** x = t e y = 1-[(1-%Dissolved/100) 1/3 ] 
 
DSC was performed on the recrystallized drug in presence of additive in the organic 
phase (P-407) and in both organic (P-407) and aqueous phase (Chitosan) in comparison to 
DSC data for original and recrystallized CRS 74 without additives. The DSC curves of 
samples are shown in Figure 4.22. From DSC data summarized in Table 4.22, it was 
concluded that stabilizers did not change the physical state of CRS 74.   
Interestingly, CRS 74 recrystallized in presence of P-407 and Chitosan needs less 
energy for melting when compared to the other samples (ΔHm=74.8 J/g), which could be 
related to a less energy it must overcome to dissolve in according to its faster dissolution rate. 
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Table 4.22. Melting Temperature (Tm(Onset)), Heat of Fusion (ΔHf) for the original and 
LAS recrystallized drug in presence and absence of additives. 
Thermal and 
dissolution 
parameters 
Original 
CRS 74 
LAS 
recrystallized 
CRS 74 
LAS recrystallized 
CRS 74-P-407 
LAS recrystallized 
CRS 74-P-
407+Chitosan 
Tm(Onset)(°C) 188.6 187.8 189.0 186.6 
ΔHm(J/g) 86.6 79.2 87.9 74.8 
Relative enthalpy(%) 100 91.5 101.5 86.37 
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(a) (b) 
 
 
(c) (d) 
 
 
(e) (f) 
Figure 4.22. a) DSC thermograms of original CRS 74 (first heating), which consists of a melting 
endotherm (peak onset temperature Tm(Onset) = 188.64oC) and LAS recrystallized drug, which consists of a 
melting endotherm (peak onset temperature Tm(Onset) = 187.79oC); b) DSC thermograms of original CRS 74 
(cooling after first heating), which consists of a crystallization exotherm (peak onset temperature Tc(Onset) = 
132.12oC) and LAS recrystallized drug, which consists of a crystallization exotherm (peak onset temperature 
Tc(Onset) = 138.43oC). c) DSC thermograms of original CRS 74 (first heating), and LAS recrystallized drug in 
presence of P-407>CMC, which consists of a melting endotherm (peak onset temperature Tm(Onset) = 189.01oC); 
d) DSC thermograms of original CRS 74 (cooling after first heating), and LAS recrystallized drug in presence 
of P-407>CMC, which consists of a crystallization exotherm (peak onset temperature Tc(Onset) = 137.61oC) ; e)
DSC thermograms of original CRS 74 (first heating) and LAS recrystallized drug in presence of P-
407>CMC+Chitosan 0.5% (w/w), which consists of a melting endotherm (peak onset temperature Tm(Onset) = 
186.58oC); f) DSC thermograms of original CRS 74 (cooling after first heating) and LAS recrystallized drug in 
presence of P-407>CMC+Chitosan 0.5% (w/w), which consists of a crystallization exotherm (peak onset 
temperature Tc(Onset) = 136.21oC).  
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4.4. CONCLUSION 
To improve particle size control during the LAS crystallization process of CRS 74, and 
they were introduced in the solvent (P-407) or in the anti-solvent (all the other ones) in our 
CRS 74-ethanol-water system. A maximum concentration was fixed for all additives to give a 
mass ratio of 1:4 (additive:drug). This corresponds to 0.5%w/w for HPMC, Chitosan, Tween 
20 and SDS and 0.02% (w/w) for P-407. 
The first results showed that additives enhanced the drug solubility in the ethanol-water 
mixture, markedly or very little, depending on the additive used. Among them, SDS 0.5% 
presented the higher capacity to solubilize CRS 74 in the binary solvent mixture, which is 
attributed to the better solubilization power of anionic surfactants.   
Chitosan and SDS 0.5% were proven to be the best additives to ensure an electrostatic 
repulsion between freshly CRS 74 crystals formed in the LAS process. The higher particles 
are equally charged, the higher is the electrostatic repulsion between particles. The 
electrostatic repulsion given by Chitosan (crystals positively charged) played a decisive role 
in controlling aggregation of freshly formed crystal drug to the mixer walls, also charged 
positively at pH of the liquid mixture. Contrarily, drug particles highly negatively charged by 
SDS 0.5% showed a strong affinity to T-mixer material walls (blockage of the mixer 
operation in a shorter time). 
The primary role of stabilizers is to inhibit excessive crystal growth. In a general way, 
most CRS 74 crystals produced in presence of additives had a smaller particle size compared 
to original or recrystallized powder without additives. Additives such as HPMC and Tween 
20 (concentration below CMC) modestly inhibited agglomeration, while a higher 
concentration of Tween 20 (above CMC) had a very positive effect on particle size control. 
Agglomerates or aggregates were obtained in presence of HPMC. A possible 
explanation could be an inappropriate diffusion (too slow) of the solvent toward the anti-
solvent caused by a high viscosity of the anti-solvent containing 0.5%w/w HPMC. A high 
viscosity could prevent diffusion between solution and anti-solvent and result in nonuniform 
supersaturation and agglomeration. 
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Concerning surface properties, the unique additive placed in the aqueous phase, which 
was able to reduce consistently the contact angle of this drug with water to approximately 
100°, was Tween 20 0.5%. 
In the second part of the additive screening study, P-407 was incorporated in the organic 
phase (ethanol + drug + P-407). The effect of the polymer concentration was investigated by 
incorporating the additive in ethanol in two different concentrations: 0.0003%w/w (<CMC) 
and 0.02%w/w (> CMC), before the incorporation of the drug. 
These particles were slightly more negative charged (-5.4/-7.5mV) compared to those of 
drug suspension without additives (-2.1mV). 
This result confirmed that the microcrystals, which normally aggregate in order to lower 
the surface energy, could be stabilized sterically against crystal growth by a layer of 
protective polymer. The higher concentration of P-407 also modified the surface properties of 
the recrystallized powder. Contact angle of the powder with water was reduced from 
133.5o±1.8 (without additive) to 85.3 o ±0.8 (P-407 0.5%w/w). The remarkable effect on the 
contact angle can confirm this finding: the additive probably remained attached to the 
hydrophobic drug particle surface lowering the interfacial tension. 
The dry particles produced in presence of Chitosan were not bigger than the other ones. 
Maybe, Chitosan was less effective than SDS in stopping the particle growth, but more 
effective to prevent aggregation (higher absolute zeta potential) 
The association of additives in both aqueous and organic phases had a positive effect, 
reducing the contact angle of the drug powder with water to 94.1°± 4.3 with P-407/Chitosan 
and to 74.7°± 5 with P-407/SDS, in comparison to the original drug (136.4°± 0.8).   
Finally, X-ray powder diffraction patterns confirmed that these additives are not within 
the crystal lattice, but only adsorbed on the surface. 
Dissolution study confirmed the enhancement of the dissolution rate of CRS 74 crystals 
in presence of additives because of an increase of surface area and of a modification of 
surface properties of crystal. 
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Résumé Chapitre 5- Conclusion 
Dans cette étude, la cristallisation par effet anti-solvant a été utilisée pour recristalliser 
un nouveau médicament antirétroviral. L'objectif était d'améliorer ses propriétés de 
dissolution. Pour générer un mélange efficace et une sursaturation rapide et uniforme, des 
mélangeurs spécifiques ont été utilisés (T-mélangeur, mélangeur Roughton). Les meilleures 
conditions de cristallisation de cette nouvelle molécule ont été définies par une étude de 
solubilité, un développement de méthodes de dissolution et un screening des paramètres 
opératoire de la cristallisation et d’additifs. 
Il a été démontré la poudre présente une faible solubilité en phase aqueuse et une vitesse 
de dissolution lente en milieu acide. Ce travail a permis de construire à travers différentes 
caractérisations une monographie préliminaire de ce solide.  
La molécule étudiée est soluble dans l'éthanol (92,6 mg/g de solution) à 30°C. Les 
résultats de la modélisation des équilibres liquide-solide par un modèle à coefficient d’activité 
(UNIQUAC) indiquent que ce modèle est un outil approprié pour représenter le 
comportement de solubilité de ce solide dans des mélanges de solvants (éthanol-eau). Les 
solubilités expérimentales et calculées présentent un bon accord. La modélisation a permis 
d’évaluer un ratio éthanol/eau optimum (25/75 % m/m) pour maximiser le rendement 
théorique en solide. 
Le développement du protocole expérimental de recristallisation a montré que les 
paramètres opératoires (débits d’entrée des solutions, type de pré-mélangeur, concentration) 
n'ont pas d'influence sur les particules recristallisées. De plus, préparer de fines particules de 
ce solide est un véritable défi, en raison de la croissance et l’agglomération très rapides des 
particules produites.  Des problèmes de colmatage des canaux du pré-mélangeur ont aussi été 
constatés.  
Il a été montré que la cristallisation de ce solide donne naissance à des particules de 
tailles nanométriques en sortie de pré-mélangeur. Cependant ces nanoparticules ont une forte 
tendance à croître et à s’agglomérer. Afin de limiter la croissance et l’agglomération des 
cristaux, des additifs ont été sélectionnés et introduits dans les solutions initiales. Chaque 
additif a montré un comportement différent en empêchant la croissance des cristaux. La 
combinaison de deux additifs (P-407 et chitosane) a été la plus efficace : diminution de la 
  
croissance des cristaux, amélioration de la mouillabilité des particules formées, 
modification de charge de surface de particules (elle devient positive). Cette modification de 
charge de surface a empêché le colmatage des canaux au cours de la cristallisation (répulsion 
électrostatique avec les parois de mélangeur). Dans l’ensemble, les microcristaux synthétisés 
en présence d'additifs ont montré une vitesse de dissolution nettement plus élevée que les 
cristaux de la poudre initiale. 
L’amélioration de la vitesse de dissolution est principalement due à l'amélioration des 
propriétés de mouillage grâce à des interactions spécifiques entre la poudre et les additifs. Par 
conséquent, les microcristaux synthétisés ont de meilleures propriétés physico-chimiques. 
L’utilisation de cette technique serait donc une alternative pour l’obtention d’une poudre avec 
de meilleures caractéristiques de dissolution et par conséquent une meilleure biodisponibilité.  
Pour continuer ses travaux sur l'amélioration de la biodisponibilité du CRS 74, 
différentes voies peuvent être suggérées en terme de procédé, de compréhension du 
mécanisme de stabilisation, et du potentiel du principe actif.  
En termes de procédé, il serait intéressant d'étudier l'influence des paramètres 
opératoires de la cristallisation (débit, concentration en additifs, température …) pour la 
formulation comprenant les deux additifs (P-407 et chitosane) afin d'optimiser le processus de 
production des cristaux. De plus, la cristallisation par effet anti-solvant pourrait être comparée 
à d'autres technologies « bottom-up » prometteuses pour la préparation de nanocristaux de 
CRS 74, comme par exemple : la préparation de dispersions solides par atomisation ou par 
extrusion à chaud.  
Au cours de cette étude, il était clair que la cristallisation en présence d'additifs peut 
avoir un effet positif sur la vitesse de dissolution. Il est donc nécessaire d'approfondir la 
compréhension du mécanisme d'adsorption de l'additif et de déterminer quel est le niveau 
d'adsorption nécessaire pour obtenir un effet prononcé sur les propriétés de surface des 
particules. Pour comprendre cette propriété, une détermination quantitative de l’adsorption de 
l'excipient devra être effectuée. Il sera intéressant d'étudier différentes hypothèses 
d’attachement à l'échelle moléculaire. L’interaction de l'additif sur la surface cristalline 
pourrait être étudiée, par exemple, par spectroscopie Raman.  
Enfin, la méthodologie de dissolution développée dans cette étude devra être validée 
afin de pouvoir l’utiliser en tant que technique sensible, fiable et reproductible pour les tests 
  
de bioéquivalence. De plus l'effet biologique du solide recristallisé par rapport au solide 
d'origine devra être identifié afin d'évaluer les changements de la poudre synthétisée et 
déterminer le réel effet sur l’amélioration de la biodisponibilité. 
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This study concerned a novel antiretroviral promising drug candidate, named CRS 74. 
It could be proven in this study that the original drug powder (as currently produced 
industrially) exhibits poor aqueous solubility and slow dissolution rate. 
 The limited low aqueous solubility at 37 o C (< 0.004 mg/g) can be explained by its 
high crystallinity, its high melting point (188.6oC) and high enthalpy of fusion (86.6 J/g). The 
low dissolution rate is related to its large particle size (micrometric range, with a broad 
particle size dispersion) and very poor water wettability (Θ =136.4 ± 0.8°). 
This molecule is soluble in ethanol (92.6mg/gsolution) and presented a maximum in 
solubility in ethanol-water mixtures as determined in this study using UNIQUAC-based 
model. To the best of our knowledge, there are no published data of the solubility of such 
given solute in ethanol-water mixtures to compare with.  
There is no monograph of this drug in any pharmacopoeia and, from the 
characterization study carried out in this thesis, a monograph proposition is suggested: 
CRS 74 monograph 
Synonym: (2S, 3S, 5S)-2, -5 bis- [N-[N-[[N- methyl- 
N-[(2-isopropyl- 4- tiazolyl) methyl] 
amino] carbonyl] vanilyl] amino- 1,6- 
diphenyl- 3- hydroxyhexane 
Therapeutic category HIV protease inhibitor 
Formula C46H66N8O5S2 
Description white powder 
Molecular weight (g/mol) 875.2 
Melting point (°C) 
Melting enthalpy (J/g) 
187-189 
78-87 
Solubility 
  
0.102 mg/gsolution in 0.1M HCl pH 1.2, 
37oC - Very slightly soluble 
lower than 0.004 mg/g in water at 37 o C – 
Insoluble 
92.6 mg/gsolution in ethanol (solvent) at 
30°C -Very soluble 
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To predict in vitro CRS 74 dissolution behavior, a conventional acid medium was 
chosen. The development of the analytical methodology of quantification and dissolution 
assays is very important. The inexistence of specific method for CRS 74 in official summaries 
highlights the importance of above-cited tests for the definition of specific method for such 
purpose appropriates method to quality control of the drug. The quantification method was 
developed in this work to quantify the drug in acid media (0.1M HCl) or in water-ethanol 
solutions. Both developed methods were linear and specific for the drug.  
Several original data were experimentally obtained concerning the solubility of CRS 74 
in liquid media. They are: 
• Acidic aqueous medium (0.1 M HCl) at 37°C; 
• Acidic aqueous medium in presence of five different additives at 37°C; 
• Hydroalcoholic solutions in different water-ethanol mass proportions at 30°C; 
• Pure ethanol at different temperatures (5, 10, 15, 20, 25 and 30°C) 
• Water (LAS recrystallized drug) at 37°C. 
 
In hydro-alcoholic solutions, the drug solubility increases as the ethanol ratio in ethanol-
water increases, presenting a maximum as determined in this study using UNIQUAC-based 
model. The calculated data showed good agreement with experimental results and revealed a 
maximum solubility of CRS 74 of 130.20 mg/gsolution for a mass ratio of ethanol/water of 
0.83/0.17 (w/w).  
The results of the modeling indicate that this model is the appropriate tool for 
representing the solubility behavior of CRS 74 in ethanol-water solvent mixtures. The 
measurements and correlation of CRS 74 solubility in binary solvent mixtures provided useful 
data to estimate the theoretical efficiency of the LAS recrystallization process as a function of 
ethanol/water mass ratios. An ethanol-water mixture containing 25% (w/w) ethanol was found 
favorable for the crystallization process and was fixed for the LAS crystallization.  
For experimental design to CRS 74 LAS crystallization, two different types of mixers 
were tested: a T-mixer with two radial entries and a two jets vortex mixer also called 
Roughton mixer. It was clearly observed, that nano-sized particles were obtained at the outlet 
of both mixers. However, no remarkable effect of the supersaturation level was observed on 
the reduction of the drug particle size.   
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The T-mixer was chosen for further experiments because it generated less 
agglomerated particles. However to prepare fine particles of CRS 74 without polymer became 
quite a challenge, due to the rapid growth and agglomeration of the produced particles and 
problems of blockage of the mixer.  
Recrystallized solids were compared to the original drug crystals in terms of particle 
size, solid state, physical and dissolution properties. The particles of the original powder were 
found to be larger and exhibited a broad particle size distribution compared to the LAS 
recrystallized drug. In turn, recrystallized solids seemed more agglomerated than the original 
ones. In addition, recrystallization did not modify the dissolution profile compared to the 
original drug. It could be concluded that to improve dissolution kinetics, smaller particles 
with a more hydrophilic surface need to be produced. So the LAS crystallization was then 
carried out in presence of different additives. 
Stabilizers were screened and introduced in the solvent, or in the anti-solvent, or in both 
phases. For steric stabilization, we used nonionic surfactant (Polyoxyethylene sorbitan 
monooleate –Tween 20) polymers (Hydroxypropylmethylcellulose-HPMC) and amphiphilic 
block copolymers (Poloxamer 407-P-407). For electrostatic repulsion, the anionic surfactant 
Sodium Dodecyl Sulfate (SDS) was chosen. For a combined effect of steric stabilization and 
electrostatic repulsion, we tested Chitosan, a copolymer of glucosamine and N-acetyl 
glucosamine. 
The primary role of stabilizers is to inhibit excessive crystal growth. In a general way, 
most CRS 74 crystals produced in presence of additives had a smaller particle size compared 
to the original or recrystallized powder without additives. 
As a result of introduction of additives in the LAS crystallization study, the crystal size, 
agglomeration state, dissolution kinetics and drug wettability varied over a wide range 
depending on the additive involved and its concentration. According to the results, the zeta 
potential remained almost unchanged when nonionic stabilizers were used. In other hand, 
charged additives like SDS (negatively charged) and Chitosan (positively charged) adsorbed 
with the charged parts of the respective molecules onto the drug particle surface.  
Over the additives screened, changes on surface properties were observed. A 
remarkable decrease of contact angle (θ<100°) was observed for two formulations, one with 
P-407 (concentration of 0.02 % in organic phase) and another with P-407 combined with 
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chitosan (P-407 concentration of 0.02 % in organic phase and chitosan concentration equal to 
0.5 % in aqueous phase) at the recrystallized powder in the higher concentration of P- 407, P- 
407 and Chitosan. The enhancement of wetting properties can be attributed to multiple 
attachments of hydrophobic domains of P-407 on the drug particle surface. 
Each additive showed different behavior in preventing crystal growth, but the 
association of P-407 in the organic phase and chitosan in the aqueous phase was most 
effective in preventing crystal growth, improving surface wettability, and providing enough 
electrostatic repulsion due to highly positive charged drug surface.  
When placed in the organic phase, P-407 chains are more available to precipitate drug 
particles upon mixing, since they do not need to diffuse across the interface through the 
volume of the aqueous phase, which exceeded the organic phase volume. This reduction in 
time for diffusion of polymer to the drug surface leads to more rapid stabilization against 
coagulation and condensation. The presence of surfactant at the surface of the clusters may be 
expected to lower the interfacial tension between the solid surface and solvent mixture and 
raise the nucleation rate. 
Drug microcrystals recrystallized in presence of additives showed significantly 
improved dissolution velocity in comparison to microcrystals (raw material and without 
additive). Among the additives tested, P-407 and P-407 + Chitosan gave the best results. They 
enhanced dramatically the drug dissolution rate from 4% to almost 40% drug dissolved at 20 
min. In addition, the presence of chitosan in the crystallization process solved the problem 
related to the process, the blockage, due to charge repulsion between the positively charged 
crystals and surface charge of stainless steel.  
Overall, the results of this research showed conclusively that the liquid anti-solvent 
crystallization technique in presence of additives used in this research produced microcrystals 
that exhibited significantly faster dissolution rates than the original (as-received) CRS 74 
crystals. The improved dissolution is attributable to the modification of the particle size of 
drug crystals and enhancement of wetting properties due to specific interactions between the 
drug and the additives. Therefore, CRS 74 microcrystals yielded better physicochemical 
properties and would be one alternative for better CRS 74 dissolution characteristics and 
thereby bioavailability for commercial purposes. 
To continue the work concerning the improvement of the bioavailability of CRS 74, 
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some strategies are suggested in different fields (process, stabilization mechanism and drug 
potential). 
In term of process, it will be interesting to study the influence of crystallization 
operating conditions with the association of two additives (P-407, Chitosan) on solid 
properties in order to optimize and eventually scale up the process. This process could be 
compared to others promising technologies based on bottom-up preparation of CRS 74 drug 
nanocrystals, like the preparation of solid dispersions by spray drying and hot melt extrusion. 
Still in terms of process, there is a need for further understanding excipient adsorption, e.g., 
what is the level of adsorption needed to provide a pronounced effect on particle properties? 
In order to understand this point, a quantitative determination of excipient adsorption should 
be carried out.  
During this study it was clear that crystallization in the presence of additives can have a 
positive effect on dissolution rate. For instance, some hypotheses about the attachment on 
molecular level of additive on crystal surface were explored. However, a better understanding 
of these interactions should be carried out. The interaction additive crystal-surface could be 
explored by Confocal Raman Spectroscopy. 
The last research field is related to the drug. The dissolution methodology developed in 
this study could be validated and used as a sensitive, reliable, and reproducible for 
bioequivalence testing. Finally, the biological effect of recrystallized solid compared to 
original solid should to investigate in order to assess the changes of the synthesized powder 
and its improved bioavailability. 
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Human Immunodeficiency Virus (HIV) is a retrovirus (constituted by RNA) 
belonging to the Lentivirinae subfamily, capable to sponge human immunologic system 
causing the infectious disease known by the acronym AIDS (Acquired Immuno Deficiency 
Syndrome).
HIV comprises an outer envelope consisting of a lipid bilayer with spikes of 
glycoproteins (gp), gp41 and gp120. These glycoproteins are linked in such a way that gp 120 
protrudes from the surface of the virus. Inside this envelope is a nucleocapsid (p 17), which 
surrounds a central core of protein, p24. Within this core, are two copies of single-stranded 
RNA (the virus genome). Proteins, p7 and p9, are bound to the RNA and are believed to be 
involved in regulation of gene expression. Multiple molecules of the enzyme, reverse 
transcriptase (R T), are also found in the core. This enzyme is responsible for converting the 
viral RNA into proviral DNA (ABBAS, 2000), as shown in the Figure I.1. 
 
Figure I.1. Schematic drawing of the lentivirus HIV (ENKIRCH, 2011) 
 
HIV may only infects certain types of cells. In general, these are cells which carry 
CD4 receptors on their surface. Some cells in the immune system have these receptors, in 
particular, T4-lymphocytes or T-helper cells. Cellular infection occurs when HIV virus binds 
to a cellular receptor, generally the T CD4+, by means of the gp120 protein; then, virus 
merges to the cell membrane and the capsid content is released into the cell cytoplasm. The 
HIV enzyme, reverse transcriptase, catalyses the DNA copy production starting from HIV 
virus RNA. The double helix DNA copy is then transported to the cellular nucleus where a 
second HIV enzyme, the integrase, catalyses the incorporation of viral DNA to the host 
genetic material. Subsequent viral genes expression results in RNA transcription starting from 
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HIV DNA and in translation of viral proteins. However, newly formed viral proteins are 
produced in the form of polyproteins precursors that are long unities consisting of viral 
enzymes and structural proteins added to each other. Polyproteins and viral RNA move to the 
cell surface where they are incorporated to the new viruses that spring from cell membrane 
taking part of it with them to form the external layer of the viruses (figure I.2). Newly formed 
viruses, however, could not be infectious without the action of a third essential HIV enzyme, 
the protease, that turns viral polyproteins in functional and structural proteins and enzymes. 
Proteases are enzymes that cleave others proteins at highly specific sites. HIV protease, an 
aspartyl protease, cleaves viral polyproteins in essential functional proteins during the process 
of maturation of the "virion" (complete viral particle). This process occurs when each new 
"virion" springs to outside of the infected cell membrane and it continues after the release of 
immature virus by the cell. If polyproteins are not cleft, virus formation does not finish and it 
becomes unable to infect a new cell. Protease inhibitors, as this name implicate, are 
substances able to inhibit protease enzyme function. They perform their inhibitory effect 
disabling the enzyme before it cleaves gag/pol polyprotein to form its essential products. It 
means that, blockage of HIV protease leads to the formation of immature non-infectious- PCT 
document number 111006 (BOCKELMANN et al., 2005; BOCKELMANN et al., 2010 ). 
 
 
Figure I.2. Life cycle of HIV (HOGGARD and OWEN, 2003).
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In order to validate the flow of gear pumps (mzr-7255-hs-f S, mzr-7205-hs-f S; HNP 
Mycrosysteme) for the solvent and the anti-solvent system and digital mass flow 
meter/controller (MIX, Bronhorst), the pumps calibration was realized. 
For this purpose, a beaker with the fluid to be pumped was weighed and the software 
was activated, starting the pump. At the end, after all the fluid has being pumped, the beaker 
was weighed and the theoretical mass flow of fluid was calculated with the mass used and the 
time spent in the experiment. Finally, the value of the calculated flow was compared with the 
flow indicated by the software. 
The calibration test was realized for both pumps with water used as the fluid for the 
anti-solvent’s pumps and ethanol to the solvent’s pump. According to the table II.1, the value 
of the calculated flow is in agreement with the flow value indicated by the software. 
 
Table II.1. Data obtained in the pumps calibration 
Pumped liquid Mass (g) Time (min) 
Flow rate calculated 
(g/min) 
Flow rate software 
(g/min) 
Error 
(%) 
Ethanol 109.3 15 7.29 7 4.0 
Water 749.5 15 49.97 50.17 0.4 
 
In a second time, to ensure that the pumps were pumping fluids in the correct ratio a 
simple test was performed. Mixtures between ethanol and water in different proportions were 
made without the aid of the pumps and measured up their refractive indices. Later, the same 
mixtures were performed using the pumps and they also had their refractive indices measured. 
Each result is an average of at least 3 replicates. 
No changes of refractive indices were observed, for all different ratio ethanol/water 
using different manners of preparation, as seen in the table II.2. It can be supposed that, the 
pumps can respond correctly to request flow values and they pumped the fluids in the correct 
proportions. It means that pumps are working as it should. 
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Table II.2. Values of the refractive indices measured ±  standard deviation . 
Proportion 
ethanol/water (w:w) 
Physical mixture Mixture with pumps 
1:1 1.3582 ± 0.0001 1.3592 ± 0.0002 
2:1 1.3523 ± 0.0004 1.3548 ± 0.0001 
3:1 1.3476 ± 0.0004 1.3478 ± 0.0002 
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LAS crystallization process conditions   
 
• T-Mixer 
• Ratio solvent (ethanol):anti-solvent (water) - 1:3 (25%:75%) ; 
• Presence of additive  
• Temperature of organic and aqueous phases at 30°C  
• Crystals collection: vessel under magnetic stirring  
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Additive in  aqueous phase 
 
 
 
Figure III.1.  Particle size distribution pattern for as HPMC 0.5 % (w/w) 
 
 
Figure III.2.  Particle size distribution pattern for as SDS 0.5 % (w/w) and SDS < 
CMC.   
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Figure III.3.  Particle size distribution pattern for as Tween20 0.5 % (w/w) and 
Tween20 < CMC.   
 
 
 
Figure III.4.  Particle size distribution pattern for as Chitosan 0.5 % (w/w).   
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Addtive in  organic phase  
 
 
 
 
 
 
Figure III.5.  Particle size distribution pattern for as P-407 0.5 % (w/w) and P-407  < 
CMC.   
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Additive in both, organic and aqueous phase 
 
 
 
Figure III.6.  Particle size distribution pattern for as P-407 < CMC + SDS  0.5 %  
(w/w)  and P-407 >  CMC + SDS 0.5 %(w/w).  
 
 
Figure III.7.  Particle size distribution pattern for as P-407 < CMC + Chitosan 0.5 %  
(w/w)  and P-407 >  CMC + Chitosan 0.5 %(w/w).   
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Supersaturation degree 
 
 
 
Figure III.8.  Particle size distribution pattern for as  P-407 0.5 % (w/w) (S =156.41) 
and  P-407 0.5 % (S =374.51)  
 
 
Figure III.9.  Particle size distribution pattern for as P-407 > CMC + SDS 0.5 %  (w/w)  
(S = 43.25)  and P-407 >  CMC + SDS 0.5 % (w/w) (S = 104.5).   
 
 
 
 
 
  265 
 
 
 
 
 
 
 
 
 
Figure III.10.  Particle size distribution pattern for as P-407 > CMC + Chitosan 0.5 %  
(w/w)  (20 %)  and P-407 >  CMC + Chitosan 0.5 % (w/w) (50 % ).   
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contact angle (θ°) as a function of time 
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LAS crystallization process conditions   
 
• T-Mixer 
• Ratio solvent (ethanol):anti-solvent (water) - 1:3 (25%:75%) ; 
• Presence of additive  
• Temperature of organic and aqueous phases at 30°C  
• Crystals collection: vessel under magnetic stirring  
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Original CRS 074 
 
 
Figure IV.1 Contact angle (°) as a function of time for as CRS 74. 
 
LAS recrystalized drug 
 
 
Figure IV.2. Contact angle (°) as a function of time for as LAS recrystalized drug . 
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Additive in aqueos phase  
 
 
Figure IV.3. Contact angle (°) as a function of time for as HPMC 0.5 % (w/w). 
 
 
 
Figure IV.4. Contact angle (°) as a function of time for as SDS < CMC. 
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Figure IV.5. Contact angle (°) as a function of time for as SDS 0.5 % (w/w). 
 
 
 
Figure IV.6. Contact angle (°) as a function of time for as Tween 20 < CMC. 
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Figure IV.7. Contact angle (°) as a function of time for as Tween 20  0.5 % (w/w). 
 
 
 
Figure IV.8. Contact angle (°) as a function of time for as Chitosan 0.5 % (w/w). 
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Additif in the organic phase  
 
 
 
Figure IV.9. Contact angle (°) as a function of time for as P-407 < CMC. 
 
 
 
Figure IV.10. Contact angle (°) as a function of time for as P-407 0.5 % (w/w). 
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Additif in both, organic and aqueos phases 
 
 
Figure IV.11. Contact angle (°) as a function of time for as P-407< CMC +  SDS 
0.5%(w/w). 
 
 
 
Figure IV.12. Contact angle (°) as a function of time for as P-407 >CMC +  SDS 
0.5%(w/w). 
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Figure IV.13. Contact angle (°) as a function of time for as P-407< CMC +  Chitosan 
0.5 % (w/w). 
 
 
 
Figure IV.14. Contact angle (°) as a function of time for as P-407 > CMC +  Chitosan 
0.5 % (w/w). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Morphology of crystals in suspension 
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